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Abstract 
Inflammation is a complex physiological process that involves host defense mechanisms in 
response to the intrusion of harmful external stimuli. Uncoordinated inflammatory responses, 
however, are the underlying pathophysiological cause of many chronic diseases. Inflammation is 
characterised by the burgeoning migration of leukocytes to the point of injury and subsequent 
release of pro-nociceptive mediators, generating inflammatory pain. Dynorphin 1-17 (DYN 1-17) is 
endogenously produced and released from leukocytes upon stimulation by local inflammatory 
factors in the inflamed area. This opioid peptide primarily binds to kappa-opioid receptor (KOR) to 
produce analgesia. Under inflammatory milieu, DYN 1-17 undergoes spontaneous degradation, 
yielding a variety of opioid and non-opioid fragments that may have significant implications in 
inflammation. The underlying cellular effects of these fragments remain unclear. This thesis seeks 
to explore potential mechanistic insights into selected major DYN 1-17 fragments, identified from a 
previous biotransformation study of DYN 1-17 in rodent inflamed tissue. This thesis examines the 
DYN 1-17 fragments modulation of intracellular signals associated with inflammation and thereby, 
gain an insight into novel therapeutic targets through exploring these endogenous mechanisms.  
 
Utilising THP-1 macrophages as an in vitro model of inflammation, this thesis begins with a semi-
quantitative assessment of nuclear factor-kappa B/p65 (NF-κB/p65) translocation, a major 
transcription factor that regulates genes responsible for immune and inflammatory responses. The 
findings presented in Chapter Three of this thesis demonstrated that DYN 1-17 and selected major 
fragments (DYN 1-6, 1-7, 1-9, 1-10, 1-11, 3-14, 6-12, 2-17 and 7-17) significantly attenuated NF-
κB/p65 nuclear translocation induced by lipopolysaccharide (LPS), with the greatest reduction 
observed with DYN 1-7 at 10 nM. A selective KOR antagonist, ML-190, was used to examine 
KOR involvement in this inhibitory action. ML-190 significantly reversed the inhibition of NF-
κB/p65 translocation produced by DYN 1-17, DYN 1-6, DYN 1-7 and DYN 1-9, but not DYN 1-10 
and DYN 1-11.   
 
Cytokine production is linked as a downstream process to NF-κB activation; hence it is necessary to 
evaluate the ability of DYN 1-17 and selected biotransformation fragments in the modulation of IL-
1β and TNF-α release in differentiated THP-1 cells, as presented in Chapter Four, to gain an insight 
into the effects on major pro-inflammatory cytokines. DYN 1-17 and the fragments, demonstrated 
differential modulatory effects on LPS-induced release of IL-1β and TNF-α. DYN 1-7 and DYN 1-
6, inhibited and elevated the secretion of both cytokines, respectively, in a concentration-dependent 
manner (10-11 to 10-7 M). DYN 1-17, however, only inhibited IL-1β release from differentiated 
iii 
 
THP-1 cells and had no effect on TNF-α secretion. Intriguingly, DYN 3-14 at 10-17 to 10-11 M 
demonstrated significant inhibition on IL-1β release and paradoxically increased TNF-α levels at 
10-11 to 10-7 M. Subsequent antagonism with ML-190 only reversed the effects produced by DYN 
1-17, DYN 1-6 and DYN 1-7 on IL-1β release at 10-7 M, 10-9 M and 10-11 M, respectively. 
Likewise, the effects of DYN 1-6 (10-7 M) and DYN 1-7 (10-11 M and 10-9 M) on TNF-α release 
were also blocked by ML-190. Taken together, the findings from Chapter Three and Four, 
collectively demonstrated that DYN 1-17 and a select of biotransformation fragments involve in the 
regulation of inflammatory response through inhibition of NF-κB/p65 translocation and modulation 
of cytokine release via KOR-dependent and -independent pathways.  
 
Chapter Five of this thesis investigates the effects of DYN 1-17 and selected biotransformation 
fragments at the Toll-like receptor 4 (TLR4), implicated in LPS-induced activation of NF-κB 
signaling pathway. Of these fragments, only DYN 3-14 showed significant concentration-dependent 
attenuation on TLR4 activation in HEK-Blue™-hTLR4 cells, albeit 300-fold lower than LPS-RS, a 
potent TLR4 antagonist. This result thus describes a potential role for DYN 3-14 as an antagonist at 
TLR4, and as a consequence, highlights its involvement in regulating inflammatory signals through 
a non-opioid mechanism.  
 
In conjunction with the immunomodulatory effects seen in select fragments of DYN 1-17, Chapter 
Six of this thesis aims to extend previous findings of DYN 1-17 biotransformation study in rodent 
inflamed tissues, by further characterising the degradation of DYN 1-17 in the context of human 
inflammatory disease, chronic rhinosinusitis (CRS). Data obtained by LC-MS analysis revealed a 
similar range of fragments in inflamed human nasal tissue homogenates from those found in 
incubations with rodent inflamed paw tissues. Intriguingly, DYN 3-14 and DYN 1-5 were the major 
hydrolysis fragments produced until the end of the incubation period, suggesting that these 
fragments may possess important roles in the immunoregulation and therefore, may be useful as 
potential therapeutic agents for the treatment CRS. 
 
In conclusion, the findings presented within this thesis collectively highlight the pharmacological 
differences that exist between DYN 1-17 and its biotransformation fragments on inflammatory 
signalling pathways, through opioid- and non-opioid-dependent pathways. Furthermore, this thesis 
postulates that the effects of DYN 1-17 in inflammation may not be solely dependent on the parent 
molecule, but may also be attributed to the modulatory effects of other major biotransformation 
fragments. 
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1.  I nt r oduct i on 
Inflammation is a physiological response that provides protection against harmful stimuli and is part 
of the tissue healing process. Pathological inflammation due to uncoordinated inflammatory 
processes can lead to a range of chronic diseases such as rheumatoid arthritis and cancer (1). There 
has been an increase in the incidence of chronic pain in recent years, imposing a serious 
socioeconomic burden on the human population, reflected by diminished quality of life, increased 
mortality rates and high costs for therapy and care (2). Despite the currently available anti-
inflammatory and analgesic agents, the accompanying adverse effects of these therapies remain a 
major challenge in treating inflammatory-related disorders effectively. The notion of resolving 
inflammation without serious adverse effects has been the emphasis of recent research involving 
endogenous compounds, such as opioid peptides (3, 4). In addition to their analgesic effects, these 
opioid peptides have also been shown to modulate the function of the innate and acquired immune 
systems through various mechanism (5). Hence, understanding the regulatory control mechanisms 
of endogenous opioids on immune functions is fundamentally important for optimising their 
therapeutic potential for treating inflammation.  
 
1.1. Study background  
Opioids are extensively prescribed in clinical practice as potent analgesics. Their actions have long 
been thought to be mediated exclusively within the central nervous system (CNS) (6). Regardless of 
their remarkable pain-relieving properties, systemic administration of opioids is associated with 
various unwanted adverse effects largely attributed to their actions at central opioid receptors; these 
side effects include respiratory depression, sedation, tolerance and addiction (7-9). These spurred 
research into opioid pharmacological actions outside the CNS, leading to the discovery of 
peripheral opioid receptors, located on the peripheral sensory neurons (10). It has been reported 
previously that peripheral opioid receptor activation produced significantly potent and clinically 
measurable analgesia (11, 12). Intriguingly, peripheral opioid action in treating pain is devoid of 
central side effects, thus underpinning this as a novel approach to treat pain (13).  
 
While inflammatory pathways can result in hyperalgesia e.g. through the arachidonic acid cascade, 
they also play a role in mediating endogenous peripheral analgesia, as reflected by the increased 
expression of opioid receptors on the peripheral terminals of sensory neurons and heightened local 
production of opioid peptides at the site of inflammation (10, 14-26). This suggests an integral role 
of the immune system in mediating analgesia in response to noxious stimuli. In inflamed tissues, 
opioid peptides such as beta-endorphin (β-END), dynorphin A (DYN A), and methionine-
enkephalin (Met-ENK) are released upon stimulation by interleukin-1beta (IL-1β), corticotrophin-
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releasing factor (CRF) and noradrenaline thereby, producing analgesia through specific interaction 
with their respective opioid receptors (19, 27, 28). Several underlying mechanisms of opioid-
mediated peripheral analgesia have been shown including alteration in calcium influx, inhibition of 
calcitonin gene related peptide (CGRP) and cyclic adenosine monophosphate (cAMP) as well as 
activation of transient receptor potential vanilloid 1 (TRPV1) (13). Likewise, modification of 
inflammatory cascades has also been observed, thereby expanding the perspective that peripherally 
active endogenous opioids are not only restricted to analgesia but also possess on 
immunomodulatory component which is therapeutically beneficial in inflammation-induced pain (4, 
11).  
 
Dynorphin 1-17 (DYN 1-17) is an opioid peptide, comprising of 17 amino acid residues, that is 
abundantly released from neuronal and non-neuronal cells upon enzymatic cleavage of the 
precursor pro-dynorphin (PDYN) molecule (29, 30). It preferentially binds to the kappa-opioid 
receptor (KOR) and may also interact with other opioid receptors (delta-opioid receptor [DOR], 
mu-opioid receptor [MOR] and nociceptin receptor [NOP]) (29, 31-33) as well as non-opioid 
receptors (N-methyl-D-aspartate [NMDA] and bradykinin receptors) (34, 35). In peripheral 
inflamed tissue, DYN 1-17 is produced and released from immune cells and activate KOR that 
present on peripheral terminals of sensory neurons. This interaction results in endogenous opioid 
peripheral analgesia (10). Furthermore, the presence of KOR on immune cells might provide an 
insight into the regulation of cellular and innate and adaptive immune functions of DYN 1-17 upon 
opioid receptor activation (27, 36). It is now well established, from a variety of in vitro and animal 
investigations that, peripherally-acting opioid peptides modulate inflammatory mechanisms through 
several pathways i.e. inhibiting the release of pro-inflammatory cytokine and neuropeptide as well 
as reducing plasma extravasation (37).   
 
DYN 1-17 is susceptible to rapid enzymatic degradation, generating a variety of smaller fragments 
(38). Blockade of DYN 1-17 metabolic degradation in inflamed tissue has been shown to promote 
peripheral analgesia and to alleviate inflammatory pain (39). However, a biotransformation study of 
DYN 1-17 in rodent inflamed tissue has revealed that a wide range of fragments, different from 
those observed within non-inflamed tissue or blood, were produced. This study postulated that 
DYN 1-17 is metabolised into more stable fragments that possess particular importance during 
inflammation (40). Supporting this, earlier findings have documented that several fragments of 
DYN 1-17 have been implicated in the modulation of various immune-mediated responses through 
opioid and non-opioid pathways (41-43). 
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It is now well established from a variety of studies that, in response to many divergent external 
stimuli, the cytoplasmic nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
transcription factor is activated and translocated into the nucleus, thereby encoding a diverse array 
of responsive genes that are responsible for cell proliferation, survival, apoptosis and immunity (44-
46). Whilst NF-κB plays a crucial role in regulating these physiological responses, increasing 
evidence has linked multiple pathological conditions such as cancer, chronic inflammation, 
autoimmune diseases and neurodegenerative diseases with aberrant NF-κB activation (46, 47). One 
of the potent activator of NF-κB pathway is the bacterial endotoxin lipopolysaccharide (LPS) that 
directly binds to Toll-like receptor 4 (TLR4). This interaction initiates multiple intracellular 
signalling cascades that trigger NF-κB activation, resulting in the production and release of a 
number of pro-inflammatory cytokines such as IL-1β and tumour necrosis factor-alpha (TNF-α) 
(48, 49). Emerging evidence has been published on the importance of TLR4-mediated NF-κB 
signalling pathway in both innate and adaptive immune responses (50-52). Interestingly, few recent 
studies have demonstrated the interaction of opioids with TLR4, thereby suggests the implication of 
this signalling pathway in the regulation of peripheral analgesia and inflammation mediated by 
exogenous and endogenous opioid peptides (53-56).  
 
1.2. Purpose of study 
The existing literature has described the involvement of DYN 1-17 and some of the 
biotransformation fragments in the regulation of immune responses separate from their analgesic 
effects. The underlying intracellular signalling mechanisms contributing to this effect remain 
unclear and warrant further investigations. In addition to this, the previous biotransformation study 
of DYN 1-17 in inflamed rodent tissue set a platform for translating research evidence from animals 
to humans, enabling further exploration on the impact of different human inflammatory diseases on 
differential enzymatic processing of DYN 1-17. Up to now, no previous study has assessed the 
metabolism of DYN 1-17 in inflamed human tissue.  
 
Since there is a paucity of research investigating the immunomodulatory effects of DYN 1-17 
fragments, this study set out to identify and to gain some mechanistic insights of their immune-
modulation properties on major inflammatory signalling pathways. In addition to this, this study 
also seeks to examine the biotransformation of DYN 1-17 in the context of human inflammatory 
disease that may extend findings of the previous biotransformation study of DYN 1-17 in inflamed 
rodent tissue homogenates by characterising the fragments produced following incubation of DYN 
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1-17 with inflamed human nasal tissue, which may have clinical relevance in the context of human 
inflammatory diseases. 
 
1.3. Research hypotheses  
DYN 1-17 and its major biotransformation fragments modulate NF-κB signalling and the 
downstream release of pro-inflammatory cytokines (IL-β and TNF-α) during inflammation via 
opioid and non-opioid pathways.  
 
DYN 1-17 undergoes biotransformation in excised, inflamed ethmoid sinuses, producing a wide 
range of fragments. 
 
1.4. Thesis aims and objectives 
The main aim of this study is to evaluate and elucidate the possible roles and functions of DYN 1-
17 and selected major biotransformation fragments in the modulation of intracellular signals 
associated with inflammation.  
 
The specific objectives of this thesis are: 
 
1. To explore the modulatory activity of DYN 1-17 and selected biotransformation fragments on 
LPS-induced NF-κB/p65 nuclear translocation in differentiated THP-1 cells.  
2. To evaluate the effects of DYN 1-17 and selected biotransformation fragments on LPS-induced 
release of IL-1β and TNF-α in differentiated THP-1 cells.  
3. To examine the modulatory effects of DYN 1-17 and selected biotransformation fragments at 
TLR4 in LPS-induced NF-κB signaling pathway. 
4. To characterise the fragments produced following biotransformation of DYN 1-17 in inflamed 
human ethmoid sinuses.  
 
1.5. Significance of study  
This study provides one of the first investigations of how DYN 1-17 and its biotransformation 
fragments modulate inflammatory signals at intracellular level, leading to the discovery of opioid-
related or non-opioid sites of action. Modifications of these fragments may contribute to the 
discovery of new drug leads that may be valuable in treating inflammatory-related diseases and 
clinically relevant to patients receiving long-term opioid therapy for malignant and non-malignant 
pain. Undoubtedly, new advances in understanding the complex control of DYN 1-17 fragments on 
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the resolution of inflammation could add to our knowledge of peripheral mechanisms of 
endogenous opioid peptides. Furthermore, characterisation of the fragments produced following 
metabolic degradation of DYN 1-17 in inflamed human nasal tissue is necessary to enrich our 
understanding on the effects of tissue biotransformation in managing inflammation, providing 
unique insights into the pathophysiology and aetiology of human inflammatory diseases, and the 
utility of these fragments as possible human directed therapeutic agents.  
 
1.6. Thesis outline 
Chapter One presents an introduction to the immunomodulatory functions of DYN 1-17 and its 
biotransformation fragments by addressing the study background, purpose of study, research 
hypotheses, thesis objectives and the significance of this study. Chapter Two begins by laying out 
the current understanding of peripheral opioid mechanisms in controlling pain and inflammation. In 
Chapter Three, the effects of DYN 1-17 and selected major biotransformation fragments on the NF-
κB signalling pathway are investigated, utilising a THP-1 cell line as an in vitro model for 
inflammation and the application of a high-content imaging approach to measure the NF-κB nuclear 
translocation. Modulation of the downstream release of pro-inflammatory cytokines (IL-1β and 
TNF-α) by these major biotransformation fragments, measured by AlphaLISA, a bead-based 
proximity assay is described further in Chapter Four. Chapter Five examines the potential activity 
of DYN 1-17 and the major biotransformation fragments at TLR4, using HEK 293 cells that stably 
express TLR4. Liquid chromatography-mass spectrometry (LC-MS) was used in Chapter Six to 
characterise the biotransformation fragments of DYN 1-17 produced inflamed human nasal tissue, 
which may be clinically relevant towards disease pathology. Finally, Chapter Seven summarises the 
overall findings of these studies and includes a discussion of the implication of these findings to 
future research and also addresses the limitations of these studies.  
 
1.7. Definition of terms 
Throughout this thesis, the terms ‘N-terminal fragments’ and ‘opioid fragments’ are used 
interchangeably to refer to the peptides starting with tyrosine-1 of DYN 1-17 at their N-terminus, 
namely, DYN 1-6, DYN 1-7, DYN 1-9, DYN 1-10 and DYN 1-11. ‘Intermediate fragments’, also 
defined as internal peptides that do not have tyrosine-1 and glutamine-17, will be used to refer to 
both DYN 3-14 and DYN 6-12. The ‘C-terminal fragments’, are polypeptide chains that do not 
have tyrosine-1 but incorporate glutamine-17 at the C-terminus, comprising DYN 2-17 and DYN 7-
17.  
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2.  For ewor d 
2.1. Inflammation  
Inflammation is a complex localised biological response to cellular injury or tissue destruction 
caused by detrimental stimuli and provides a vital, immediate protective response to promote tissue 
healing. The classic cardinal signs of inflammation include redness, warmth, oedema, pain and loss 
of tissue function (57). These signs are attributed to several mechanisms that arise during the injury: 
(a) vasodilatation to increase the blood supply to the injured site, (b) increased vascular 
permeability to direct the entrance of the diffusible components to the affected area, (c) cellular 
infiltration by chemotaxis or migration of the inflammatory cells to the damaged area, (d) activation 
of immune and enzymatic systems, and (e) tissue acidification (58, 59). Inflammation is beneficial 
in providing protection and limiting further tissue damage by restoring the tissue structure to its 
normal physiological function. However, the injured tissue may also be predisposed to the 
exaggeration of inflammatory response due to the imbalance release of pro- and anti-inflammatory 
mediators, causing exacerbation of inflammation (60).  
 
2.2. Inflammatory pain 
Inflammatory pain is an integral part of various painful conditions including soft tissue injuries, 
post-operative pain and chronic arthritis. It is further characterised by increased sensitivity to 
mechanical or heat stimuli of the affected tissue. In response to injury, the resident immune cells 
(e.g. tissue macrophages and dendritic cells) generate an inflammatory response by releasing a 
variety of pro-inflammatory mediators such as cytokines, chemokines, nerve growth factor, 
prostaglandins and adenosine triphosphate (ATP). Other inflammatory mediators involved are the 
circulating bradykinins and hydrogen ions from cell destruction (61). These mediators, referred to 
as ‘inflammatory soup’, eventually recruit more leukocytes (neutrophils and mast cells) that will 
further amplify the local inflammatory changes at the inflamed site (62). Direct activation of the 
inflammatory mediators and tissue acidification on the nociceptors have been shown to trigger the 
release of pro-algesic neurotransmitters such as CGRP and substance P in the ‘inflammatory soup’. 
Such activation helps to increase the sensation of pain and cause hyperalgesia (63). To counteract 
pain, endogenous analgesic mediators such as opioid peptides, somatostatin, endocannabinoids and 
anti-inflammatory cytokines are thus, secreted simultaneously within the inflamed tissue. Hitherto, 
immune-derived opioid peptides are the most extensively studied and established as clinical 
relevance in peripheral inflammatory pain control (64, 65).  
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2.3. Interaction between immune cells and nociceptors 
Innate immunity refers to first line, non-specific defence mechanisms to protect the host from 
invading organisms or foreign particles. It comprises of three components; the mechanical barriers, 
including skin and mucosae; secreted products or complements such as C-reactive protein and 
lysozyme as well as cellular components (mast cells, monocytes and macrophages, neutrophils and 
the complement system) (66, 67). These immune cells are recruited to the site of injury to release 
soluble factors that interact directly with the nociceptors, leading to peripheral sensitisation (68).  
 
2.3.1. Mast cells  
Mast cells are resident immune cells located in connective tissue associated with blood vessels and 
close to primary nociceptive neurons. The mast cells therefore, play an important role in innate 
immunity and during allergic reactions. These cells are loaded with secretory granules that contain 
inflammatory substances such as histamine and bradykinin, released immediately upon an 
inflammatory reaction, resulting in vascular permeability, vasodilatation in local blood vessel 
followed by recruitment of other immune cells (67). Interaction between mast cells and peripheral 
sensory neurons is a prerequisite for the degranulation process which is mediated by calcium-
dependent cell adhesion molecule, N-cadherin, expressed by both mast cells and primary sensory 
neurons (69). The release of inflammatory mediators from mast cells contributes towards mast cell-
induced nociceptors activation in cystitis pain (70), irritable bowel syndrome (71) and also triggers 
a rapid onset of nerve growth factor-induced thermal hyperalgesia (72).  
 
2.3.2. Monocytes and macrophages  
Monocytes which migrate into the inflamed tissues, differentiate into macrophages, undergo 
maturation and proliferation as a preparation for phagocytosis. Previous studies showed that the 
number of macrophages increased significantly in parallel with the development of mechanical 
allodynia due to stimulation by several inflammatory cytokines (e.g. TNF-α), secreted by the 
Schwann cells at the nerve damage area (73). The increase in TNF-α triggers the matrix 
metallopeptidase-9 (MMP-9) to degrade the extracellular matrix to allow migration of additional 
macrophages into the inflamed area. Besides that, another group of researchers also demonstrated 
that IL-1β activates nociceptors and directly generate action potentials, inducing pain 
hypersensitivity at the site of the inflamed tissue (74). Hence, these findings confirmed that the 
macrophages possess an important role during peripheral sensitisation on the nociceptors. 
Supporting this, depletion of macrophages have been associated with reduction of axonal 
degeneration and hyperalgesia following nerve injury (75).  
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2.3.3. Neutrophils 
Neutrophils, the most abundant blood leukocytes are primarily generated in the bone marrow and 
released into the blood circulation. These cells contains cytoplasmic granules and secretory vesicles 
consisting of microbial effector molecules such as bactericidal proteins and cytokines, proteinases 
and reactive oxygen species. Neutrophils are not observed in normal nerves but are found 
abundantly at the site of injury in injured peripheral nerves (76). During a tissue injury, activated 
mast cells secrete inflammatory mediators, which eventually promote the transmigration of 
neutrophils from the blood vessels into the inflamed tissue through the vascular endothelium (77). 
In addition to this, the propagation of impulse from the primary afferent neurons through 
neighbouring nociceptors nerve endings during neurogenic inflammation leads to the release of 
vasoactive neuropeptides substance P and CGRP at the peripheral nerve endings (78). Other 
researchers also demonstrated that IL-1β can bind onto the nerve terminals and induce substance P 
release followed by transendothelial migration of neutrophils to the injury site (79). In previous 
works, neutral endopeptidase (NEP) knockout mice displayed a higher pain intensity and worsening 
of neurogenic inflammation due to uncontrolled release of substance P and CGRP. It has been 
known that NEP plays an important role in controlling neurogenic inflammation (80). Taken 
together, the recruitment of the neutrophils facilitates the sensitisation of the peripheral nociceptors 
at the site of injury, however, a balanced release of these hyperalgesic molecules should be 
outweighed to avoid further tissue damage. 
 
2.4. Intracellular signals in inflammation 
During tissue injury and cellular stress, the innate immune system is activated upon recognition of 
exogenous pathogen-associated molecular patterns (PAMPs), consisting of microbial components 
e.g. bacterial carbohydrates, nucleic acids and bacterial peptides by the pattern-recognition 
receptors (PRRs) such as Toll-like receptors (TLRs). In addition, the TLRs also identify the 
endogenous ligands of the danger-associated molecular patterns (DAMPs) e.g. heat shock proteins 
and uric acid which are released from necrotic cells due to inflammatory response in many 
pathological processes (81). The PRRs are abundantly expressed in both neuronal and non-neuronal 
cells including the immune cells (e.g. monocytes, macrophages, dendritic cells and other immune-
related cells such as keratinocytes) (82, 83). Other types of PRRs include RIG-like helicases 
(RLHs), C-type lectins (CTLs) and the recently discovered, Nod-like receptors (NLRs) (84). The 
nociceptors on the primary sensory neurons also express TLRs (e.g. TLR4 and TLR7) in order to 
sense both PAMPs and DAMPs and involve directly in the process of inflammatory pain (85). 
11 
 
Recognition of PAMPs and DAMPs by these PRRs subsequently leads to formation of the 
inflammasomes (86, 87). 
 
2.4.1. Activation of inflammasomes  
Inflammasomes are newly-identified multiprotein complexes in the cytoplasm of immune cells 
(Figure 2.1). In addition to its important role as sensor of cellular signals produced during tissue 
injury and death (84), inflammasomes also regulate organ homeostasis (88). There are four 
individual inflammasomes namely NLRP-1, NLRC4/NALP4, AIM2 and the most extensively 
studied is, the NLRP3 (89). Each of these inflammasomes consists of a sensor NLR molecule, 
which is the adapter protein known as apoptosis-associated speck-like protein containing CARD 
(ASC) and the inflammatory protease caspase-1 enzyme (90). The latest findings from experimental 
models of inflammatory and fibrotic liver disease on expression analysis of inflammasomes showed 
that there is a possibility of co-expression of multiple inflammasomes within the same cell type in 
the inflamed tissue, indicating the requirement of co-factors for inflammasome activation (86). 
 
Formation of inflammasomes is initiated upon recognition of PAMPs and DAMPs by nucleotide-
binding oligomerisation domain-like receptor (NLR) family of proteins followed by activation of 
caspase-1, leading to proteolytic cleavage of IL-1β and interleukin-18 (IL-18) precursor molecules 
to release IL-1β and IL-18, respectively (90, 91). The transcription of pro-IL-1β is induced upon the 
activation of inflammatory signalling pathways such as NF-κB and mitogen-activated protein 
kinase (MAPK) (92). The caspase 1-mediated activation of IL-1β cytokine family ultimately leads 
to recruitment and activation of immune cells such as neutrophils and platelets at the site of tissue 
injury/infection (91). The active caspase-1 could also cause a rapid, pro-inflammatory form of cell 
death known as pyroptosis (86). An excessive caspase 1-mediated release of pro-inflammatory 
cytokines and pyroptosis due to uncontrolled activation of inflammasomes could further exacerbate 
the tissue damage or worsen the infection in the host; therefore, a fine balance between the 
activation and inhibition of inflammation is necessary to guard the cytosolic sanctity (87). 
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Figure 2.1 Inflammasomes activation and signalling pathways. Upon activation by PAMPs or 
DAMPs, NLRs oligomerise to form multiple protein complexes for the recruitment, cleavage and 
activation of inflammatory caspases. This oligomerisation activates caspase-1, resulting in the 
maturation and release of IL-1β and IL-18, and in some cases, an inflammatory form of cell death 
known as pyroptosis. Image courtesy of R&D Systems, Inc., Minneapolis, MN, USA.  
 
2.4.2. Nuclear factor-kappaB (NF-κB) transcription factor  
NF-κB plays a crucial role in regulating the transcription of pro-inflammatory genes including 
cytokines, chemokines and adhesion molecules in the pathogenesis of chronic inflammatory 
diseases such as rheumatoid arthritis, inflammatory bowel disease, asthma and chronic obstructive 
pulmonary disease (93). NF-κB transcription factor comprises five related subunits namely p50, 
p52, p65 (also known as RelA), c-Rel and RelB. These subunits share a common dimerisation 
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domain called REL homology domain (RHD) and form various homo- or heterodimers proteins 
including NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB in mammals and 
capable to activate their own characteristic set of genes (44). Under cell resting condition, the NF-
κB complexes are conserved in the latent form in the cytoplasm by binding to the inhibitory IκB 
proteins (94). As shown in Figure 2.2., the canonical signalling pathway is triggered by a variety of 
NF-κB activating stimuli such as pro-inflammatory cytokines (e.g. TNF-α), LPS, growth factors 
and antigen receptors, leading to the activation of IKK complex. Also known as IκB kinase, IKK 
complex comprises two kinases (IKKα and IKKβ) and a regulatory subunit, NEMO/IKKγ. 
Subsequently, the activated IKK complex phosphorylates IκB protein, resulting in ubiquitination 
and proteasomal degradation to release active NF-κB complexes in the cytoplasm. These complexes 
are then translocated into the nucleus followed by transcription of the specific target genes such as 
IL-1β and TNF-α (95, 96).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Canonical NF-κB signalling pathway. Under resting conditions, NF-κB dimers are 
bound to IκB proteins. Ligand binding to a receptor (e.g. TLR4 activation by LPS)  leads to the 
recruitment and activation of an IKK complex. The IKK complex subsequently phosphorylates IκB 
leading to ubiquitination and proteasomal degradation, releasing and translocating the bound NF-κB 
dimers to the nucleus to activate the target genes (e.g. pro-inflammatory cytokines). Figure adapted 
from Gilmore (97).  
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2.4.3. Interleukin-1beta (IL-1β) 
IL-1β is a potent pro-inflammatory cytokine that is important as a central mediator of inflammatory 
response during innate immunity and mediates various cellular activities including cell 
proliferation, differentiation and apoptosis (98). Apart from its beneficial roles in initiating and 
amplifying a variety of effects associated with tissue injury and host responses to microbial 
invasions, overproduction of this cytokine produces detrimental effects by promoting tumour 
invasiveness (99) and exacerbating the tissue damage in the pathogenesis of chronic inflammatory 
diseases (100). A variety of diseases have been linked to the excessive production of IL-1β. 
Elevation of IL-1β levels are observed in microbes infection (e.g. virus, bacteria, fungi and 
parasites), reflecting the degree of disease severity. Other inflammatory-related diseases such as 
atherosclerosis, type 2 diabetes, autoimmune and neurodegenerative disorders have also been 
characterised by the augmented IL-1β production (100-102). Blockade of IL-1β production with 
synthetic IL-1β receptor has been demonstrated to alleviate the severity of acute pancreatitis, 
juvenile arthritis and selected autoinflammatory disorders such as osteoarthritis (103, 104). 
 
2.4.3.1. Synthesis of IL-1β 
The production and release of IL-1β involves multiple steps i.e. (i) production of the active pro-IL-
1β, (ii) cleavage of pro-IL-1β by caspase-1 and (iii) secretion of mature and active IL-1β into the 
extracellular milieu (100). Under cell resting conditions, none of IL-1β messenger ribonucleic acid 
(mRNA) or IL-1β protein are constitutively expressed in the monocytic lineage cells such as blood 
monocytes, tissue macrophages and dendritic cells, which are the primary sources of IL-1β 
production. In fact, stimulation of TLRs by PAMPs or DAMPs is a prerequisite for the expression 
of IL-1β in these cells (105). Upon TLR activation, IL-1β mRNA is transcribed and translated into 
an inactive precursor protein, pro-IL-1β, followed by a subsequent transcription and translation of 
IL-1β production via NF-κB pathway (106). In addition to TLR activation, the processing and 
production of IL-1β from pro-IL-1β is also dependent on the auto-proteolytic maturation by the 
activated caspase-1 (91).  
 
2.4.3.2. Secretion of IL-1β 
There are two distinct secretory pathways of protein secretion: the classical and non-classical 
pathways. The classical secretory pathway involves protein translocation across the endoplasmic 
reticulum membrane followed by transportation to the plasma membrane directly by Golgi 
apparatus or via secretory granules. On the other hand, the non-classical pathway, which is 
independent of endoplasmic reticulum and Golgi apparatus, mediates the release of protein 
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molecules that lacks conventional hydrophobic signal sequence, known as leaderless protein. The 
different models of non-classical secretory pathway mediate the secretion of leaderless cytokine IL-
1β including: (i) via exocytosis of secretory lysosomes, (ii) by shedding of plasma membrane 
microvesicles, (iii) via exocytosis of exosomes, (iv) by plasma membrane transporters or (v) cell 
lysis (107). Several factors that trigger IL-1β-containing cells lysis are the release of the 
cytoplasmic enzyme lactate dehydrogenase (108), loss of membrane integrity due to prolonged 
exposure to ATP or antimicrobial peptide (109) and formation of membrane pores following 
caspase-1 activation (110). Therefore, the aspects which influence the secretion of IL-1β include the 
cell type, species, source and concentration of PAMPs and DAMPs, duration of stimulation as well 
as cell microenvironments (e.g. temperature, pH, redox balance, osmolarity, culture conditions and 
time in culture) (111). 
 
2.4.4. Tumour necrosis factor-alpha (TNF-α)  
TNF-α plays a crucial role in cell proliferation, survival, differentiation and apoptosis. This 
cytokine also exerts a pleiotropic role in mediating multiple immune-mediated processes including 
mitogenesis, cytolysis and, recruitment of neutrophils and lymphocytes to the site of inflammation 
(112). It also mediates the orchestration of other cytokines, particularly IL-1β and IL-6 during the 
development of inflammatory hyperalgesia and in the generation of central and peripheral 
neuropathic pain (113). Overproduction of TNF-α, however, has been associated with the 
pathogenesis of diverse diseases such as rheumatoid arthritis, obesity, psoriasis, Crohn’s disease 
and sepsis. Increasing evidence has described that modulation of TNF-α is therapeutically beneficial 
in alleviating the worsening conditions of these diseases (114). Several anti-TNF-a therapies such as 
etanercept and infliximab have been shown to be effective in treating rheumatoid arthritis and 
ulcerative colitis, respectively (115, 116).   
 
2.4.4.1. Synthesis of TNF-α 
TNF-α belongs to tumour necrosis factor/tumour necrosis factor receptor (TNF/TNFR) super 
family. The mRNA of TNF-α is mainly expressed in monocytes and tissue macrophages. A wide 
range of factors are involved in the induction of TNF-α synthesis including viruses, bacterial and 
parasitic products, tumour cells, complement, cytokines, ischemia, trauma and irradiation (117). 
The expression of TNF-α gene is regulated at the transcriptional level, involving NF-κB and nuclear 
factor-activated T cells (NFAT) factors, followed by translation into membrane TNF-α (mTNFα). 
Eventually, mTNFα undergoes proteolytic cleavage by TNFα-converting enzyme, releasing soluble 
TNF-α (sTNFα) (114). Previous studies have demonstrated that mTNFα regulates biological 
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responses at autocrine/paracrine levels whereas sTNFα mediates this process at endocrine level 
(118).  
 
2.4.4.2. TNF-α signal transduction 
There are two TNF-α transmembrane receptors, namely, TNF receptor 1 (TNFR1) and TNF 
receptor 2 (TNFR2). While TNFR1 is expressed abundantly in mammalian tissues, TNFR2 is 
constitutively expressed in immune cells (114). Both receptors function independently, albeit they 
may cross-talk to each other via different signalling pathways induced by TNFR1 and TNFR2 
(119). TNF-α is known to regulate multiple signalling pathways at cellular level including MAPKs 
and NF-κB transcription, leading to the expression of target genes such as proteases, chemokines 
and cytokines (117, 120). Majority of the TNF-α-induced cellular responses are predominantly due 
to the activation of TNFR1 which include cytotoxity, NF-κB transcription, and up-regulation of 
adhesion and cytokine genes (114). On the other hand, TNFR2 is responsible for proliferation of 
lymphoid cells and, in some type of cells, activation of TNFR2 plays a key role for NF-κB 
activation and cell death (121, 122). A previous study using a knock-out TNFR2 mice has 
demonstrated a normal T cell development in these mice, as a result of the inhibition of TNF-
mediated tissue necrosis (123). Taken together, TNFR1 and TNFR2 exhibit different roles in TNF-α 
signal transduction and gene expression, depending on the cell types (114).  
 
2.5. Pain modulatory mechanisms 
Modulation of pain is mediated through the descending pain modulatory pathway. It is believed 
that, upon processing in the somatosensory cortex, the noxious inputs are transmitted to the 
midbrain periaqueductal grey matter (PAG) and subsequently to the rostral ventromedial medulla 
(RVM) that contains nucleus raphe magnus (NRM). Then, the neurons in RVM are projected to the 
spinal or medullary dorsal horns, responsible for pain modulation (124). Pain inhibition is mediated 
by either one of these two mechanisms; via stimulation-produced analgesia (SPA) or opiate-
mediated analgesia (OA). Established studies have shown that the intracranial electrical stimulation 
especially at PAG and NRM leads to profound analgesia. An electrical stimulation of PAG results 
in the release of endogenous enkephalins in response to painful stimuli that eventually produces 
opiate analgesia (125). It is the stimulation of NRM which induces serotonin release in the spinal 
cord and involves in the descending pain inhibition pathway (126). 
 
Endogenous mechanisms of pain control are not limited within CNS but also involve peripheral 
mechanisms shown by the interaction between the immune cells and the sensory nerve terminals 
17 
 
(58). The immune cells play a prominent role in releasing endogenous analgesic mediators 
including the opioid peptides (127), somatostatin (128) and endocannabinoids (129) within the 
peripheral inflamed tissue to modulate pain signals in the nociceptive pathway. Among these, 
endogenous opioid system is the best-characterised anti-nociceptive agent that has been studied 
extensively and is clinically relevant in post-operative pain in humans and animal models (61). 
 
2.6. Endogenous opioid systems in pain modulation 
There is an interplay between the central and peripheral mechanisms of the endogenous opioid 
system in modulating pain associated with inflammation. Evidence from the literature demonstrates 
that activation of opioid receptors not only occurs in the CNS but also on the peripheral sensory 
neurons (8, 14-18, 20-23, 25, 26). Furthermore, the role of endogenous opioid peptides as anti-
nociceptive agents in the CNS has long been known (130). In the CNS, the opioid-induced anti-
nociception is triggered in PAG, NRM and substantia gelatinosa of the spinal cord upon stressful 
stimuli without the involvement of any tissue injury such as foot shock, restraint and cold water 
swimming. These components in the central mechanism are heavily innervated with opioidergic 
neurons and contain opioid receptors (125, 131). The peripheral mechanism of opioid analgesia on 
the other hand, involves bidirectional communication between the neuroendocrine and immune 
systems and are associated with tissue injury (132). During an acute stage of inflammation, both 
central and peripheral mechanisms are involved in the intrinsic pain inhibition with a significant 
role played by the central opioid receptors. The anti-nociception at the later stages of inflammation, 
however, is exclusively mediated by the immune-derived opioid peptides acting at the peripheral 
opioid receptors. Apart from this, immune cells have also been identified as an important peripheral 
source of opioid peptides at both stages of inflammation (133). 
 
2.6.1. Immune-derived opioid peptides  
2.6.1.1. Synthesis and distribution of opioid peptides in leukocytes 
Immune cells have been identified as the major source of endogenous opioid peptides production in 
the periphery. Other peripheral loci of opioid peptides production include the adrenals, pituitary and 
primary afferent neurons (127, 134, 135). For instance, a full-length of pro-opiomelanocortin 
(POMC) transcripts encoding POMC genes which contain the essential sequence for the peptide 
signalling are found in rat mononuclear leukocytes (22, 136). Deletion of genes coding for pro-
enkephalin (PENK) in the brain and immunocytes results in down-regulation of Met-ENK release, 
suggesting that ENK is synthesised from the same precursor protein molecule in both nervous and 
immune systems (137). In addition, the production of peripheral opioid peptides involves both 
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circulatory and resident inflammatory cells such as T- and B-lymphocytes, granulocytes (during 
early inflammation) and monocytes/macrophages (during late inflammation) (16, 18, 138-141). 
Interestingly, opioid peptides are highly expressed in activated/memory cells. This is demonstrated 
by β-END production in the activated or memory T-lymphocytes in comparison to naïve cells 
within the inflamed tissue (24, 142). Furthermore, endopeptidase enzymes including 
carboxypeptidase E and pro-neuropeptide-converting (PC) enzymes (PC2 and PC3) that are 
necessary for the post-translational processing of the opioid precursor molecules, are also found in 
immune cells (143). Other observations, however, demonstrated the absence of opioid peptide 
production in non-inflamed paws (133), thus, eluding to the importance of the immune cells as a 
source for opioid peptides in the periphery. 
 
2.6.1.2. Migration of opioid-containing leukocytes to inflamed tissue 
Opioid-containing leukocytes are recruited from the circulation into the inflamed tissue via 
leukocyte extravasation which involves specific adhesive and chemotactic mechanisms (127) as 
shown in Figure 2.3. Firstly, the circulating leukocytes tether and roll along the endothelial cell wall 
and this process is mediated via interaction of selectins with their respective ligands expressed on 
the leukocytes (L-selectin) and on the endothelial cells (P- and E-selectin). Then, intercellular 
adhesion molecule-1 (ICAM-1) mediates the adhesion process between leukocytes and the 
endothelial cells, followed by the transmigration of the leukocytes through the endothelial cell wall. 
This latter process is further mediated by platelet-endothelial cell adhesion molecule-1 (PECAM-1). 
Ultimately, the opioid-containing leukocytes migrate into the inflamed tissue. Following this, the 
opioid-containing leukocytes are then activated by the chemokines released from both the 
inflammatory and endothelial cells (144).  
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Figure 2.3 Migration of opioid-containing leukocytes to inflamed tissue. The opioid-containing 
leukocytes are initially tethered along the inflamed endothelium vessel wall by L- and P-selectins, 
followed by extravasation of the leukocytes mediated by ICAM-1 and PECAM-1 into inflamed 
tissue. OP, opioid peptides; CRHR, corticotropin-releasing hormone receptor; IL-1R, interleukin-1 
receptor; EO, exogenous opioids. Reprinted by permission from Macmillan Publishers Ltd: [Nature 
Medicine] (144), copyright 2003.  
 
Previous studies demonstrated that during endogenous control of inflammatory pain, the integrins 
α4 and the chemokines (e.g. C-X-C motif chemokine ligand 1 [CXCL1] and C-X-C motif 
chemokine ligand 2 [CXCL2]) are produced by the leukocytes, shown by the elevated mRNA and 
protein levels under inflammatory conditions (145). In addition to this, the adhesion molecules such 
as P- and E-selectins, ICAM-1 and PECAM-1 are also found to be up-regulated within the inflamed 
paw tissues (145, 146). Mousa et al. showed that L-selectin is constitutively co-expressed by 
opioid-containing leukocytes that reside in lymph nodes and on cells that have migrated into the 
inflamed subcutaneous paw tissues (147). The importance of adhesion molecules during the 
migration of immune-derived opioid peptides to the injured tissue is confirmed by the significant 
reduction in the number of β-END-containing leukocytes infiltrating the inflamed tissues after pre-
treatment of fucoidin, an anti-selectin, in rats (146). The recruitment of opioid-producing leukocytes 
to inflamed tissue is also governed by neurokinins (i.e. substance P). Inhibition of neurokinin-1 
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(NK1) receptors, however, has been shown to block this process, causing impairment to the opioid-
mediated anti-nociception in the periphery (148). 
 
2.6.1.3. Release of opioid peptides from leukocytes 
Opioid peptides are released into the inflamed tissue upon stimulation of local inflammatory factors 
such as CRF and IL-1β (142). The CRF is usually found in immune cells, fibroblasts and vascular 
endothelium and its expression is further enhanced under inflammatory conditions, resulting in the 
release of opioid peptides from the secretory granules via exocytosis (149, 150). Likar et al. 
recently demonstrated a significant involvement of intra-articular injection of CRF in releasing 
opioid peptides followed by induction of a transient naloxone-sensitive analgesic effect (151). 
Further observation also showed that both IL-1β and CRF receptors are expressed on immune cells, 
but not on peripheral sensory nerve endings in inflamed tissue (152). In fact, the release of opioid 
peptides from the secretory vesicles is regulated in a receptor-selective and calcium-dependent 
manner (19, 28). Such release of opioid peptides within peripheral inflamed tissue is also dependent 
on the activation of adrenergic receptors by noradrenaline due to the abundance expression of α1- 
and β2-receptors on β-END-producing immunocytes located in close proximity postganglionic 
sympathetic neurons in inflamed tissue (153). 
 
2.6.2. Peripheral opioid receptors 
Varied studies described the expression of opioid receptors on the primary afferent nociceptors, 
suggesting the presence of peripheral opioid receptors. These receptors are initially synthesised in 
cell bodies of dorsal root ganglion (DRG) neurons and transported axonally towards the sensory 
nerve terminals of inflamed tissue and exert analgesic activity in both animals and humans (24, 
154). Earlier binding studies showed similar characteristics of peripheral opioid receptors with 
those expressed in the dorsal horn of the spinal cord and brain (135, 154). Supporting this 
phenomena, a western blot analysis of the rat sciatic nerve that consists mainly of primary afferent 
neurons, also reported the identical molecular mass between peripheral and central MOR (24).  
 
Opioid receptors are the prototypical ‘‘Gi/Go-coupled’’ receptors that utilise Gi subfamily members 
for signal transduction, upon receptor activation by the opioid peptides (155). One of the 
intracellular mechanisms of opioid-induced analgesia is the inhibition of high-voltage activated 
calcium currents, thereby, hindering the release of pain neurotransmitters at the presynaptic 
terminals of DRG neurons (156, 157). Earlier studies also portrayed that activation of opioid 
receptors led to membrane hyperpolarisation due to the elevation of potassium currents within the 
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CNS, resulting in decreased excitability of neurons to transmit the pain signal (158, 159). This 
inhibition occurs in both calcium-dependent (160, 161) and concentration-dependent manner in the 
DRG neurons (162). Another intracellular mechanism of opioid-induced anti-nociception is through 
inhibition of sodium currents and subsequent inhibition of adenylyl cyclase pathway downstream 
on sensory neurons (163, 164). Taken together, activation of opioid receptors by opioid peptides 
results in the inhibition of pain transmission. This inhibition is regulated through the 
electrophysiological changes at the ion channels on peripheral sensory neurons, in which 
modulation of Ca2+ currents has been identified as the principal mechanism to attenuate the 
excitability of the peripheral nociception (161). 
 
2.6.3. Opioid-induced peripheral analgesia 
Accumulating evidence in the literature corroborated the notion of opioid receptors localisation on 
the primary sensory neurons in mediating peripheral analgesia (127, 135, 142). Under inflammatory 
conditions, the number of peripheral opioid receptors synthesised and expressed in DRG is greatly 
enhanced, thereby increasing the efficacy of opioid-induced peripheral analgesia (165). Supporting 
this notion, a significant up-regulation of MOR expression on small-diameter DRG neurons is 
detected in the ipsilateral DRG of the inflamed rodent hind paw on day 4 post-injection of complete 
Freund’s adjuvant (CFA) (24). Another study also reported the similar increment of opioid 
receptors following carrageenan-induced peripheral inflammation (166). Furthermore, in vivo 
treatment with capsaicin, a neurotoxin that selectively acts on primary afferent C-fibre in DRG, 
results in termination of peripheral analgesia mediated by opioid receptors (32). It was depicted 
previously that the expression of immune-derived opioid receptors is functionally coupled to signal 
transduction mechanism and eventually these receptors are transported in fibres of the sciatic nerve 
towards the peripheral sensory nerve terminals (167). 
 
Another underlying mechanism of peripheral analgesia is the enhancement of axonal transport of 
opioid receptors induced by IL-1β release in the inflamed tissue, therefore enabling the accessibility 
of opioid receptors on the sensory neurons (154, 166). Studies showed that inflammation enhances 
axonal and site-directed transport of opioid receptors in the sciatic nerve, leading to increased 
density in peripheral nerve terminals. The up-regulation of these receptors, however, is abolished 
following ligation of the sciatic nerve, further supporting the transport notion (24, 154). The 
permeability of perineural barrier is also increased due to the sprouting of sensory nerve terminals 
under inflammatory microenvironment, thus facilitating the access of opioid ligands to opioid 
receptors on primary afferent neurons (168). Furthermore, the release of protons in inflamed tissue, 
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resulting in lower pH values in the inflamed site is associated with the increased efficacy of opioid 
agonist due to decreased inactivation of G-proteins in neuronal membranes in vitro as demonstrated 
previously (169). This is in line with the latter finding, showing that acidic environment contributes 
towards the increased in opioid efficacy at the injured site (170). 
 
In addition to peripheral opioid receptors, immune-derived opioid peptides also play an important in 
in mediating peripheral analgesia. An abundance of opioid peptides are found residing in the 
immunocytes, indicating that they are produced in the circulating immune cells and migrated to 
subcutaneous inflamed tissue. For instance, previous studies revealed that a significant amount of β-
END, DYN 1-17 and met-ENK in the immunocytes are released into the inflamed area upon 
activation by local inflammatory factors and stress-induced catecholamine (27, 30, 142). However, 
the opioid peptides, are absent in the non-inflamed tissue (171, 172). Ligation of endogenous opioid 
ligands to opioid receptors on peripheral sensory nerve terminals eventually inhibit inflammatory 
pain (144). Opioid peptides are largely predisposed to enzymatic degradation, hence, a recent 
finding suggested that a blockade of leukocytic and neuronal opioid peptidase in the peripheral 
inflamed tissue may be useful in optimising peripheral opioid analgesia (39). 
 
2.6.4. Opioid-induced immunosuppression 
The degree of pain associated with disease or injury is intensified especially among the 
immunocompromised individuals, particularly in those with acquired immunodeficiency syndrome 
(AIDS) or cancer patients. This happens because of the reduction in CD4+ cell numbers, which 
consequently leads to polyneuropathic pain (173). Extensive studies revealed that opioid-induced 
immunosuppression is mediated by direct interaction between opioids and their receptors on the 
immune cells or within the CNS (174). The exacerbation of pain in the inflamed tissue of animal 
models’ immunosuppression, is significantly increased as demonstrated in cyclosporine A-induced 
immunosuppression (175) and whole-body X-irradiation in rats with hind paw inflammation (171). 
Moreover, reduction in lymphocyte counts following cyclosporine A-induced immunosuppression 
is found to contribute towards the loss of IL-1β-, CRF- and stress-induced analgesia in rats (28). 
 
2.6.5. Clinical implications of peripherally-acting opioid peptides 
The classic alkaloid opiates such as morphine and fentanyl are used primarily for pain relief. These 
compounds demonstrate their ability to alter the neurotransmission pathway by reducing pain 
impulse transmission upon binding with opioid receptors in the CNS (176). In addition to their 
remarkable pain-relieving properties, narcotic opioid compounds are also reported to produce a 
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number of unwarranted adverse effects such as nausea, convulsions, constipation, respiratory 
depression, sedation, paradoxical hyperalgesia, tolerance and addiction to the host. This is the result 
of the wide distribution of opioids and their receptors both centrally and peripherally (177, 178). 
This has led to the growing number of studies aiming to discover the potential potent synthetic 
opioid analgesics with reduced side effects. However, a large number of synthetic opioids that have 
been introduced in the clinical area share the liabilities of classical opioids, meaning the side effects 
are still unavoidable (179). Other common local pain relief compounds are the cyclooxygenase 
(COX) inhibitors (e.g. acetylsalicylic acid, ibuprofen, diclofenac, naproxen), that inhibit final 
common pathway of most pro-algesic mediators. COX inhibitor, however, is frequently associated 
with adverse side effects such as gastrointestinal ulcer formation, bleeding or thromboembolic 
events (180). 
 
Ample evidence demonstrated the clinical relevance of peripherally-mediated opioid analgesia due 
to the presence of opioid receptors on peripheral terminals of sensory nerves (127, 135, 142). This 
led to the development of potent opioid agonists with high peripheral selectivity, which without 
crossing the blood-brain barrier, alleviates the central adverse effects (133). Previous clinical 
studies also detected opioid receptors residing in human synovial tissue that are involved in pain 
control (152). These receptors are activated upon interaction with opioid agonists (e.g. morphine), 
which attenuate pain transmission in patients who suffer from chronic rheumatoid and 
osteoarthritis, bone pain, post-dental surgery laparoscopic, urinary bladder and knee surgery (78, 
151, 181, 182). Intra-articular administration of morphine, a MOR agonist, is associated with 
reduced pain scores and decreased supplemental analgesic consumptions without any remarkable 
adverse effects (183). Furthermore, it is equally potent, comparable to the intra-articular local 
anaesthetics and steroid in producing analgesia during acute (post-operative) and chronic (arthritic) 
pain in dose-dependent manner with additional prolonged effects that could be due to its anti-
inflammatory activity (184). Previous studies by Stein et al. demonstrated that intra-articular 
blockade of opioid receptors with naloxone in patients undergoing knee surgery result in significant 
intensity in pain and proposed the involvement of opioid-mediated peripheral mechanism to control 
the pain (172, 185). Thus, continuous intra-articular administration of morphine provides analgesia 
in patients regardless of enhanced inflammation and secretion of endogenous opioid peptides within 
synovial tissue, indicating that the immune-derived opioids counteract the development of tolerance 
at peripheral opioid receptors, unlike those commonly observed in the CNS (185). 
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There are several remarkable advantages of targeting peripheral mechanism of endogenous opioid 
peptides such as reduction in tolerance, receptor down-regulation and desensitisation. Therefore, the 
exacerbation of inflammatory pain could be limited, besides avoiding the unwanted central side 
effects (39). Peripherally-acting endogenous opioids, hence, has a beneficial potential for prolonged 
treatment of inflammatory pain with reduced opioid tolerance incidence (78). In summary, targeting 
peripherally-restricted opioid agonist at the site of painful tissue injury provides new insights into 
intrinsic mechanism of pain control and ultimately avoids the typical detrimental systemic side 
effects of currently available opioid and non-opioid analgesics and anti-inflammatory drugs (3). 
 
2.7. Dynorphin 1-17 (DYN 1-17) 
DYN is one of the endogenous opioid peptides family that is the first to be isolated from porcine 
pituitary (186, 187) and gut (188). This peptide comprises 13 amino acids sequence and contains 
Leu-enk (Tyr-Gly-Gly-Phe-Leu) at the amino-terminal (N-terminal) of the peptide chain (189, 190). 
The name dynorphin is originally derived from a Greek word, dynamis which means ‘power’ 
because of its significant potency in inhibiting muscle contractions upon electrical conduction in 
guinea pig ileum preparation in comparison with Leu-enk and β-END (189). Further investigation 
by Goldstein and his colleagues successfully characterised the complete sequence of biologically 
active dynorphin, consisting of 17 amino acids, also known as DYN 1-17, through the addition of 
four amino acids (Trp-Asp-Asn-Gln) at the carboxy-terminal (C-terminal) (Figure 2.4). However, 
this addition, is insignificant towards the potency of DYN 1-17 (191). 
 
 
 
 
 
 
 
Figure 2.4 Molecular structure of DYN 1-17. Figure redrawn from Goldstein et al. (191). 
 
Another large polypeptide chain, consisting of 32 amino acids, known as DYN AB 1-32 or ‘big 
dynorphin’, links the DYN 1-17 at the N-terminus and a novel tridecapeptide at the C-terminus with 
a pair of basic amino acids (Lys-Arg). The 13-amino acid at the C-terminus is identified as DYN B 
whereas the previously described 17-amino acid is also known as DYN A (192). A bioactive 
octapeptide related to DYN 1-17 is isolated by Minamino et al. from porcine hypothalamus and 
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identified as DYN 1-8 (193). The other dynorphin-related peptides isolated are alpha-neo-endorphin 
(α-NE) and beta-neo-endorphin (β-NE). α-NE is a 10-residue peptide that has the first six amino 
acids sequence similar to DYN 1-17 and DYN B (194, 195). β-NE on the other hand, has a similar 
amino acid sequence as compared to α-NE with the exception that it lacks of amino acid lysine at 
the position 10 (196). The summary of dynorphin-related peptides is shown in Table 1.  
 
Table 2.1 Dynorphin-related neuropeptides 
Peptide Amino acid sequence 
DYN A 1-8 Tyr1-Gly-Gly-Phe-Leu-Arg-Arg-Ile8 
DYN A 1-13 Tyr1-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys13 
DYN A 1-17 
Tyr1-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-
Gln17 
DYN AB 1-32 
Tyr1-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-
Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr32 
DYN B 1-13 Tyr1-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr13 
α-NE Tyr1-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys10 
β-NE Tyr1-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro9 
 
2.7.1. Processing and distribution of DYN 1-17 
A variety of DYN-like peptides is derived from a commonly large biologically inactive precursor 
PDYN protein upon multiple enzymatic cleavages (197). PDYN genes are found in rat, mouse, 
porcine and human at both mRNA and protein levels (198-200). The expression of this prohormone 
is identified both in the CNS (i.e. striatum, hypothalamus, hippocampus, cerebral cortex and 
pituitary) and also in the periphery tissues (i.e. adrenal, gut and testis) (197). The endoproteolysis of 
PDYN is mediated by PC1 and PC2 hormones, and also carboxypeptisase E (201). PC1, firstly 
targets at the Lys-Arg pair N-terminal to α-neo-endorphin, yielding a 10kDa C-terminal fragments, 
containing all known PDYN-derived peptides. Thereafter, an 8 kDa intermediate peptide chain is 
produced upon cleavage at a single Arg by removing the 2 kDa carboxyterminal fragment. 
Subsequent to this, PC2 and carboxypeptidase E synergistically catalyse the trimming action and 
eventually produce biologically active peptides including α-NE, DYN 1-17, DYN 1-8, DYN 1-13 
and DYN 1-32 (202, 203). (Figure 2.5). DYN is found to localise abundantly in the hypothalamus, 
posterior pituitary lobe, and spinal ganglia (204). DYN is also found in the peripheral tissues 
including gastrointestinal tract, adrenals, sex glands, placenta, and in immune system cells (205). 
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Figure 2.5 Major post-translational products of prodynorphin. PDYN is enzymatically 
cleavage into multiple bioactive peptide fragments including α-NE, DYN 1-32, leumorphin, DYN 
A 1-17, DYN B 1-13 and DYN 1-8. Figure adapted from Day et al. (203). 
 
Previous studies showed that the production of DYN 1-17 within inflammatory cells, in the sensory 
nerves within the inflamed tissue of the rats (30). The release of this peptide from the lymphocytes 
are thought to be in a calcium-dependent manner as demonstrated by Cabot (142). Interestingly, 
PC2 hormone that is involved in the post-translational process of DYN has also been found in rat 
neutrophils and macrophages (206). Further in vitro study has successfully detected PDYN mRNA 
expression in human macrophages (U-937 cells) under basal conditions by using standard reverse 
transcription polymerase chain reaction (RT-PCR). The majority of the PDYN genes expressed by 
these cells are similar to the adult brain-type. The activation of these cells with LPS has resulted in 
down-regulation of PDYN mRNA expression due to the inhibition of PDYN gene transcription 
(207). 
 
2.7.2. Kappa-opioid receptor (KOR) 
DYN 1-17 prefentially binds to KOR with a lesser binding selectivity at MOR and DOR (208). A 
previous study on structural analysis of the DYN sequence revealed that C-terminal domain 
comprising arginine-7, arginine-11 and lysine-13 residues exert a strong kappa selectivity (209). 
KOR, expressed abundantly within the CNS, are responsible for regulating emotion, motivation and 
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cognitive function (210). The expression of KOR is also observed in the periphery, for instance on 
immune cells such as T cells, macrophages and microglia (211). In an earlier study, the nucleotide 
sequence of KOR expressed on R1.1 thymoma cells, is reported to resemble 99.8 % sequence 
homology with the murine brain KOR (212). KOR is previously shown to mediate the inhibition of 
T-cell mediated antibody production in macrophages and T cells (213). In addition to this, KOR is 
also involved in the down-regulation of HIV-1 virus expression in human microglial cells. This is 
demonstrated by the reversed inhibitory effect of DYN 1-17, DYN 1-13 and U50,488H in these 
cells upon antagonism of the treatments with a selective KOR antagonist, nor-Binaltorphimine (nor-
BNI) (214). Gavériaux et al. has also demonstrated a significant expression of KOR transcripts in 
human peripheral blood lymphocytes and monocytes, thus, highlighting the involvement of KOR in 
the modulation of immune response (215). 
 
KOR belongs to the GPCRs, the family of seven transmembrane receptors that are coupled to G-
protein. Activation of KOR by dynorphin triggers the activation of Gα subunit, and the dissociation 
of Gβγ subunits from the heterotrimetric GPCR complex. Interaction of Gβγ subunits with various 
effectors eventually lead to various signalling cascades such as cAMP inhibition (216), reduction of 
Ca2+ conductance (217) and mobilisation of intracellular calcium (218). Furthermore, agonist-
induced stimulation of KOR has also been shown to result in the induction of MAPKs signalling 
pathway which is important in regulating numerous biological responses including neuronal 
differentiation and immune response (219). 
 
2.7.3. Biotransformation of DYN 1-17 
Similar to other endogenous opioids, DYN 1-17 is susceptible to rapid enzymatic degradation, 
yielding a unique array of fragments, depending on the site at which it is biotransformed (40). For 
instance, there are some common and distinct fragments produced upon biotransformation of DYN 
1-17 in the rat and human blood in comparison to the rhesus monkey blood (220-223). 
Biotransformation of DYN 1-17 is also dependent on the degree of disease severity. This is evident 
by the differential range of fragments produced in rodent model of Parkinson’s disease vs. control 
group (224). Recent findings showed that biotransformation of DYN 1-17 in inflamed rat paw 
tissues produces a variety of opioid and non-opioid fragments. The majority of DYN 1-17 
fragments were produced in acidic pH, which resembles the naturally occurring inflammatory 
environment (40). The factors contributing to this biotransformation could be the enzymes from the 
inflamed tissue such as metalloproteinase and aminopeptidase (225, 226) and also the acidic 
environment which are likely to cause changes to the degradative enzymes activity (40). 
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2.7.4. The immunomodulation of DYN 1-17 and its derivatives 
Previous studies denoted a significant up-regulation of opioid receptors simultaneously with the 
abundant release of endogenous opioids in the inflamed tissue, indicating that activation of the 
immune system directly influences the opioid-mediated peripheral analgesia (30, 142). Despite the 
overwhelming findings on the peripheral analgesic effects of DYN 1-17, a substantial of evidence 
has described the immunomodulation of DYN 1-17 and its derivatives during inflammatory 
response in vitro and in vivo. DYN 1-17 fragments elicit a variety of immunopharmacological 
functions, from inactivating the parent compound to a changed behaviour at the opioid and non-
opioid receptors (40). Supporting this, the N-terminal fragments of DYN 1-17 retain their 
opioidergic activity by increasing or decreasing the efficacy and potency, depending on the 
fragment’s cleavage point (209). Upon binding to KOR on immune cells, DYN 1-17 and the related 
fragments showed negative regulation of multiple immune responses including the antigen-induced 
proliferation of T cells (227), antibody production by B cells (228), phagocytosis (229) and also 
cytokine production by the macrophages (230, 231). Conversely, DYN 1-17 was reported to also 
promote the tumouricidal activity of macrophages (232, 233) and enhance the release of pro-
inflammatory cytokines IL-1β and TNF-α in glial cells (234). Other immune responses mediated by 
DYN 1-17 include chemotaxis of human mononuclear cells (235), increment of superoxide 
production in polymorphonuclear leukocytes and macrophages (236), and zymosan-induced 
oxidative burst in macrophage cell line (237). In relation to this, a number of in vivo studies 
discovered potent anti-inflammatory activity of KOR agonists in the periphery in the early and the 
later phases of post carrageenan-induced inflammation in the hind paw of the rats (238, 239). This 
is supported by a previous finding, which showed an anti-inflammatory action of asimadoline, a 
peripherally selective KOR agonist in the treatment of adjuvant arthritis. Upon blockade of KOR 
with naloxone methiodide and MR2266 (a selective KOR antagonist), the peripheral anti-arthritic 
effects of asimadoline are fully reversed, causing exacerbation of CFA-induced inflammation in the 
rats paw (240).  
 
DYN 1-17 and its derivatives are also functionally active at the non-opioid sites such as NMDA, 
bradykinin and melanocortin receptors (241-243) in mediating inflammatory responses. The 
involvement of the N-terminal and C-terminal fragments of DYN 1-17 showed that it promotes 
peritoneal macrophage phagocytosis via a non-opioid mechanism (41). Others revealed that 
treatment of DYN 1-17 in murine macrophage cell line J774 induced with LPS plus interferon-
gamma (IFN-γ) significantly diminishes the nitric oxide release and cytotoxic ability of the 
macrophages. None of these effects, however, could be blocked by nor-BNI, thus, suggesting the 
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involvement of a non-opioid-mediated mechanism (244). The intermediate fragment of DYN 6-12, 
consisting of Arg-Arg-Ile-Arg-Pro-Lys-Leu amino acid sequence is postulated as a significant 
analog in mediating the non-opioid anti-inflammatory actions of DYN 2-17 during thermal oedema 
(43). DYN 1-13, on the other hand, induces histamine release from rat mast cells which appears to 
be mediated through an anaphylactic histamine release mechanism (245). Taken together, these 
findings highlight the involvement of DYN 1-17 and its related peptides in the regulatory control of 
both cellular and humoral immune responses. 
 
2.8. Inflammatory signalling in opioid-induced analgesia 
There is a close association between the opioidergic and immune system, involving both GPCR and 
non-GPCR sites in mediating a variety of opioid immunomodulatory effects centrally and 
peripherally (246). An increasing number of studies revealed the involvement of non-opioid 
mechanisms via activation of TLR4 in mediating opioid-induced analgesia (54, 247, 248). During 
tissue injury or infection, TLR4 is activated upon specific recognition of exogenous (e.g. Gram-
negative bacterial endotoxin LPS) or endogenous ligands (heat-shock proteins, inflammatory 
mediators), inducing transcription of NF-κB protein followed by downstream release of 
inflammatory cytokines such as IL-1β and TNF-α (249). A recent finding indicated the role of 
TLR4 as a regulator of peripheral endogenous opioid-mediated analgesia in inflammation. In this 
study, β-END is released from monocytes in a calcium-dependent manner via activation of TLR4, 
therefore, suggesting the involvement of endogenous opioids in TLR4 signalling pathway to resolve 
inflammation (56). In addition to this, previous studies also linked the involvement of NF-κB in 
opioid-mediated immunological functions, suggesting the NF-κB signalling pathway as one of the 
possible mechanisms that entails the immunomodulatory effects of opioids during inflammatory 
pain (250). Investigation by Börner & Kraus further demonstrated the association between NF-κB 
and morphine in T cells, postulating that the NFAT-mediated up-regulation of ubiquitin specific 
peptidase 15 (USP15), by opioids, is the key mechanism of NF-κB inhibition in T cells. (251).  
 
IL-1β is also involved in attenuating nociception in inflamed tissue via peripheral mechanisms. In a 
study by Schäfer et al., IL-1β and CRF synergistically triggered in vitro and in vivo release of β-
END opioid peptides through activation of MOR and DOR on immune cells (28). LPS-induced IL-
1β is also shown to stimulate the release of DYN 1-17 from the macrophages and lymphocytes 
within inflamed tissue, leading to localised analgesia (30, 142). Further administration of anti-DYN 
results in the inhibition of IL-1β-induced analgesia, suggesting that this action is mediated by IL-1β 
receptors (28). IL-1β signalling pathway is also involved during dynorphin-induced allodynia. In a 
30 
 
central model of neuropathic pain, the administration of anti-inflammatory cytokine IL-10 and the 
antagonist of IL-1 receptor significantly impeded the development of allodynia by interfering the 
central pro-inflammatory cascade, thus, suggesting the involvement of cytokine in dynorphin-
induced allodynia (252). It has also been demonstrated previously that the analgesic effects of 
morphine are enhanced with fewer side effects and tolerance development following blockade of 
IL-1 receptor, resulting in inhibition of IL-1β and TNF-α release (253).  
 
2.9. Chronic rhinosinusitis (CRS)  
CRS is defined by persistent mucosal inflammation of the nasal cavities and paranasal sinuses and 
is manifested by at least two symptoms. These symptoms are nasal obstruction, nasal discharge, 
facial pain or olfactory dysfunction which last for a minimum of 12 weeks (254). There are two 
subtypes of CRS: without nasal polyps (CRSsNP) and with nasal polyps (CRSwNP). This 
classification is based on the examination of the nose either by direct inspection, endoscopic 
assessment, or computerised tomography imaging (255). Sinonasal fibrosis, basement membrane 
thickening, epithelial damage, mononuclear cell infiltration and goblet cell hyperplasia are the 
accompanying features of CRSsNP (256). CRSwNP, on the other hand, is characterised by 
pseudocyst formation, epithelial injury, stromal oedema and basement membrane thickening (257). 
The common predisposing factors in the aetiology of CRS are allergy, anatomical obstructions and 
variations, nasal polyps, immune deficiencies, bacteria, viruses and fungi (258). These factors are 
likely to drive T helper (Th) cells responses and induce NF-κB activation, contributing to the 
pathogenesis of CRS.  
 
The activated CD4+ Th cells are subdivided into Th1, Th2 and Th17 subsets based on production of 
signature cytokines that possess different roles during immune response (259). IL-2 and IFN-γ, 
produced by Th1 cells target on macrophages and involved in cellular immunity. Th2 cells, on the 
other hand, predominantly produce IL-4, IL-5 and IL-13, and these cytokines are important in the 
humoral immune responses, mast cell proliferation and eosinophil production (259, 260). Th17 cells 
plays a major role in promoting inflammation by producing IL-17 and IL-22 to recruit neutrophils 
and monocytes to the inflamed site (259). A previous study has shown significant levels of 
inflammatory cytokines in sinonasal secretions of patients with acute rhinosinusitis, CRSsNP and 
CRSwNP, produced from Th cell subsets. These cytokines include TNF-α, IL-1β, IL-5, IL-8, IL-13, 
M-CSF and IL-3 (261). NF-κB activation also has a central role in CRS. Takeno et al. previously 
demonstrated a significant relationship between the degree of NF-κB activation and the levels of IL-
8, IL-16 and eotaxin mRNA expression in the epithelium of nasal polyps (262). In addition, this 
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pathway is also involved in the up-regulation of COX-2 expression in CRS (263). The above-
mentioned findings, therefore, highlights the importance of cytokines and NF-κB activation in CRS.  
 
Current available treatments for CRS are saline lavages, corticosteroids, antibiotics, anti-allergy 
agents and surgery (258). However, these treatments are accompanied with various side effects. For 
instance, although corticosteroids are widely used in the treatment of CRS due to its potent anti-
inflammatory properties, prolonged systemic administration of this treatment is associated with 
Cushing’s syndrome, steroid-induced diabetes, gastric ulcers and gastrointestinal bleeding (264). 
Extensive investigations are ongoing currently, searching for potentially active compounds to treat 
CRS.  
 
2.10. Summary 
DYN 1-17 is an endogenous heptadecapeptide that is produced by immune cells upon the activation 
of immune system during inflammatory response. It selectively binds to KOR, and this peptide may 
also interact with MOR and DOR (208). In comparison with other endogenous opioid peptides, the 
kappa-opioid peptide particularly DYN 1-17, can be more advantageous in controlling the 
inflammatory response and limiting the centrally mediated dependence liability (265), respiratory 
depression and constipation (266). Therefore, this would be beneficial in treating chronic 
inflammation that requires longer duration of treatment. In addition to the involvement of DYN 1-
17 in mediating peripheral analgesia (27), a recent finding discovered the production of smaller 
fragments of DYN 1-17, comprising N-terminal, intermediate and C-terminals fragments, resulting 
from biotransformation of DYN 1-17 in inflamed rat tissue homogenates. The resultant fragments 
possess opioid and non-opioid characteristics (40). Although the immunomodulation of several 
fragments have been previously shown, the underlying cellular signalling mechanisms mediating 
these effects remain unclear. These overall findings give an idea that DYN 1-17 may possess an 
immunomodulatory role during inflammation in addition to its remarkable peripheral analgesic 
effects (27, 30). 
 
Substantial evidence also described the peripheral mechanism of KOR agonists in mediating 
inflammation (238-240). KOR agonists have been proven previously as a powerful anti-
inflammatory therapy in a dose-dependent, time-dependent, stereo-selective and antagonist 
reversible manner during development of arthritis. The ligation of these agonists to KOR at 
peripheral level significantly attenuated the disease severity (240, 267). This is consistent with a 
notion that peripherally active opioids can negatively regulate the release of pro-inflammatory 
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neuropeptides and cytokines, plasma extravasation, vasodilation, expression of adhesion molecules, 
hence avoiding tissue destruction (37). 
 
The limited findings on the possible immunomodulatory mechanisms of endogenous opioids during 
inflammatory pain, therefore, urged the needs to further investigate the immunomodulatory 
functions of DYN 1-17 and its fragments in modulating major inflammatory signals such as NF-κB 
and the pro-inflammatory cytokines. This finding can undoubtedly provide a more complete 
understanding of the complex control of DYN 1-17 and its biotransformation fragments during an 
inflammatory response and eventually on the fundamental knowledge of peripheral mechanism of 
endogenous opioid peptides. 
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●    Chapter Three    ● 
Effects of DYN 1-17 and its biotransformation 
fragments on LPS-induced NF-κB/p65 nuclear 
translocation in differentiated THP-1 cells
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3.  Chapt er  3 
3.1. Foreword 
The mechanisms and pathways mediating inflammation are transcriptionally regulated, establishing 
an association between the transcriptional mediator, NF-κB and inflammatory pain. NF-κB 
activation is a central pathway during inflammation; thereby modulation of NF-κB translocation by 
opioid peptides contributes to opioid-mediated immune responses. The work being presented in this 
chapter examines the effects of DYN 1-17 and its biotransformed fragments on the LPS-induced 
NF-κB/p65 translocation in differentiated THP-1 cells. Furthermore, the involvement of KOR in the 
mediation of NF-κB/p65 nuclear translocation is also elucidated.  
 
3.2. Introduction 
Overwhelming evidence is pointing at the central role that NF-κB family of transcription factors 
plays in inflammation and innate immunity (44, 93, 268, 269). This transcription protein is 
described as a ‘smoke sensor’ or a ‘switch’ that ‘turns on’ inflammatory process in response to a 
variety of endogenous and exogenous stimuli and has been implicated in various disease 
pathologies (270). Activation of NF-κB provides a positive autoregulatory loop that maintains 
immune responses towards infection or foreign stimuli (271). For instance, NF-κB activation of the 
innate immune system triggers the release of pro-inflammatory cytokines. This eventually promotes 
infiltration and migration of adaptive immune cells at the inflammatory site to produce pain signals 
(58). This activation is demonstrated either through stimulation or inhibition of cytoplasmic NF-κB 
protein translocation into the nucleus. In cases of an excessive inflammatory response, such as 
autoimmune diseases and cancer, these diseases are often linked to pathological dysregulation of 
NF-κB (272), thereby supporting that NF-κB nuclear translocation is a critical signal leading to 
transcriptional activation of specific host defence target genes in response to extracellular stimuli 
(273). 
 
Opioids modulate physiological and pathophysiological effects of inflammatory pain (250) and 
other chronic inflammatory-related diseases via the NF-κB signalling pathway (274, 275). The 
MOR agonist, morphine, has been reported to have differential modulation on LPS-induced 
activation of NF-κB, and the resulting gene expression of TNF-α and IL-6 cytokines in 
macrophages, in a concentration-dependent manner (276). Conversely, morphine was found to 
inhibit TNF-triggered NF-κB translocation in primary human T cells and Jurkat T cells. This 
apparent discrepancy might arise from the MOR being coupled to different second messenger 
systems in different cell types, causing cell type-specific effects of morphine (251, 277). 
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Irrespective of the outcome, these findings, suggest an association between opioids and the NF-κB 
pathway in modulating the severity of inflammatory disorders. 
 
A variety of approaches for the quantification of NF-κB nuclear translocation which requires prior 
subcellular fractionation in cells or tissues have been established. For instance, electromobility gel-
shift assay (EMSA) measures the nuclear translocation of NF-κB protein semi-quantitatively upon 
incubation of nuclear extracts with 32P-labelled oligonucleotides of NF-κB binding sites followed 
by an electrophoretic separation on a non-denaturing polyacrylamide gel. This method involves 
labour-intensive protocol and large scale cell culture (278). Another technique is the enzyme linked 
immunosorbent assay (ELISA) of NF-κB, which is largely influenced by the quality of the antibody 
and is an expensive option for large sample analysis, albeit the assay’s quantitativeness and 
reproducibility (279). The conventional microscopic visualisation of NF-κB translocation is not 
quantitative and this technique is often limited to its poor standardisation, high variability and 
specialist training requirement (280).  Flow cytometric analysis of phospho-protein-specific staining 
on the other hand, only measures the degree of NF-κB phosphorylation without determining the 
intracellular translocation of NF-κB (281). Recent advances in cell imaging enable quantification of 
NF-κB protein transport from the cytoplasm to nucleus using a high content imaging method that 
involves automated fluorescent microscopy and computer-assisted image analysis (273, 282). This 
novel approach allows the observation of the sub-cellular spatial distribution of the target proteins 
and the effects of target perturbation on cellular processes. Furthermore, it enables the measurement 
of various cellular spatial measurements such as translocation or redistribution, receptor 
internalisation and cell signalling on a small scale at single-cell level (282).  
 
The measurement of NF-κB nuclear translocation is based on the identification of the cell nuclei 
stained with nucleic acid probe reporters such as 4',6-diamidino-2-phenylindole (DAPI) and the 
immunolabelling of NF-κB in the nucleus and/or cytoplasm and their visualisation using image 
analysis algorithms. The commonly used outputs of image analysis algorithm to detect NF-κB 
translocation are (i) NF-κB intensity in the nucleus (Nuc) and (ii) NF-κB intensity in the cytoplasm 
(Cyt). The translocation value is calculated by measuring the average intensity ‘difference’ of the 
immunolabelled NF-κB protein in the cytoplasmic and nuclear regions separately, known as Cyt-
Nuc Difference. In addition, a calculation based on the ‘ratio’ of the average intensity of the nuclear 
region to the average intensity of the cytoplasmic region, the Nuc/Cyt Ratio, is also applicable in 
determining the translocation value (273). A simple diagrammatic view illustrating the basic 
principles of NF-κB translocation is shown in Figure 3.1.  
36 
 
 
 
 
 
 
 
 
 
Figure 3.1 Diagrammatic view of NF-κB nuclear translocation in macrophages. NF-κB 
(green), normally resides in the cytoplasm. Translocation of NF-κB into the nucleus occurs upon 
stimulation by the respective stimuli. Figure redrawn from Trask (273). 
 
In this chapter, monocytic THP-1 cells were differentiated into macrophages by phorbol 12-
myristate 13-acetate (PMA) and employed as an in vitro model of inflammation. The 
immunomodulatory effects of DYN 1-17 and its major biotransformation fragments on LPS-
induced NF-κB/p65 nuclear translocation were visualised and quantified using a high-content 
imaging approach. 
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3.3. Materials and methods 
3.3.1. Materials 
DYN 1-17 and a range of biotransformation fragments (DYN 1-6, DYN 1-7, DYN 1-9, DYN 1-10, 
DYN 2-17, DYN 7-17, DYN 3-14 and DYN 6-12), with purity greater that 95 % for all peptides 
were supplied by Mimotopes Pty. Ltd. Australia. Details of all other materials and chemicals 
(including catalogue number and supplier) are listed alphabetically in Appendix I and mentioned in 
the text. 
 
3.3.2. THP-1 cell culture  
The human monocytic cell line, THP-1 (ATCC No TIB-202) cells were generous gifts from Assoc. 
Prof Marie-Odile Parat (School of Pharmacy, The University of Queensland, Australia). These cells 
were grown in suspension for up to 30 passages in culture medium containing RPMI 1640 
supplemented with 10 % foetal bovine serum (FBS), 100 units/mL penicillin and 100 µg/ml 
streptomycin in a humidified atmosphere of 5 % CO2 at 37 °C. Cells were sub-cultured in a ratio of 
1:10 every 3-4 days, when the cell confluency reached approximately 80-90 % (283, 284). 
 
3.3.2.1. Cell differentiation  
The confluent cells were centrifuged at 300 x g for 2 min and the supernatant was discarded 
followed by cell pellet re-suspension in pre-warmed culture medium. Next, the viable cell count 
was measured using a haemocytometer and indicated by trypan blue exclusion stain. Cells were 
then seeded into 96-well black microplates at a desired density depending on the experimental 
design and 50 nM of PMA was added to induce the differentiation of THP-1 cells for 48 h at 37 °C 
under 5 % CO2 in the incubator. Stimulation with PMA has been shown to induce the 
differentiation of THP-1 cells into functional macrophages (285).  
 
3.3.2.2. Cell cryopreservation and recovery  
A THP-1 cell suspension was cryopreserved for long-term storage using the following protocol: 
Upon attaining 80-90 % confluency, the cell suspension was centrifuged at 200 x g for 6 min and 
the supernatant discarded. The cell pellet was then resuspended in cryopreservation medium 
(composition: see Appendix 2, section 2.6), containing dimethyl sulfoxide (DMSO), the 
cryoprotective agent. Aliquots of cell suspension (1 mL each) were stored in cryogenic storage 
vials, individually wrapped with cotton wool and kept in a -80 °C freezer for at least 24 h. These 
vials were then transferred to liquid nitrogen for long term storage or maintained at -80 °C (up to 6 
months).  For cryopreserved cell recovery, the cryovial was thawed by gentle agitation in a 37 °C 
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water bath until 80 % defrosted. The contents of the vial were then pipetted into a centrifuge tube 
containing pre-warmed culture medium followed by centrifugation at 300 x g for 2 min to remove 
DMSO. The cell pellets were resuspended in an appropriate amount of culture medium before being 
transferred into culture flask and incubated at 37 °C and 5 % CO2.  
 
3.3.3. Evaluation of PMA-induced differentiation of THP-1 cells  
3.3.3.1. Morphological examination 
THP-1 cells were grown at a density of 1.5 x 105 cells/mL in 75 cm2 culture flask at 37 °C under 5 
% CO2 and the differentiation was induced following addition of 50 nM PMA for 24 and 48 h. Cells 
without PMA induction served as control. The changes in cell morphology were observed at 10× 
magnification and the images were acquired using a Leica DFC 295 digital microscope colour 
camera (Leica Microsystems Pty Ltd, NSW, Australia).  
 
3.3.3.2. Expression of CD11b marker  
THP-1 cells were cultured at a density of 1 x 105 cells/mL (150 µL/well) and differentiated as 
described in section 3.3.2 and section 3.3.2.1. For fluorescent immunocytochemistry assay, the 
differentiated cells were fixed with freshly prepared, cold 3.7 % formaldehyde (30 µL/well) for 15 
min at room temperature before being incubated with 50 µL/well of blocking buffer (composition: 
see Appendix 2, section 2.3) for an hour at room temperature. This is to allow cell permeabilisation 
and to block non-specific protein-protein interactions. Following aspiration of blocking buffer, 30 
µL of primary anti-CD11b antibody (0.386 mg/mL), diluted at 1:150 in antibody dilution buffer 
(composition: see Appendix 2, section 2.1) was dispensed into each well. The microplate was then 
wrapped with aluminium foil, placed in a humidified chamber and incubated overnight at 4 °C. 
Next, the cells were incubated with 30 µL/well of secondary Alexa Fluor® 555 goat anti-rabbit IgG 
(H+L) polyclonal antibody (2 mg/mL, diluted at 1:500 in antibody dilution buffer), for 2 h at room 
temperature followed by DAPI staining at 2 µg/mL (30 µL/well) for 10 min at room temperature 
under subdued laboratory lighting for nucleic acid detection. Cells were washed with 50 µL/well of 
phosphate buffered saline (PBS) in triplicate between the incubations. Finally, 50 µL of PBS was 
added into each well and the microplates were stored in the dark at 4 °C overnight. Cells were then 
visualised using Nikon Eclipse Ti inverted fluorescent microscope through a 20× objective lens 
equipped with a 12-bit Coolsnap HQ2 CCD camera (Photometrics, AZ, USA) and the captured 
images were processed using NIS Elements (version 3.13) imaging software (Nikon, NY, USA). 
Specificity of the CD11b antibody was previously demonstrated (286, 287) and confirmed here 
through lack of non-specific binding (see Appendix 3, section 3.1).  
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3.3.4. Assessment of THP-1 cell viability  
The viability of THP-1 cells following treatment with DYN 1-17 and biotransformation fragments 
was determined by a microculture tetrazolium assay (MTT) as described previously (288, 289) and 
as outlined below. THP-1 cell differentiation was performed as detailed in section 3.3.2.1. Next, 
PMA-induced THP-1 cells were seeded in 24-well plates (5 x 105 cells/well) and cultured in 1 mL 
of culture medium containing DYN 1-17 and selected fragments at two concentrations (10 nM and 
1 μM) for 24 h at 37 °C under 5 % CO2. Cells incubated with culture medium alone served as 
positive control for this assay. Pre-warmed MTT reagent, thiazolyl blue tetrazolium bromide was 
then added to the cell cultures (220 μL/well) to reach a final concentration of 2.5 mg/mL and 
incubated for an additional 2 h at 37 °C. The dark crystals formed were dissolved by adding DMSO 
(1200 μL) into each well at 37 °C. The plates were wrapped with aluminium foil to avoid light 
exposure. Subsequently, the plate was incubated with gentle continuous agitation for 20 min on an 
orbital shaker (Ratek Instruments, VIC, Australia). Aliquots of 100 μL from each well were then 
transferred in duplicate into 96-well transparent microplates. Wells containing DMSO alone in 
equal volume were used as blanks. The optical density of the intracellular formazan, proportional to 
the number of viable cells present, was measured using a microplate reader (Bio-Rad Laboratories, 
CA, USA) at 590 nm. The average viable cell value after blank absorbance subtraction was 
calculated as a fraction of the average value obtained from cells incubated with medium alone. 
 
3.3.5. Assessment of NF-κB/p65 translocation assay through high-content imaging 
system 
3.3.5.1. Image acquisition 
Cells were seeded in 96-well black microplates at a density of 1.5 x 105cells (150 μL/well) and 
induced by PMA (50 nM) for 48 h as described in section 3.3.2.1. This is followed by a 24-h 
incubation in PMA-free culture medium (150 μL/well). After differentiation into macrophages, the 
cells were serum-starved in pre-warmed 2 % FBS-containing RPMI 1640 medium (150 µL/well) 
for 15 h before the medium was discarded. LPS (1 μg/mL, as previously optimised) was used to 
stimulate the differentiated THP-1 cells whilst non-stimulated cells only received culture medium in 
equal volume, to serve as negative control. To assess the functionality of the NF-κB/p65 
translocation assay performed, a synthetic selective NF-κB inhibitor, N-(3, 5-bis-trifluoromethyl-
phenyl)-5-chloro-2-hydroxy-benzamide or IMD-0354 at 10 µM was used to treat both LPS- and 
non-stimulated cells for an hour in a constant environment of 5 % CO2 at 37 °C. A corresponding 
DMSO concentration (0.1 % v/v) was similarly prepared as a diluent control for IMD-0354. At this 
concentration, DMSO did not affect the NF-κB nuclear translocation induced by LPS (see 
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Appendix 3, section 3.2) The nuclear translocation of the p65 subunit of NF-κB in the treated cells 
were examined using a fluorescence immunolabelling method as detailed in section 3.3.3.2, using 
primary anti-NF-κB/p65 rabbit monoclonal antibody (0.0365 mg/mL) at a dilution of 1:400 (as 
previously optimised). Images were acquired using the widefield ImageXpress® Micro XLS 
automated high-content imaging system (Molecular Devices, CA, USA). Four fields of view (2000 
pixel × 2000 pixel each) were captured from each well with a 10× Plan Fluor (NA 0.3) objective.  
 
3.3.5.2. Image analysis 
To quantify NF-κB/p65 nuclear translocation, the acquired images were analysed using a 
customised Translocation-Enhanced application module built in the MetaXpress® version 6.1 image 
analysis software (Molecular Devices, CA, USA). In brief, this module first identified and 
segmented the nuclear area for each cell using the DAPI stain (DAPI channel image). Based on this 
segmentation, it will create a cytoplasmic ring region for the NF-κB/p65 signal (FITC channel 
image). The translocation of the NF-κB/65 was expressed as ratio of nuclear to cytoplasmic 
intensity. Nuclear translocation was quantified by calculating the correlation coefficient of the 
overlap spatial fluorescence intensity between the cytoplasmic and nuclear compartments. Cells 
with an overlap coefficient above a threshold set at 0.7 (as previously configured) were scored 
positive for NF-κB/p65 translocation by the algorithm. Well-level translocation data was exported 
into an Excel spreadsheet and reported as a percentage of cells in the well (% Classified Positive). 
After analysis was completed, the numerical data in each well was compared in parallel with the 
acquired images for quality control of the algorithm performance. The average nuclear translocation 
percentage from each well for the entire treatment groups was then calculated manually as follows: 
 
 
 
 
3.3.6. Assessment of LPS-induced NF-κB/p65 translocation in differentiated THP-1 
cells 
To examine higher quality images for the purpose of visualisation and confirmation of subcellular 
translocation of NF-κB/p65 in THP-1 cells, similar method described in section 3.3.5 was 
performed with a slight modification, special 96-well optical polystyrene black microplates with 
clear bottom were used. The immunolabelled cells were observed through Nikon Eclipse Ti 
inverted fluorescent microscope equipped with a motorised stage with a 63× objective (oil 
immersion, EC Plan, NA 1.25 objective, Carl Zeiss Pty Ltd, NSW, Australia) and a 12-bit Coolsnap 
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HQ2 cooled CCD camera (Photometrics, AZ, USA). The data were captured as digital images and 
processed using the NIS Elements (version 3.13) imaging software (Nikon, NY, USA).  
 
3.3.7. Treatment of THP-1 cells with DYN 1-17 and biotransformation fragments 
Approximately 22,500 THP-1 cells were seeded into each well of 96-well imaging microplates, 
differentiated and stimulated with LPS, as previously described section 3.3.5. In the presence of 
DYN 1-17 and selected biotransformation fragments at two different concentrations (10 nM and 1 
μM) and a volume of 150 µL/well, the cells were incubated for an hour in a humidified atmosphere 
at 37 °C and 5 % CO2. The test solutions of DYN 1-17 and the fragments were prepared by diluting 
stock solutions in RPMI 1640 supplemented with 10 % FBS. LPS alone and non-stimulated groups 
were prepared as described previously. The KOR activities of DYN 1-17 and other fragments on 
NF-κB/p65 translocation were determined using ML-190, a selective KOR antagonist. The cells 
were pre-treated with ML-190 at 1 μM for an hour followed by co-treatment with DYN 1-17 
fragments (10 nM) and ML-190 (1 μM) for an additional hour at 37 °C under 5 % CO2. Treatment 
with ML-190 (1 μM) alone was also performed separately to confirm that this compound did not 
affect the NF-κB nuclear translocation induced by LPS (see Appendix 3, section 3.3). A 
corresponding DMSO concentration (0.1 % v/v) was similarly prepared as a diluent control for ML-
190. Semi-quantitative measurement of NF-κB/p65 nuclear translocation in each treatment group 
was performed similarly as described in section 3.3.5.1 and section 3.3.5.2.  
 
3.3.8. Assessment of KOR expression in differentiated THP-1 cells  
To determine the expression of KOR in PMA-differentiated THP-1 cells, a method similar to the 
one described in section 3.3.3.2 was used, except that, a commercial mouse KOR monoclonal 
antibody (30 μg/mL, as previously optimised) and secondary Alexa Fluor® 647 goat anti-mouse IgG 
(H+L) polyclonal antibody at a dilution of 1:300 in antibody dilution buffer (as previously 
optimised) were utilised. The images of KOR expression were observed using a Nikon Eclipse Ti 
inverted fluorescent microscope at 20× magnification. The specificity of the monoclonal KOR 
antibody used in the study was verified previously, showing no positive immunolabelling in this 
negative control experiment (see Appendix 3, section 3.5).  
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3.3.9. Statistical analysis 
All experiments were performed in triplicate and the data acquired are presented as mean ± SEM 
(standard error of the mean) from at least three independent experiments. Data calculations and 
comparisons between the groups were analysed with GraphPad Prism software (Version 6.07) using 
one-way ANOVA followed by the Bonferroni post-hoc test. A significant difference between 
groups was defined as p ≤ 0.05.  
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3.4. Results 
3.4.1. PMA induces morphological and phenotypic changes in THP-1 cells 
In order to examine the monocyte-derived macrophage properties of THP-1 cells, PMA (50 nM) 
was used to induce cell differentiation. As shown in Figure 3.2A, there were no morphological 
changes observed in cells in the absence of PMA induction throughout the incubation period. The 
non-induced THP-1 cells remained small and round in shape, grew in suspension form and did not 
adhere to the surface of the culture flask. Exposure to PMA at 24 and 48 h induced morphological 
changes in differentiated cells as shown in Figure 3.2B. The PMA-induced THP-1 cells changed 
from being small and round into more flattened cells, star-shaped or elongated spindle-shaped, 
slightly enlarged in size, and aggregated. They too adhered to the surface of the flask and developed 
the morphological characteristics of macrophage-like phenotypes such as pseudopodia. In 
comparison to 24 h incubation time, these characteristics were more prominently observed after 48 
h, thus the latter was chosen as the optimal PMA induction time throughout this study.  
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Figure 3.2 THP-1 cells differentiation time course. Cells were grown at a density of 1.5 x 105 
cells/mL in 75 cm2 culture flasks. They were induced with 50 nM PMA at 0, 24 and 48 h. The 
non-induced cells (A, top row) remained in spherical shape without any morphological 
changes. The PMA-differentiated cells (B, bottom row) adhered to the flask and formed various 
cell shapes throughout the induction period. The red arrows indicate flattened and elongated 
shapes with pseudopodia formation in differentiated THP-1 cells. Images were acquired using 
Leica DFC 295 digital microscope (10×). Scale bar: 50 µM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
Next, the observed morphological changes associated with maturation of THP-1 monocytic cells 
into macrophages were further verified by looking at the cell surface expression relevant to 
macrophage differentiation. CD11b, a macrophage surface marker, was employed as it has been 
shown to be uniquely expressed on monocyte-derived macrophages following differentiation with 
PMA (286) . Through an indirect immunofluorescence method, no CD11b expression was observed 
on the surface of non-differentiated THP-1 cells (Figure 3.3A, top row). However, exposure to 
PMA (50 nM) significantly induced the expression of CD11b (red) on the surface of differentiated 
THP-1 cells (Figure 3.3B, bottom row), with a direct relation to the morphological changes.  
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Figure 3.3 Expression of CD11b surface markers in differentiated THP-1 cells. THP-1 cells 
with and without PMA induction (50 nM) were fixed and permeabilised followed by an indirect 
immunofluorescence assay. The CD11b expression on (A) non-differentiated (overlay, top row) and 
(B) PMA-differentiated THP-1 cells (overlay, bottom row) was detected using anti-CD11b rabbit 
monoclonal antibody and visualised using Alexa Fluor® 555 goat anti-rabbit IgG antibody (red). 
The nuclei were counterstained with DAPI (blue). The images were acquired using Nikon Eclipse 
Ti inverted fluorescent microscope (10×) with suitable TRITC and DAPI filters. Scale bar: 25 µm. 
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3.4.2. DYN 1-17 and biotransformation fragments have no effect on cell viability in 
PMA-differentiated THP-1 cells 
To determine the effect of DYN 1-17 and biotransformation fragments on THP-1 cell viability, 
differentiated cells were treated with the selected biotransformation fragments at high (1 µM) and 
low (10 nM) concentrations followed by an MTT assay. From Figure 3.4, it is apparent that the 
viability of differentiated THP-1 cells was not affected by the treatment with DYN 1-17, and opioid 
and non-opioid biotransformation fragments at both concentrations (p > 0.05).  
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Figure 3.4 Treatment with DYN 1-17 and its biotransformation fragments do not affect the 
viability of differentiated THP-1 cells. PMA-differentiated THP-1 cells (1.5 x 105 cells/mL) were 
incubated for an hour with DYN 1-17 and a range of biotransformation fragments at 10 nM and 1 
µM concentrations. Cell viabilities following exposure to: (A) DYN 1-17 and N-terminal 
fragments; (B) intermediate and C-terminal fragments were determined using an MTT reduction 
assay and the absorbance was measured at 595 nm. The cell viability percentage in each treatment 
group was normalised and expressed relative to control group. Data are expressed as mean ± SEM 
from three independent experiments performed in triplicate (One-way ANOVA, Bonferroni post-
hoc test). 
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3.4.3. LPS stimulates nuclear translocation of NF-κB/p65 in PMA-differentiated THP-1 
cells 
The LPS-mediated NF-κB/p65 nuclear translocation in THP-1 cell-derived macrophages was 
observed qualitatively upon immunolabelling of the cells with NF-κB/p65 primary antibody and 
detection by Alexa Fluor® 555 goat anti-rabbit IgG using TRITC filter and a 63× oil objective. As 
illustrated in Figure 3.5A, in the absence of LPS, p65 subunit of NF-κB (green) was observed 
predominantly in the cytoplasm of non-stimulated cells (middle, top row). An LPS stimulation 
resulted in a distinct nuclear labelling of NF-κB/p65 in stimulated cells (Figure 3.5B, middle, 
bottom row), reflecting the translocation of cytosolic NF-κB/p65 protein into the nuclei. This result 
confirmed that LPS stimulation results in NF-κB/p65 translocation to the nucleus in PMA-
differentiated THP-1 cells.  
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Figure 3.5 LPS induces NF-κB/p65 nuclear translocation in differentiated THP-1 cells. 
Differentiated THP-1 cells with and without LPS stimulation (1 µg/mL) were fixed and 
permeabilised, followed by an indirect immunofluorescence assay. The NF-κB/p65 nuclear 
localisation was detected with anti-NF-κB/p65 rabbit monoclonal antibody and visualised using 
Alexa Fluor® 555 goat anti-rabbit IgG antibody (green). The nuclei were counterstained with DAPI 
(blue). Microscopy images of (A) inactive NF-κB/p65 protein localisation in the cytoplasm of the 
non-stimulated, differentiated THP-1 cells (overlay, top row) and (B) translocated NF-κB/p65 
proteins into the nuclei of differentiated THP-1 cells following LPS stimulation (overlay, bottom 
row). The images were acquired using Nikon Eclipse Ti inverted fluorescent microscope (63×) with 
suitable FITC and DAPI filters. Scale bars: 10 µm. 
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3.4.4. IMD-0354 inhibits LPS-induced NF-κB/p65 nuclear translocation in PMA-
differentiated THP-1 cells assessed by ImageXpress® analysis 
LPS-stimulated macrophages, derived from the differentiation of THP-1 cells, were further 
incubated with IMD-0354, a potent and selective IκB kinase inhibitor to verify the efficiency of the 
NF-κB/p65 nuclear translocation assay performed. IMD-0354 acts by blocking IκBα 
phosphorylation and thus prevents the induction of NF-κB/p65 nuclear translocation (290). The 
results, as shown in Figure 3.6 revealed that IMD-0354 (10 µM) produced a significant reduction in 
the NF-κB/p65 nuclear translocation compared to the LPS control group (LPS, 100.00 ± 0.49; IMD-
0354, 64.95 ± 1.14; p ≤ 0.05). No significant difference in NF-κB/p65 nuclear translocation were 
observed in non-stimulated macrophages receiving IMD-0354 (no treatment, 13.67 ± 2.33; IMD-
0354, 9.518 ± 1.52; p > 0.05). In addition, DMSO 0.1 % v/v did not affect the NF-κB/p65 nuclear 
translocation in LPS-stimulated THP-1 cells (see Appendix 3, section 3.2).  
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Figure 3.6 IMD-0354 attenuates LPS-induced NF-κB/p65 nuclear translocation in 
differentiated THP-1 cells. Differentiated THP-1 cells (1.5 x 105 cells/mL) were incubated with 
and without LPS (1 µg/mL) for an hour, in the presence of IMD-0354 (10 µM) or DMSO (0.1 % 
v/v, as diluent control). The treated cells were fixed, permeabilised and immunolabelled with 
primary anti-NF-κB/p65 rabbit monoclonal antibody and visualised using Alexa Fluor 555® goat 
anti-rabbit secondary antibody. DAPI staining was used to identify the nuclei. The nuclear 
translocation of NF-κB/p65 in each treatment group was assessed using the ImageXpress® imaging 
system. The percentage of NF-κB/p65 nuclear translocation in each treatment group was normalised 
and expressed relative to the LPS control group. Data are represented as mean ± SEM of at least 
three independent experiments performed in triplicates, *p ≤ 0.05 (One-way ANOVA, Bonferroni 
post-hoc test). 
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3.4.5. DYN 1-17 and its biotransformation fragments inhibit LPS-induced NF-κB/p65 
nuclear translocation in PMA-differentiated THP-1 cells 
 
3.4.5.1. DYN 1-17 and N-terminal fragments (DYN 1-6, DYN 1-7, DYN 1-9, 
DYN 1-10 and DYN 1-11)  
The ability of DYN 1-17 and its N-terminal fragments to inhibit the NF-κB/p65 nuclear 
translocation in differentiated THP-1 macrophages was measured quantitatively using 
ImageXpress® analysis. As shown in Figure 3.7, LPS induced greater than 50 % of the NF-κB/p65 
translocation in differentiated cells in comparison with the non-stimulated cells (LPS, 100.00 ± 
0.60; non-stimulated, 16.77 ± 2.23; p ≤ 0.05). There was a statistically significant attenuation of 
NF-κB/p65 nuclear translocation (between 20-40 %) following incubation of the stimulated cells in 
the presence of DYN 1-17 and the N-terminal fragments (DYN 1-6, 1-9, 1-10 and 1-11), in 
comparison to LPS control group at both high and low concentrations [at 1 μM: LPS, 100.00 ± 
0.60; DYN 1-17, 76.72 ± 2.47; DYN 1-6, 70.24 ± 4.57; DYN 1-9, 70.94 ± 3.55, DYN 1-10, 65.81 ± 
5.48 and DYN 1-11, 71.44 ± 7.74; p ≤ 0.05) and at 10 nM: LPS, 100.00 ± 0.60; DYN 1-6, 72.93 ± 
2.20; DYN 1-9, 67.40 ± 6.82; DYN 1-10, 75.33 ± 2.43 and DYN 1-11, 60.52 ± 8.58; p ≤ 0.05)]. 
The data obtained also highlighted that DYN 1-7 at 10 nM inhibited NF-κB/p65 translocation to the 
greatest extent, with around 44 % inhibition relative to the LPS control group (LPS, 100.00 ± 0.60; 
DYN 1-7, 56.73 ± 7.04; p ≤ 0.05). In contrast, the inhibition of the nuclear translocation by DYN 1-
7 (1 µM) was noted to be not significant (LPS, 100.00 ± 0.60; DYN 1-7, 78.53 ± 7.74; p > 0.05). 
Meanwhile, the effect of U50,488H, a selective KOR agonist on NF-κB/p65 translocation was also 
tested. Incubation of U50,488H (10 nM) in stimulated macrophages significantly reduced NF-
κB/p65 translocation by almost half, relative to the LPS control group (LPS, 100.00 ± 0.60; 
U50,488H, 61.37 ± 5.00; p ≤ 0.05). Minimal inhibition of the nuclear translocation by U50,488H 
was also observed at a high concentration (1 μM) (LPS, 100.00 ± 0.60; U50,488H, 92.16 ± 8.80; p 
> 0.05).  
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Figure 3.7 Modulation of DYN 1-17 and the N-terminal biotransformation fragments on LPS-
induced NF-κB/p65 nuclear translocation in differentiated THP-1 cells. Differentiated THP-1 
cells (1.5 x 105 cells/mL), stimulated with LPS (1 µg/mL) were incubated with DYN 1-17, N-
terminal fragments and U50,488H at 1 μM and 10 nM for an hour. The treated cells were fixed, 
permeabilised and immunolabelled with primary anti-NF-κB/p65 monoclonal antibody and 
visualised using Alexa Fluor 555® goat anti-rabbit secondary antibody. DAPI staining was used to 
identify the nuclei. The nuclear translocation of NF-κB/p65 in each treatment group was assessed 
using the ImageXpress® imaging system. Non-stimulated THP-1 cells (NS) served as the negative 
control for the experiment. The percentage of NF-κB/p65 translocation in each treatment group was 
normalised and expressed relative to LPS-stimulated control group. Data are expressed as mean ± 
SEM of at least three independent experiments in triplicate, *p ≤ 0.05 (One-way ANOVA, 
Bonferroni post-hoc test). 
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3.4.5.2. Intermediate and C-terminal fragments (DYN 3-14, DYN 6-12, DYN 
2- 17 and DYN 7-17) 
The modulatory effects of the intermediate and C-terminal biotransformation fragments of DYN 1-
17 (DYN 3-14, 6-12, 2-17 and 7-17) on NF-κB/p65 nuclear translocation in THP-1 cell-derived 
macrophages following LPS stimulation are shown in Figure 3.8. A significant inhibition of NF-
κB/p65 nuclear translocation was exhibited upon co-incubation of LPS with the respective 
fragments at high and low concentrations [at 1 μM: (LPS, 100.00 ± 0.60; DYN 3-14, 79.25 ± 8.00; 
DYN 6-12, 71.52 ± 4.13; DYN 2-17, 74.43 ± 1.99 and DYN 7-17, 72.98 ± 3.42; p ≤ 0.05) and at 10 
nM: (LPS, 100.00 ± 0.60; DYN 6-12, 71.84 ± 4.71; DYN 2-17, 77.97 ± 1.87 and DYN 7-17, 75.74 
± 2.22; p ≤ 0.05)]. Of these fragments, DYN 3-14 at 10 nM displayed a significant inhibitory effect 
on NF-κB/p65 nuclear translocation (approximately 33 %) compared to LPS alone (LPS, 100.00 ± 
0.60; DYN 3-14, 66.74 ± 5.39; p ≤ 0.05). None of the other peptides showed significant modulation 
of the basal level of NF-κB/p65 nuclear translocation in the absence of LPS stimulation of PMA-
differentiated THP-1 cells (see Appendix 3, section 3.4). 
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Figure 3.8 Modulation of the intermediate and C-terminal fragments of DYN 1-17 on LPS-
induced NF-κB/p65 nuclear translocation in differentiated THP-1 cells. Differentiated THP-1 
cells (1.5 x 105 cells/mL), stimulated with LPS (1 µg/mL) were incubated with the intermediate and 
C-terminal fragments at 1 μM and 10 nM for an hour. The treated cells were fixed, permeabilised 
and immunolabelled with primary anti-NF-κB/p65 monoclonal antibody and visualised using Alexa 
Fluor 555® goat anti-rabbit secondary antibody. DAPI staining was used to identify the nuclei. The 
nuclear translocation of NF-κB/p65 in each treatment group was assessed using the ImageXpress® 
imaging system. Non-stimulated THP-1 cells (NS) served as the negative control for the 
experiment. The NF-κB/p65 translocation percentage in each treatment group was normalised and 
expressed relative to LPS-stimulated control group. Data shown are mean ± SEM of at least three 
independent experiments in triplicate, *p ≤ 0.05 (One-way ANOVA, Bonferroni post-hoc test). 
 
 
 
 
 
 
 
57 
 
3.4.6. The expression of KOR in differentiated THP-1 cells  
DYN 1-17 has been reported to act primarily at the KOR. To assess the presence of this receptor on 
the cell surface of differentiated macrophages with or without LPS stimulation, an extracellular 
KOR targeting monoclonal antibody was used. Shown in Figure 3.9A are the representative 
fluorescent images of LPS-induced THP-1 cell-derived macrophages expressing KOR (red). The 
receptor was clearly distributed throughout the cytoplasm and also on the plasma membrane. The 
observation confirmed that the membrane-bound KOR is endogenously expressed in differentiated 
THP-1 cells with LPS stimulation. A similar expression of KOR was also observed in differentiated 
THP-1 cells without LPS stimulation (Figure 3.9B).  
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Figure 3.9 Representative fluorescent images of differentiated THP-1 cells expressing KOR. 
Differentiated THP-1 cells with (A) LPS (1 µg/mL) and (B) without LPS stimulation were fixed 
and permeabilised, followed by an indirect immunofluorescence assay. The expression of KOR was 
detected with primary KOR mouse monoclonal antibody and visualised using Alexa Fluor 647® 
goat anti-mouse secondary antibody (red). The nuclei were counterstained with DAPI (blue). The 
images were acquired using Nikon Eclipse Ti inverted fluorescent microscope (20×) with suitable 
Cy5 and DAPI filters. Scale bars: 25 µm. 
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3.4.7. The involvement of KOR in mediating the inhibitory effects of DYN 1-17 and its 
biotransformation fragments on LPS-induced NF-κB/p65 nuclear translocation 
in differentiated THP-1 cells  
With regards to DYN 1-17 and U50,488H as KOR agonists and the presence of KOR in LPS-
stimulated THP-1 cells, further investigation was performed to elucidate whether this receptor 
mediated the attenuation of activated NF-κB/p65 translocation into the nucleus by the 
biotransformation fragments of DYN 1-17 and U50,488H (as a positive control). DMSO 0.1 % v/v 
served as the diluent control for ML-190, a potent antagonist at KOR. Differentiated THP-1 cells 
stimulated with LPS were pre-treated with ML-190 (1 μM) followed by co-treatment with DYN 1-
17 and other biotransformation fragments (10 nM) or U50,488H (10 nM) in the presence of ML-
190 (1 μM). Figure 3.10 provides an overview of KOR antagonism during inhibition of NF-κB/p65 
nuclear translocation by DYN 1-17 and the N-terminal fragments. The inhibitory effects of DYN 1-
17, DYN 1-6, DYN 1-7 and DYN 1-9 on NF-κB/p65 nuclear translocation were significantly 
reversed upon addition of ML-190 (p ≤ 0.05). Blockade of KOR in differentiated THP-1 cells with 
ML-190 also significantly inhibited the attenuation of NF-κB/p65 nuclear translocation in 
U50,488H-treated macrophages. No reversal effect was observed when ML-190 was co-treated 
with DYN 1-10 and DYN 1-11. Interestingly, no evidence was found for the antagonistic activity of 
ML-190 in groups receiving intermediate and C-terminal fragments (p > 0.05) (Figure 3.11). ML-
190 treatment alone has no effect on NF-κB/p65 nuclear translocation in both non-LPS-activated 
and LPS-activated cells (see Appendix 3, section 3.3).  
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Figure 3.10 Effects of ML-190 on the attenuation of LPS-induced NF-κB/p65 nuclear 
translocation by DYN 1-17 and the N-terminal fragments differentiated THP-1 cells. 
Differentiated THP-1 cells (1.5 x 105 cells/mL), stimulated with LPS (1 µg/mL) were pre-incubated 
with ML-190 (1 μM) followed by treatment with DYN 1-17, N-terminal fragments and U50,488H 
at 10 nM in the presence of ML-190. The treated cells were fixed, permeabilised and 
immunolabelled with primary anti-NF-κB/p65 monoclonal antibody and visualised using Alexa 
Fluor 555® goat anti-rabbit secondary antibody. DAPI staining was used to identify the nuclei. The 
nuclear translocation of NF-κB/p65 in each treatment group was assessed using the ImageXpress® 
imaging system. Non-stimulated THP-1 cells (NS) served as negative control. The NF-κB/p65 
translocation percentage in each treatment group was normalised and expressed relative to LPS-
stimulated control group (contains DMSO 0.1 % as diluent control). Data shown are mean ± SEM 
of at least three independent experiments in triplicate, *p ≤ 0.05 (One-way ANOVA, Bonferroni 
post-hoc test). 
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Figure 3.11 Effects of ML-190 on the attenuation of LPS-induced NF-κB/p65 nuclear 
translocation by the intermediate and C-terminal fragments of DYN 1-17 in differentiated 
THP-1 cells. Differentiated THP-1 cells (1.5 x 105 cells/mL), stimulated with LPS (1 µg/mL) were 
pre-incubated with ML-190 (1 μM) followed by treatment of the intermediate and C-terminal 
fragments of DYN 1-17 at 10 nM in the presence of ML-190. The treated cells were fixed, 
permeabilised and immunolabelled with primary anti-NF-κB/p65 monoclonal antibody and 
visualised using Alexa Fluor 555® goat anti-rabbit secondary antibody. DAPI staining was used to 
identify the nuclei. The nuclear translocation of NF-κB/p65 in each treatment group was assessed 
using the ImageXpress® imaging system. Non-stimulated THP-1 cells (NS) served as negative 
control. The NF-κB/p65 translocation percentage in each treatment group was normalised and 
expressed relative to LPS-stimulated control group (contains DMSO 0.1 % as diluent control). Data 
recorded are mean ± SEM of at least three independent experiments in triplicate, *p ≤ 0.05 (One-
way ANOVA, Bonferroni post-hoc test). 
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3.5. Discussion  
DYN 1-17 is largely produced by the leukocytes upon activation of the immune system during 
inflammatory responses. Interestingly, this endogenous peptide is subjected to rapid enzymatic 
degradation, especially in an inflammatory environment, producing smaller fragments that interact 
with the immune cells, resulting in various immunoregulatory functions. The results reported in this 
chapter provide evidence of a functional modulation of DYN 1-17 and its biotransformation 
fragments on LPS-induced NF-κB/p65 nuclear translocation in differentiated THP-1 cell-derived 
macrophages. Given that NF-κB is essential in inducing protein transcription in the immune system, 
the findings discussed here highlight the positive roles that DYN 1-17 and selected fragments that 
may have on modulation of inflammatory pain.  
 
3.5.1. Monocyte-macrophage differentiation of THP-1 cells 
Originally derived from the peripheral blood of an acute monocytic leukaemia patient (284), THP-1 
cells are an immortalised human monocyte-macrophage cell line that was established as a suitable 
model representing a simplified and reliable in vitro model for immune modulation studies (291). 
The high variability of THP-1 cells and their differentiation phenotype, in response to PMA, has 
been reported in the literature (283, 284, 292-295). It is therefore essential to validate the 
concentration of PMA and the induction period used to differentiate THP-1 cells in the present 
study. The changes seen through morphological and phenotypical perspectives confirm that these 
monocytic cells get differentiated into mature macrophage-like state after 48 h of exposure to PMA. 
The cells changed from round and singular cells in suspension into larger, and flattened cells with 
amoeboid features that allowed adhesion to the wall of the culture flask. These observations are in 
line with morphological observations of THP-1 cells following PMA-induced differentiation in 
previous studies (285, 295, 296). Under the influence of PMA for at least 48 h, nearly all THP-1 
cells have ceased proliferation and fully differentiated into more mature phenotype including an 
increase in membrane ruffling, well-developed Golgi apparatus, rough endoplasmic reticula, 
irregular nuclei, stimulation of DNA synthesis, and large numbers of free ribosomes and phagocytic 
vacuoles in the cytoplasm. They also showed an increase in adherence, phagocytic activity and cell 
volume (285, 287, 293, 297, 298). PMA is one of the most common and effective differentiation 
agent available to induce mature THP-1 monocyte-derived macrophages (285, 296, 297, 299). The 
concentrations of PMA used for THP-1 cells differentiation vary between publications, resulting in 
different phenotypes being observed of the macrophage intermediates in the culture (297, 299). 
Nevertheless, the concentration of PMA (50 nM) used throughout this study is in accordance to the 
previously reported concentration used by Spano et al., which showed significant progression of the 
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monocyte into terminally differentiated macrophage at 60 nM (297). In addition to PMA, other 
classically used differentiation agents for THP-1 cells maturation are the biologically active 1α, 25-
dihydroxyvitamin D3 (vD3) and the macrophage colony-stimulating factor (M-CSF). These agents 
have been shown to regulate different signalling pathways in differentiated macrophages due to 
different gene transcription (287, 299, 300). 
 
Apart from the morphological changes, the expression of macrophage surface marker, CD11b, was 
also observed using an indirect immunofluorescence assay. Both CD11b and CD14 are known to be 
expressed during monocytes maturation into macrophages (301, 302). CD11b is an integrin family 
member that forms a heterodimer complex with CD18 and is functionally involved in regulating the 
migration and adhesion of macrophages to the endothelial lining of blood vessels and extracellular 
matrix components during inflammatory response (303). The CD11b surface marker expression 
finding during PMA-induced THP-1 cells differentiation in this study corroborates with earlier 
findings (287, 297). A more recent study using flow cytometry and high-content imaging approach 
also reported CD11b as one of the markers specifically expressed on PMA-differentiated THP-1 
cells (286). The expression of CD14, on the other hand, was relatively low compared to CD11b 
following PMA induction in this study. CD14 expression is prominently up-regulated upon 
incubation with vD3, a differentiation which produces mature cells with more monocytic 
characteristics (287). However, in separate studies, CD14 was significantly up-regulated following 
PMA treatment on THP-1 cells (299, 304). This apparent discrepancy could be due to different 
culture conditions adopted for cell maintenance, as different microenvironments causes 
heterogeneity in cell cultures (305). Hence, it could be deduced that CD14 is not an appropriate 
surface marker to serve as an indicator for monocyte-macrophage differentiation with the culture 
conditions being set. CD11b provides a more viable confirmatory test of maturity for THP-1 cells 
following PMA induction. To sum up, the above-mentioned findings proved that the differentiation 
method used (PMA at 50 nM for 48 h) on THP-1 cells in the present study successfully generates 
monocyte-derived macrophage cell lines to serve as in vitro cell model for inflammatory process. 
 
3.5.2. LPS stimulates nuclear translocation of NF-κB/p65 in PMA-differentiated THP-1 
cells 
Depending on the micro-environmental stimuli, the highly flexible and heterogeneous macrophages 
can be distinctly activated into two functional subtypes, classically activated (M1) and alternatively 
activated (M2) type macrophages (306, 307). Macrophages have been shown to exhibit high 
sensitivity to inducers of M1 phenotype including the Th1 cytokines (e.g. IFN-γ and GM-CSF) and 
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bacterial wall components e.g. LPS and inducers of M2 type macrophages namely Th2 anti-
inflammatory cytokines such as IL-4, IL-13 and also M-CSF (308). Elevation of pro-inflammatory 
cytokines (e.g. IL-1β, TNF-α, IL-12) along with expression of PRRs (e.g. TLRs and NLRs) driven 
by Th1 immune response are hallmarks of M1 polarisation in macrophages, which subsequently 
provide host defence against microorganisms and tumour regression. The efficient Th1 and Th17 
responses have been previously linked with the LPS-activated M1 macrophages, which serve as 
antigen presenting cells (APCs) and the IL-1β and IL-12p40 mediators’ producer (309). On the 
other hand, M2 polarisation is normally associated with anti-inflammatory and homeostatic 
functions. They play major roles in the resolution of parasitic infection, wound healing and tissue 
repair as well as immune-regulation via Th2 signalling pathway (293). LPS stimulation does 
promote PMA-differentiation of THP-1 cells towards the M1-polarisation (310). The observed 
strong immunolabelling of NF-κB/p65 in the nuclei following LPS treatment in the present work 
suggests that the macrophages are polarised towards M1 phenotype, consistent with earlier findings 
(311, 312). It is important to note that the complex LPS signalling pathway involves activation of 
numerous signalling cascades including NF-κB, signal transducer and activator of transcriptions 
(STATs) and MAPK (313, 314). Another study, by Qin et al., demonstrated that at transcriptional 
level, LPS treatment significantly induced activation of NF-κB/p65 in macrophages along with 
STAT1 and STAT3 mRNAs, thus, associating LPS stimulation with M1 gene expression (308). 
 
The NF-κB transcription factor is essential in regulating various inflammatory-related genes. 
Inhibition of NF-κB nuclear translocation terminates the transcriptional process of various pro-
inflammatory target genes in the activated macrophages, limiting the exacerbation of inflammatory 
response (269). Uncontrolled expression of NF-κB may aggravate inflammatory-related immune 
responses, leading to chronic inflammation. A well-balanced NF-κB signalling is therefore required 
(315). Among the NF-κB transcription factor family, the most abundant complex found in 
mammalian species is the heterodimeric p65-p50 (44). Whilst the p50 subunit has been suggested as 
a helper in DNA binding, the p65 subunit possesses a more important role as the activator of the 
transcriptional activity of NF-κB complex (316). Hence, in the current study, anti-NF-κB/p65 
antibody to NF-κB subunits was used in preference to antibodies targeting p50 subunit. 
Furthermore, the NF-κB/p65 nuclear translocation assay, using the ImageXpress® high-content 
automated imaging technology, allows for semi-quantitative measurement of the degree of 
translocation. It enables investigation of pharmacological modulation without the risk of losing cells 
or altering cell morphology in between protocols. This assay measures NF-κB/p65 redistribution 
from the cytoplasm to the nucleus and indirectly quantifies IκB degradation (273). With such 
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evidently significant nuclear translocation of NF-κB/p65 transcription factor in the LPS-stimulated 
M1 macrophages, differentiated by PMA from THP-1 cells, they are undoubtedly chosen as the in 
vitro model to the study of immune modulation by opioid peptides during inflammation. 
 
3.5.3. The attenuation of LPS-induced nuclear translocation of NF-κB/p65 in PMA-
differentiated THP-1 cells by DYN 1-17 and its biotransformation fragments  
In the present study, IMD-0354 demonstrated a partial reduction in NF-κB/p65 nuclear 
translocation induced by LPS in differentiated THP-1 cells. NF-κB activation is essential in 
providing protection to the host against pathogens or injury. IMD-0354 is thought to potently inhibit 
IκBα phosphorylation in NF-κB pathway without affecting host defence mechanism (317). Herein, 
the inhibitory effects of DYN 1-17 and selected fragments were shown to be comparable to IMD-
0354. The greatest inhibitory effect on NF-κB/p65 translocation was seen with DYN 1-7 at 10 nM, 
reducing translocation by two folds in comparison with the LPS control group. Majority of the 
DYN 1-17 fragments were able to elicit an inhibitory effect on NF-κB/p65 nuclear translocation at 
both 1 μM and 10 nM, suggesting their potency in immunomodulation during inflammation. The N-
terminal and C-terminal fragments of DYN 1-17 have been shown to modulate phagocytosis and 
tumouricidal activity in mice (41, 232) while the intermediate fragment of DYN 6-12 was identified 
as an important anti-inflammatory analogue during thermal oedema (43). Other studies have also 
indicated the role of DYN 1-17 fragments as positive regulators of in vitro myelopoiesis by forming 
colonies in response to M-CSF (232). The insignificant effect of the peptides on the viability of 
THP-1 cells at both concentrations in comparison to the control group excludes the non-specific 
cytotoxicity as an explanation for NF-κB/p65 inhibition. Notwithstanding the affinity of opioid 
peptides for opioid receptor is in the nanomolar range (276), the different effects seen with change 
in concentration can potentially be explained by the difference in mechanisms, with combined 
effects of the same signals. The results of the current study suggest that DYN 1-17 and its 
biotransformation fragments potentially possess immunoregulatory function during inflammation 
by attenuating cytosolic NF-κB/p65 protein translocation into the nucleus, hindering downstream 
activation of pro-inflammatory signalling.  
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3.5.4. The kappa-opioid receptor mediates inhibitory effects of DYN 1-17 and a select 
of biotransformation fragments on LPS-induced NF-κB/p65 translocation in 
PMA-differentiated THP-1 cells  
DYN 1-17 has been shown to bind to both opioid and non-opioid receptors (318, 319). Many 
studies attribute the effects of DYN 1-17 largely on the KOR (320, 321). Literature evidence 
indicates that the KOR is expressed on cell lines of both neural and non-neural origin (322). KOR 
mRNA expression has been reported in human monocytic U937 cell line (323) and THP-1 cells 
(324). The expression of KOR on the cell surface of PMA-differentiated THP-1 cells was verified 
in this study. Other immune cells that express KOR include human CEM x174 T-B hybrid cells, 
Jurkat-T4 cells, human PBMC, human CD4+ cells, monkey PBMC (215, 325) and murine 
macrophage cell line J774 (326). Up-regulation of KOR, along with the release of DYN 1-17 in 
inflamed tissue have also been reported, indicating inflammation direct influence on opioid-
mediating peripheral analgesia (30, 142). The KOR has also been demonstrated as immune system 
function mediator (327). The presence of membrane-bound KOR has led us to determine the 
mechanism of action with DYN 1-17 and its major biotransformation fragments in LPS-stimulated, 
PMA-differentiated THP-1 cells.  
 
A selective KOR antagonist, ML-190, was used to determine whether the effects of DYN 1-17 and 
the biotransformation fragments on NF-κB/p65 translocation was mediated by the KOR. ML-190 is 
a newly developed antagonist for the KOR which elicits much higher KOR potency (IC50 = 120 nM 
in a β-arrestin assay) than MOR and DOR. In comparison with other selective KOR antagonists 
such as 5'-guanidinonaltrindole (5'-GNTI) and nor-BNI, ML-190 possesses a promising potency 
with an improved selectivity for the KOR (> 267-fold selective over that of MOR and DOR), 
making this compound suitable for studies on KOR distribution and internalisation (328). 
Furthermore, ML-190 has a simplified structure that does not contain stereochemical centres, hence 
achiral, compared to the other currently available KOR antagonists. It also has a better solubility 
profile across the pH range tested. 
 
As shown in section 3.4.7, ML-190 significantly reversed the inhibitory effect of DYN 1-17, a 
select of N-terminal fragments and U50,488H on NF-κB/p65 translocation. This demonstrated that 
DYN 1-17 and the N-terminal fragments (DYN 1-7, DYN 1-6 and DYN 1-9) suppress the 
translocation of cytosolic NF-κB/p65 protein into the nuclei of PMA-differentiated THP-1 
macrophages through activation of KOR. Consistent with our findings, the activation of KOR on 
immune cells by DYN 1-17 and other derivatives has been reported to negatively regulate the 
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antigen-induced proliferation of T cells (227), antibody production by B cells (228), phagocytic 
ability (229) and also cytokine production by macrophages (230). Furthermore, anti-tumour activity 
in peritoneal macrophages has been reported for DYN 1-17 and several N-terminal sub-fragments at 
KOR (232, 329). However, previous study has suggested that DYN 1-17 and related fragments 
promote peritoneal macrophage phagocytosis, yet naloxone did not reverse the phagocytic action 
suggesting a non-opioid-receptor mediated immunomodulation (41). Furthermore, the difference in 
methods and receptors used by Szabo et al. (229) and Ichinose et al. (41) for the phagocytosis assay 
may explain the distinct responses of DYN 1-17 towards the rodent peritoneal macrophages’ 
phagocytic activity. 
 
Although many studies have depicted DYN 1-17 as a specific endogenous ligand for KOR (29, 330, 
331), others have also reported this peptide as an agonist at the MOR and DOR (208, 332). 
Metabolism at the C-terminus of DYN 1-17 was shown to produce fragments that still retain 
opioidergic activity albeit an altered receptor specificity profile (333, 334). Previous researchers 
have also demonstrated that biotransformation of DYN 1-17 resulted in fragments with higher 
affinities for MOR and DOR (131). In this study, the inhibition of NF-κB/p65 translocation by other 
N-terminal fragments (DYN 1-10 and DYN 1-11), however, was not reversed by ML-190. It is 
therefore suggested that, in this instance, the inhibitory effect of these fragments could be mediated 
by other opioid or non-opioid receptors. Several factors have been suggested to influence the 
differential binding characteristics of the opioids on the opioid receptors including the allosteric 
regulation by sodium ions (335, 336) and nucleotides (337).  
 
A previous study has also described that, in contrast to other endogenous opioid peptides, DYN 1-
17 may have two distinct biologically active sites, the opioid and non-opioid sites, which enable 
production of two sets of effects, depending on the target encountered (338). The lack of 
antagonism by ML-190 following treatment with the intermediates (DYN 3-14 and DYN 6-12) and 
C-terminal fragments (DYN 2-17 and DYN 7-17) suggest that these peptides are acting through 
opioid-independent pathways during the inhibition of LPS-induced NF-κB/p65 nuclear 
translocation. The presence of a tyrosine residue on the first position of the amino acid chain allows 
binding of opioid peptides (except for orphanin) onto specific opioid receptors. Removal of the 
amino-terminal functional group abolishes the opioidergic activity of DYN 1-17 (209), with DYN 
2-17 inactive at opioid receptors (326, 329). In addition to this, the N-terminal tetrapeptide fragment 
of DYN 1-17, consisting of Tyr-Gly-Gly-Phe sequence is regarded as important in the opioid 
activity (209). The inability to reverse the antagonistic effect at KOR for these fragments is also 
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consistent with an earlier study that postulates the capability of des-Tyr-dynorphin molecule in 
producing potent non-opioid effects due to the presence of a second biologically active site within  
the dynorphin sequence (338). These apparent non-opioid actions for the intermediate and C-
terminal fragments will be further explored in Chapter Five. 
 
3.6. Conclusion  
This chapter highlights the role of DYN 1-17 and selected biotransformation fragments in the 
modulation of inflammatory response in PMA-differentiated THP-1 cells through inhibition of 
nuclear translocation of the NF-κB/p65 protein. Based on structural-specificity of the fragments, 
this study further indicate that N-terminal fragments, comprising seven amino acids in the peptide 
sequence, are acting at KOR - as demonstrated by DYN 1-7 - to effectively inhibit NF-κB/p65 
translocation. The role of other N-terminal, intermediate and C-terminal biotransformation 
fragments in the regulation of the NF-κB/p65 signal in differentiated THP-1 cells following LPS 
stimulation also warrants further investigation. It is plausible that there is involvement of non-KOR 
mechanisms in mediating the effects of these peptides at different concentrations. 
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●    Chapter Four    ● 
Effects of DYN 1-17 and its biotransformation 
fragments on LPS-induced release of IL-1β and   
TNF-α in differentiated THP-1 cells
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4.  Chapt er  4 
4.1. Foreword 
There is a bidirectional interaction between classically defined cytokines and the endogenous opioid 
peptides, hence, opioid modulation of pro-inflammatory cytokine release could represent a broad-
acting strategy for managing inflammatory pain and inflammation. This chapter describes, in detail, 
the role of DYN 1-17 and its biotransformation fragments on LPS-induced release of IL-1β and 
TNF-α in differentiated THP-1 cells. Further assessment of KOR involvement on the modulation of 
these cytokines by DYN 1-17 and its major biotransformation fragments is also evaluated.  
 
4.2. Introduction 
Cytokine signalling plays a central role during inflammatory pain, evident by the immediate up-
regulation of inflammatory cytokines released by the resident and infiltrating immune cells at the 
site of inflammation (339). Of particular interest is IL-1β, a pleotropic pro-inflammatory cytokine 
that has been implicated in inflammatory pain at both central and peripheral levels. Upon injury, the 
production and release of IL-1β within the inflamed area facilitates the up-regulation of other pro-
nociceptive mediators and anti-inflammatory cytokines (340-342). Furthermore, IL-1β has been 
shown to modulate neuronal excitability during pain states via direct action on nociceptors and 
other neuronal receptors including TRPV1, sodium channels, gamma-aminobutyric acid (GABA) 
receptors and NMDA receptors, resulting in central sensitisation that promotes mechanical and 
thermal hyperalgesia (343). IL-1β may also cause inflammatory-related systemic effects such as 
fever and cachexia (344). Similarly, TNF-α, which is a frequent companion and close associate of 
IL-1β, has also been reported to be a key immunomodulating factor that triggers many 
physiological- and pathological-related intracellular mechanisms (345). Produced and secreted 
largely by activated macrophages at the early stages of inflammation, TNF-α is a potent initiator of 
many inflammatory cascades involving cytolysis, mitogenesis and involves in polymorphonuclear 
cells and lymphocytes trafficking (112). 
 
In addition to inflammatory cytokines, activated macrophages also synthesise and release opioid 
peptides upon induction by IL-1β and CRF within inflamed tissue (19, 27, 28, 346). Activation of 
opioid receptors on sensory neuron terminals by these opioid peptides eventually leads to a potent 
peripheral analgesia at the local inflamed area (127). This highlights the indispensable contribution 
of IL-1β signalling to modulate pain sensitivity in basal conditions and during inflammation 
through modulation of endogenous opioid release. Interestingly, overwhelming evidence has also 
reported the ability of opioid peptides to mediate cytokine release during an immune response (42, 
292, 347-352). The effect of opioid peptides on the regulation of immune function is through direct 
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activation of the opioid receptors expressed on immune cells (211). In this context, previous studies 
have demonstrated the modulatory effects of DYN 1-17 on the release of TNF-α from microglia 
and/or astrocytes (42). The regulation of IL-1β and TNF-α release by DYN 1-17 may provide 
checks and balances to prevent excessive release of inflammatory cytokines that could worsen the 
painful inflammation. As detailed previously, DYN 1-17 is subjected to rapid biodegradation in an 
inflamed microenvironment, producing a variety of smaller fragments (40). Little is known, 
however, about the potential effects of these biotransformation fragments on the regulation of pro-
inflammatory cytokine release, hence, further investigations are necessary.  
 
A great deal of literature has emphasised on the importance of cytokine level measurements in 
serum and tissues that provide useful information on the status of disease pathologies and drug 
response. It also serves as a valuable tool to monitor disease progression or inflammation (120, 
353). Some conventional methods available for cytokine measurement include radioimmunoassay 
(RIA) and ELISA. Although RIA provides sensitive and relatively specific detection of cytokines 
through the use of radioisotope-labelling, this method is associated with the production of 
radiochemical waste (120). ELISA has been recognised as the broadly accepted standard for 
cytokine measurement, given to its ability to yield highly quantitative and generally reproducible 
results. This method involves a cytokine-antibody reaction, followed by the detection of enzyme 
activity conjugated to the antibody via a colorimetric reporter-enzyme assay (279). Several 
drawbacks of ELISA include extensive wash cycles with long incubations, the requirement for 
antibody pre-coated plates and the measurement of only one cytokine at a time in a given sample 
aliquot (120, 279). Furthermore, ELISA quantification is limited to a narrow dynamic range, which 
means more sample dilutions are needed, hence, providing a source of error (279). All of these 
factors greatly influence the ability of ELISA for large scale compound screening. On the other 
hand, recent development in the ELISA assay, known as multiplex array, allows multiple cytokine 
measurements in the same sample at the same time. Whilst it offers many advantages over the 
traditional ELISA, this approach may not provide sensitive and specific cytokine measurements 
given that interactions between multiple antibodies and cytokines in the assay solution may occur, 
resulting in a broad and variable dynamic range of concentrations of the different proteins being 
assayed together (279). Thus, in this context, ELISA remains the best validated approach to 
measure individual cytokine level.  
 
AlphaLISA, a combination of an amplified luminescent proximity homogeneous assay 
(AlphaScreen®) and ELISA, is a recently developed bead-based, homogenous immunoassay that 
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offers a robust detection platform for the quantification of cytokines in an automated high-
throughput screening format. The principle of AlphaLISA technology is based on the pairing of 
‘donor’ and ‘acceptor’ beads in the presence of the analyte (i.e. cytokine). The close proximity 
between the paired beads enables the irradiated donor bead to transfer oxygen singlets to the 
acceptor bead, resulting in the emission of a highly amplified chemiluminescent signal. The amount 
of light emission is proportional to the amount of analyte present in the sample. In comparison to 
standard ELISA protocols, this chemiluminescent assay permits easy automation for the analysis of 
cytokines by reducing the multiple washing steps with shorter incubation periods, detects low 
concentrations of cytokines in relatively small sample volumes (as low as 1 µL in a total assay 
volume of 10 µL), easily miniaturised into 384-well or 1536-well microplate format and is suitable 
for detecting secreted, intracellular or membrane-bound cytokines in a variety of samples including 
cell culture supernatants, crude cell lysates, serum and plasma. With these advantages, AlphaLISA 
is the preferred method of choice for cytokine measurement due to its high sensitivity, broad 
dynamic range, with low intra- and inter-assay variability. It is also simple to perform and, most 
importantly, it delivers reliable and high-quality results with simple data manipulation in a short 
period of time (120, 354). The basic concept of AlphaLISA immunoassay is shown in Figure 4.1. 
 
 
 
 
 
 
 
 
 
Figure 4.1 The principle of indirect AlphaLISA immunoassay. The analyte’s biotinylated 
antibody attaches to the streptavidin-coated donor beads whereas the second antibody to the analyte 
is directly conjugated to the acceptor beads. In the presence of the respective analyte, both donor 
and acceptor beads come into proximity, causing the excitation of donor beads at 680 nm and the 
generation of singlet oxygen molecules. This eventually triggers a series of chemical reactions in 
the acceptor beads, resulting in the emission of light from the acceptor beads at 615 nm. The signal 
generated from the acceptor beads is proportional to the amount of analyte in the sample.  
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In this study, the AlphaLISA immunoassay was utilised to measure both LPS-induced IL-1β and 
TNF-α release in PMA-differentiated THP-1 cells following treatment with DYN 1-17 and its 
biotransformation fragments. 
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4.3. Materials and methods 
4.3.1. Materials 
Details of all materials and chemicals (including catalogue number and supplier) were obtained 
from sources as listed alphabetically in Appendix I and throughout the text.  
 
4.3.2. THP-1 cell culture and differentiation 
Detailed methods of THP-1 cell line routine cell culture and differentiation are provided in section 
3.3.2 and 3.3.2.1, Chapter Three. Briefly, THP-1 cells were maintained in RPMI 1640 
supplemented with 10 % FBS and 100 units/mL penicillin and 100 µg/mL streptomycin. Cells were 
incubated at 37 °C with 5 % CO2 in a humidified atmosphere. For differentiation, cells were 
induced with 50 nM of PMA and maintained at 37 °C in a 5 % humidified CO2 incubator for 48 h.  
 
4.3.3. LPS-induced human IL-1β and TNF-α release in differentiated THP-1 cells  
Due to LPS batch variability and various testing protocols used by individual researchers to 
measure IL-1β (355-357) and TNF-α (231, 358-360) release in macrophages, it was therefore 
necessary to determine the LPS concentration and length of exposure required in order to induce the 
optimal release of both cytokines in PMA-induced cell differentiation model of the human 
monocytic cell line THP-1 used in the present study. The determination of optimal IL-1β and TNF-
α release with LPS induction in differentiated THP-1 cells was performed as described previously 
(361). Briefly, THP-1 cells at a density of 2 x 105 cells/mL were seeded in 96-well, flat bottom cell 
culture plates (200 μL/well) and differentiated as described in section 4.3.2. The differentiated cells 
were then stimulated with increasing concentrations of LPS at 0.01, 0.1 and 1 μg/mL, in pre-
warmed treatment medium containing RPMI 1640 supplemented with 1 % FBS (100 µL/well), to 
induce the release of IL-1β and TNF-α. The non-stimulated cells received an equivalent volume of 
the treatment medium, serving as the negative control group. The cells were stimulated with LPS 
for various incubation periods from 1 h to 24 h (for IL-1β release) and for 4 h or 24 h (for TNF-α 
release) within a humidified atmosphere at 37 °C and 5 % CO2. Following each incubation period, 
the content of each well was completely aspirated and transferred into individually labelled 
microcentrifuge tubes followed by centrifugation at 6000 x g for 20 min at 4 °C. Culture 
supernatants were collected and stored at -20 °C for no longer than 3 months for later determination 
of IL-1β and TNF-α levels using the AlphaLISA assay. 
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4.3.4. DYN 1-17 and biotransformation fragments treatments in LPS-stimulated THP-
1 cells 
To evaluate the effects of DYN 1-17 and its major biotransformation fragments on LPS induced-
release of IL-1β and TNF-α in differentiated THP-1 cells, similar methods of IL-1β and TNF-α 
bioassays as described in section 4.3.2 and 4.3.3 were employed. In brief, following concurrent 
stimulation with LPS (1 µg/mL), the differentiated THP-1 cells were further treated with DYN 1-17 
and other fragments at various concentrations (10-7 M, 10-9 M and 10-11 M) (349) in pre-warmed 
treatment medium containing RPMI 1640, supplemented with 1 % FBS (100 µL/well). Non-
stimulated cells, incubated in culture medium alone, served as the negative control for the 
experiment. The treated cells were left undisturbed for 24 h in the incubator at 37 °C under 5% CO2 
atmosphere. The cytokine-containing supernatants were then collected following centrifugation for 
the determination of IL-1β and TNF-α levels using the dedicated AlphaLISA assays.  
 
To determine whether DYN 1-17 and the selected fragments act at KOR to modulate cytokine 
release, a selective KOR antagonist, ML-190, was employed. The LPS-stimulated cells were pre-
treated with ML-190 at 1 μM for an hour followed by co-treatment of the fragments (10-11 to 10-7 
M) and ML-190 (1 μM) for 24 h at 37 °C under 5 % CO2. The LPS-stimulated cells incubated with 
DMSO 0.1% v/v under similar condition served as negative control.   
 
4.3.5. AlphaLISA-based human IL-1β and TNF-α assays 
The extent of human IL-1β and TNF-α release were quantified using an AlphaLISA kit (Perkin 
Elmer, VIC, Australia) in accordance to the manufacturer’s protocol. To construct standard curves 
of concentration range from 1 x 10-7 to 3 x 10-13 g/mL in half log unit intervals, standard solutions 
of human IL-1β and TNF-α were prepared through serial dilution of the respective analyte in RPMI 
1640, supplemented with 1 % FBS (see Appendix 3, section 3.6 and section 3.7, respectively). A 
MIX solution consisting of 25 µg/mL AlphaLISA anti-analyte acceptor beads and 2.5 nM 
biotinylated antibody anti-analyte were prepared in 1X AlphaLISA immunoassay buffer (Perkin-
Elmer, VIC, Australia, composition: see Appendix 2, section 2.2). All assays were performed in 
384-well white microplates (OptiPlate-384, Perkin-Elmer, VIC, Australia). Briefly, 1 µL of the 
standard or culture supernatant was added at the bottom of the well in duplicate followed by  
addition of 4 µL/well of MIX solution. The microplates were incubated for 60 min at 23 °C on an 
orbital shaker (Ratek Instruments, VIC, Australia) with gentle continuous agitation. To detect the 
assay signal, 5 μL of streptavidin-coated donor beads solution (80 µg/mL, diluted in 1X AlphaLISA 
immunoassay buffer) was added into each well and the assay microplates were incubated for an 
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additional 30 min at room temperature (25 °C). These steps were performed in subdued and green-
filtered lighting condition due to the sensitivity of AlphaLISA donor beads towards light. The 
microplates were covered with adhesive sealing film to minimise evaporation between the 
incubations. The plates were read at room temperature with the EnSpire® Alpha 2390 plate reader 
equipped with AlphaScreen® module (Perkin Elmer, VIC, Australia). The bead complex was 
excited at 680 nm and the emission signals were collected at 615 nm. The unknown analyte 
concentration was determined using variable slope regression analysis to fit a standard curve to the 
data points.  
 
4.3.6. Statistical analysis 
All experiments were performed in triplicate and the data presented as mean ± SEM from at least 
three independent experiments. The raw data was normalised to LPS (1 µg/mL, 100%) and assay 
medium (basal, 0%). Data calculations and comparisons between the groups were analysed with 
GraphPad Prism software (Version 6.07) using one-way ANOVA followed by Bonferroni post-hoc 
test or two-way ANOVA followed by Tukey’s post-hoc test, where applicable. A significant 
difference between groups was defined as p ≤ 0.05.  
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4.4. Results 
4.4.1. LPS stimulates IL-1β and TNF-α release from PMA-differentiated THP-1 cells 
To assess the optimal release of IL-1β and TNF-α in differentiated THP-1 cells, the time and dose-
dependent effects of LPS treatment were examined concomitantly. For IL-1β release, the cells were 
incubated with a range of concentrations of LPS (i.e. 0.01, 0.1 and 1 µg/mL) over a number of time 
periods (i.e. 1, 2, 4, 6, 8, 12 and 24 h). As shown in Figure 4.2, stimulation with LPS in 
differentiated THP-1 cells induced IL-1β release in a concentration- and time-dependent manners. 
A concentration-dependent activation of IL-1β release was observed with the tested LPS 
concentrations, showing a marked increase of the cytokine release starting at 8 h and peaking after 
24 h of incubation. The maximum LPS concentration (1 µg/mL) stimulated the cells to release the 
highest level of IL-1β in comparison to LPS 0.1 µg/mL (1.5 fold) and LPS 0.01 µg/mL (4.8 fold) 
following 24 h incubation (LPS 1 µg/mL, 661.20 ± 41.59; LPS 0.1 µg/mL, 346.3 ± 17.08, LPS 0.01 
µg/mL, 156.4 ± 11.13). Unstimulated, differentiated THP-1 cells showed a minimal detectable basal 
level of IL-1β in the culture medium throughout the incubation periods.  
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Figure 4.2 Concentration- and time-dependent induction of IL-1β release by LPS in THP-1 
cells. PMA-differentiated THP-1 cells (2 x 105 cells/mL) were treated with various LPS 
concentrations for 1, 2, 4, 6, 8, 12 and 24 h. At the end of these respective times, the culture 
supernatants were collected and IL-1β release was quantified using a human IL-1β AlphaLISA 
assay. The AlphaLISA signal was measured using an EnSpire® Alpha 2390 plate reader. Non-
stimulated THP-1 cells, receiving equivalent volumes of media served as control group. Data are 
from a single experiment, performed in triplicate, representative of three experiments. Results are 
compared against the control group and presented as mean ± SEM. *p ≤ 0.05 (Two-way ANOVA, 
Tukey post-hoc test). 
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Likewise, the time- and concentration-dependent responses of TNF-α release to LPS stimulation 
were also examined in differentiated THP-1 cells. TNF-α release was in parallel with increasing 
LPS concentrations throughout the selected induction periods (Figure 4.3). Of all concentrations, 
LPS at 1 µg/mL led to a time-dependent cytokine release, shown by the significant increase of 
TNF-α level at 24 h (2.8 fold) in comparison to 4 h (at 24 h, 2563.0 ± 79.7; at 4 h, 894.9 ± 27.98; p 
≤ 0.05), denoting that prolonged incubation promotes higher secretion of TNF-α from the 
stimulated cells. LPS stimulation (0.01 µg/mL), did not induce TNF-α release beyond baseline 
levels despite the longer treatment period (at 24 h: LPS 0.01 µg/mL, 115.3 ± 7.35; control, 22.4 ± 
2.93; p > 0.05). Thus, in the rest of the study, differentiated THP-1 cells were treated with 1 µg/mL 
of LPS and incubated through a 24-h post-initial treatment time in order to obtain the optimal 
release levels of both IL-1β and TNF-α following the stimulation.  
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Figure 4.3 Concentration- and time-dependent induction of TNF-α release by LPS in THP-1 
cells. PMA-differentiated THP-1 cells (2 x 105 cells/mL) were treated with increasing 
concentrations of LPS, as indicated in the bar graph, for 4 and 24 h. At the end of the incubation 
period, cell culture supernatants were collected and assayed for TNF-α using the AlphaLISA 
method. The signal was measured using an EnSpire® Alpha 2390 plate reader. Non-stimulated 
THP-1 cells, receiving equivalent volumes of media, served as control group. Data are from a 
representative experiment of three. Results are compared against the control group and presented as 
mean ± SEM. *p ≤ 0.05 (Two-way ANOVA, Tukey post-hoc test). 
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4.4.2. Modulatory effects of DYN 1-17 and its biotransformation fragments on LPS-
induced IL-1β release in PMA-differentiated THP-1 cells  
 
4.4.2.1. DYN 1-17 and N-terminal fragments (DYN 1-6, DYN 1-7, DYN 1-9, 
DYN 1-10 and DYN 1-11) 
The effect of DYN 1-17 and its N-terminal fragments on the release of IL-1β following LPS 
stimulation was investigated between concentrations of 10-11 M to 10-7 M and the experimental data 
obtained are presented in Figures 4.4 and 4.5, respectively. Treatment with DYN 1-17 (Figure 4.4) 
resulted in a significant reduction of IL-1β release, as compared to the LPS control group (LPS, 
100.00 ± 2.00; DYN 1-17: at 10-11 M, 84.17 ± 2.77; at 10-9 M, 85.15 ± 2.35; at 10-7 M, 79.02 ± 
3.53; p ≤ 0.05). In contrast, DYN 1-6 (Figure 4.5A) significantly augmented the release of IL-1β 
from differentiated THP-1 cells in the presence of LPS (LPS, 100.00 ± 2.29; DYN 1-6: at 10-11 M, 
115.90 ± 3.36; at 10-9 M, 116.40 ± 3.18; at 10-7 M, 116.60 ± 2.95; p ≤ 0.05). Interestingly, DYN 1-7 
(Figure 4.5B) also revealed a concentration-dependent suppression on the release of IL-1β (15-30 % 
reduction compared to LPS alone), with the largest effect on IL-1β release observed at 10-11 M 
(LPS, 100.00 ± 2.09; DYN 1-7: at 10-11 M, 70.62 ± 3.50; at 10-9 nM, 77.99 ± 2.95; at 10-7 M, 85.05 
± 3.13; p ≤ 0.05). DYN 1-9, DYN 1-10 and DYN 1-11, however, had no effect on LPS-induced IL-
1β release in differentiated THP-1 cells (Figure 4.5C, D and E, respectively). Assessment of the 
LPS-induced IL-1β in differentiated THP-1 cells was also determined in the presence of selective 
KOR agonist, U50,488H (Figure 4.5F). In comparison to the LPS control group, U50,488H 
modulated the release of IL-1β in the culture medium over the 24-h incubation period with a 
significant reduction observed at 10-11 M (LPS, 100.00 ± 1.66; U50,488H, 84.70 ± 3.21; p ≤ 0.05). 
DYN 1-17, the N-terminal fragments and U50,488H, however, showed no effect on the modulation 
of IL-1β release in unstimulated,  differentiated THP-1 cells (see Appendix 3, section 3.8A).   
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Figure 4.4 The modulation of DYN 1-17 on the release of IL-1β in LPS-stimulated THP-1 
cells. The LPS-stimulated THP-1 cells were treated with DYN 1-17 at 10-11 to 10-7 M for 24 h. 
followed by antagonism of the treatment with ML-190 (1 µM) under similar conditions. The culture 
supernatants were collected and IL-1β release was measured using the IL-1β AlphaLISA assay. The 
signal was measured using an EnSpire® Alpha 2390 plate reader. The release of IL-1β in each 
treatment group was normalised and expressed relative to LPS-stimulated control group. Data are 
expressed as mean ± SEM of at least three independent experiments performed in triplicate. The 
asterisk (*) and hash (#) represent a significant difference of DYN 1-17-treated without or with 
ML-190 (solid-line and dotted line, respectively) in comparison to LPS control group, p ≤ 0.05 
(One-way ANOVA, Bonferroni post-hoc test). 
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Figure 4.5 The modulation of N-terminal fragments of DYN 1-17 and U50,488H on the release 
of IL-1β in LPS-stimulated THP-1 cells. The LPS-stimulated THP-1 cells were treated with (A) 
DYN 1-6, (B) DYN 1-7, (C) DYN 1-9, (D) DYN 1-10, (E) DYN 1-11 and (F) U50,488H at 10-11 to 
10-7 M for 24 h followed by antagonism of the treatments with ML-190 (1 µM) under similar 
conditions. The culture supernatants were collected and IL-1β release was measured using the IL-1β 
AlphaLISA assay. The signal was measured using an EnSpire® Alpha 2390 plate reader. The 
release of IL-1β in each treatment group was normalised and expressed relative to LPS-stimulated 
control group. Data shown are mean ± SEM of at least three independent experiments performed in 
triplicate. The asterisk (*) and hash (#) represent a significant difference of peptide-treated without 
or with ML-190 (solid-line and dotted line, respectively) in comparison to LPS control group, p ≤ 
0.05 (One-way ANOVA, Bonferroni post-hoc test). 
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To determine whether the modulation effects observed with DYN 1-17 and the N-terminal 
fragments on IL-1β release in differentiated THP-1 cells were mediated by KOR, ML-190 was used 
to block the receptor. Simultaneous addition of ML-190 significantly blocked the inhibitory effect 
of DYN 1-17 at 10-7 M by 20 % (DYN 1-17, 79.02 ± 3.53; DYN 1-17 + ML-190, 99.14 ± 4.13; p ≤ 
0.05) (Figure 4.4). The stimulatory effect of DYN 1-6 (10-9 M) on LPS-induced IL-1β was also 
reversed significantly by ML-190 (DYN 1-6, 116.40 ± 3.18; DYN 1-6 + ML-190, 99.95 ± 2.73; p ≤ 
0.05) (Figure 4.5A). As can be seen in Figure 4.5B, comparison of the mean values demonstrated 
that co-incubation of DYN 1-7 (10-11 M) and ML-190 resulted in a modest yet significant increase 
of IL-1β level (DYN 1-7, 70.62 ± 3.50; DYN 1-7 + ML-190, 94.36 ± 4.87; p ≤ 0.05). Further 
observation also demonstrated that blockade of KOR with ML-190 completely antagonised the 
inhibitory effect of U50,488H at 10-11 M on LPS-activated macrophages, thereby reversing the level 
of IL-1β release towards the basal level (U50,488H, 84.70 ± 3.21; U50,488H + ML-190, 99.98 ± 
2.47; p ≤ 0.05) (Figure 4.5F). To note, ML-190 or DMSO 0.1 % v/v alone had no effect on IL-1β 
secretion in LPS-stimulated or non-stimulated THP-1 cells (see Appendix 3, section 3.9A).  
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4.4.2.2. Intermediate and C-terminal fragments (DYN 3-14, DYN 6-12, DYN 
2-17 and DYN 7-17) 
The modulatory effects of the intermediate (DYN 3-14 and DYN 6-12) and C-terminal (DYN 2-17 
and DYN 7-17) fragments of DYN 1-17 on LPS-induced IL-1β release in THP-1 cell-derived 
macrophages were also examined and are shown in Figure 4.6. Interestingly, in the presence of 
DYN 3-14 at 10-11 M, the induction of IL-1β release by LPS was significantly inhibited in 
comparison to the LPS control group (LPS, 100.00 ± 2.00; DYN 3-14, 81.08 ± 4.74; p ≤ 0.05). The 
LPS-stimulated cells were then further treated with DYN 3-14 at ultra-low concentrations (10-17 to 
10-13 M) and the results demonstrated that DYN 3-14 effectively attenuates the release of LPS-
induced IL-1β in a concentration-independent manner, as shown in Figure 4.6A (LPS, 100.00 ± 
2.68; DYN 3-14: at 10-17 M, 83.69 ± 2.86; at 10-15 M, 84.13 ± 2.26; at 10-13 M, 88.73 ± 2.20; p ≤ 
0.05). The other fragments (DYN 6-12, DYN 2-17 and DYN 7-17) did not display any significant 
effect on release of IL-1β induced by LPS (Figure 4.6B). Non-stimulated THP-1 cells treated with 
DYN 3-14 showed no effect on IL-1β release (see Appendix 3, section 3.8A). Simultaneous 
antagonism with ML-190 was not performed with the intermediate and C-terminal fragments 
because their mechanisms of action were anticipated to be opioid-irrelevant due to the absence of 
first tyrosine residue in these peptides (209).  
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Figure 4.6 The modulation of the intermediate and C-terminal fragments of DYN 1-17 on the 
release of IL-1β in LPS-stimulated THP-1 cells. The LPS-stimulated THP-1 cells were treated 
with (A) DYN 3-14 (10-17 to 10-7 M) and (B) DYN 6-12, DYN 2-17 and DYN 7-17 at 10-11 M to 
10-7 M for 24 h. The culture supernatants were collected and IL-1β release was measured using the 
IL-1β AlphaLISA assay. The signal was measured using an EnSpire® Alpha 2390 plate reader. The 
release of IL-1β in each treatment group was normalised and expressed relative to LPS-stimulated 
control group. Data recorded are mean ± SEM of at least three independent experiments performed 
in triplicate. *p ≤ 0.05 (One-way ANOVA, Bonferroni post-hoc test). 
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4.4.3. Modulatory effects of DYN 1-17 and its biotransformation fragments on LPS-
induced TNF-α release in PMA-differentiated THP-1 cells 
 
4.4.3.1. DYN 1-17 and N-terminal fragments (DYN 1-6, DYN 1-7, DYN 1-9, 
DYN 1-10 and DYN 1-11) 
Besides IL-1β, TNF-α is also released upon induction by LPS on the differentiated THP-1 cells, 
thus the effects of DYN 1-17 and the N-terminal fragments on TNF-α modulation were elucidated. 
The results obtained are displayed in Figure 4.7 and Figure 4.8, respectively. Unlike its modulatory 
effect on IL-1β secretion, no significant modulation on TNF-α release was observed following 
incubation of LPS-stimulated cells with DYN 1-17 (Figure 4.7). Similar to its action on IL-1β 
release, DYN 1-6 (10-9 M and 10-7 M) further augmented the LPS-induced secretion of TNF-α in 
the cultures of differentiated THP-1 cells as depicted in Figure 4.8A (LPS, 100.00 ± 2.78; DYN 1-6: 
at 10-9 M, 112.60 ± 3.15; at 10-7 M, 117.70 ± 2.28; p ≤ 0.05). Further experiments also 
demonstrated that DYN 1-7 (10-11 to 10-7 M) produced significant inhibitory effects on TNF-α 
release (around 20-30%) following LPS induction (LPS, 100.00 ± 1.76; DYN 1-7: at 10-11 M, 77.81 
± 3.53; at 10-9 M, 77.95 ± 3.18; at 10-7 M, 80.60 ± 3.91; p ≤ 0.05) (Figure 4.8B). In the presence of 
DYN 1-9, DYN 1-10 and DYN 1-11, no significant modulation of LPS-induced TNF-α release was 
found (Figure 4.8C, D, and E). In parallel to these findings, U50,488H-treated cells also modulated 
TNF-α release with a significant reduction of TNF-α release induced by the activated macrophages 
at 10-11 M (LPS, 100.00 ± 1.30; U50,488H, 81.66 ± 2.63; p ≤ 0.05). In cultures that were not 
stimulated with LPS, no effects on the TNF-α concentrations were produced by these peptides (refer 
Appendix 3, section 3.8B). 
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Figure 4.7 The modulation of DYN 1-17 on the release of TNF-α in LPS-stimulated THP-1 
cells. The LPS-stimulated THP-1 cells were treated with DYN 1-17 at 10-11 to 10-7 M for 24 h 
followed by antagonism of the treatment with ML-190 (1 µM) under similar conditions. The culture 
supernatants were collected and TNF-α release was measured using the TNF-α AlphaLISA assay. 
The signal was measured using an EnSpire® Alpha 2390 plate reader. The release of TNF-α in each 
treatment group was normalised and expressed relative to LPS-stimulated control group. Data 
shown are mean ± SEM of at least three independent experiments performed in triplicate (One-way 
ANOVA, Bonferroni post-hoc test). 
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Figure 4.8 The modulation of N-terminal fragments of DYN 1-17 and U50,488H on the release 
of TNF-α in LPS-stimulated THP-1 cells. The LPS-stimulated THP-1 cells were treated with (A) 
DYN 1-6, (B) DYN 1-7, (C) DYN 1-9, (D) DYN 1-10, (E) DYN 1-11 and (F) U50,488H at 10-11 to 
10-7 M for 24 h followed by antagonism of the treatments with ML-190 (1 µM) under similar 
conditions. The culture supernatants were collected and TNF-α release was measured using the 
TNF-α AlphaLISA assay. The signal was measured using an EnSpire® Alpha 2390 plate reader. 
The release of TNF-α in each treatment group was normalised and expressed relative to LPS-
stimulated control group. Data are recorded as mean ± SEM of at least three independent 
experiments performed in triplicate. The asterisk (*) and hash (#) represent a significant difference 
of peptide-treated without or with ML-190 (solid-line and dotted line, respectively) in comparison 
to LPS control group, p ≤ 0.05 (One-way ANOVA, Bonferroni post-hoc test). 
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The involvement of KOR on the modulation of TNF-α release in differentiated THP-1 cells was 
also assessed through simultaneous incubation of the fragments with ML-190. The results 
demonstrated that, upon blockade of KOR with ML-190, the augmentation of TNF-α secretion by 
DYN 1-6 at 10-7 M was reduced to the basal level (DYN 1-6, 117.70 ± 2.28; DYN 1-6 + ML-190, 
104.7 ± 1.51; p ≤ 0.05) (Figure 4.8A). As shown in Figure 4.8B, the inhibition of TNF-α release by 
DYN 1-7 was also significantly reversed by ML-190 at 10-11 M (DYN 1-7, 77.81 ± 3.53; DYN 1-7 
+ ML-190, 97.89 ± 3.40; p ≤ 0.05) and 10-9 M (DYN 1-7, 77.95 ± 3.18; DYN 1-7 + ML-190, 94.67 
± 2.27; p ≤ 0.05). The attenuation of U50,488H on TNF-α release at 10-11 M was remarkably 
reversed when the KOR of the LPS-stimulated cells were blocked with ML-190 over the 24-h 
incubation period (U50,488H, 81.66 ± 2.63; U50,488H + ML-190, 101.00 ± 3.87; p ≤ 0.05) (Figure 
4.8F). Co-treatment of DYN 1-9, DYN 1-10 and DYN 1-11 with ML-190 showed no significant 
alteration on LPS-stimulated TNF-α release (Figure 4.8C, D and E). Consistent with the IL-1β data, 
ML-190 or DMSO 0.1% v/v alone had no effect on LPS-induced TNF-α secretion in differentiated 
THP-1 cells (see Appendix 3, section 3.9B). 
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4.4.3.2. Intermediate and C-terminal fragments (DYN 3-14, DYN 6-12, DYN 
2-17 and DYN 7-17) 
Figure 4.9 illustrates the effects of the intermediate (DYN 3-14 and DYN 6-12) and C-terminal 
(DYN 2-17 and DYN 7-17) fragments of DYN 1-17 on the modulation of TNF-α levels following 
LPS stimulation in differentiated THP-1 cells. Of these fragments, only DYN 3-14 showed 
significant modulatory effects on the secretion of TNF-α. Interestingly, in contrast to its inhibitory 
activity on IL-1β release, LPS-induced TNF-α secretion in differentiated THP-1 cells was 
unexpectedly further amplified in the presence of DYN 3-14 in concentrations of 10-11 M to 10-7 M 
(LPS, 100.00 ± 1.99; DYN 3-14: at 10-11 M, 112.70 ± 3.57; at 10-9 M, 116.80 ± 2.80; at 10-7 M, 
114.80 ± 4.03; p ≤ 0.05) (Figure 4.9A). Unlike its significant inhibition of IL-1β release at ultra-low 
concentrations, DYN 3-14 at 10-17 M to 10-13 M did not show any significant difference on TNF-α 
secretion induced by LPS. No significant effects on TNF-α release were also observed in 
differentiated cells that treated with DYN 6-12, DYN 2-17 and DYN 7-17 in comparison to LPS 
stimulation alone (Figure 4.9B). Furthermore, no modulation of TNF-α release was observed 
following treatment with the intermediate and C-terminal fragments in non-stimulated THP-1 cells 
(see Appendix 3, section 3.8B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 The modulation of the intermediate and C-terminal fragments of DYN 1-17 on the 
release of TNF-α in LPS-stimulated THP-1 cells. The LPS-stimulated THP-1 cells were treated 
with the (A) DYN 3-14 (10-17 to 10-7 M) and (B) DYN 6-12, DYN 2-17 and DYN 7-17 (10-11 to 10-
7 M) for 24 h. The culture supernatants were collected and TNF-α release was measured using the 
TNF-α AlphaLISA assay. The signal was measured using an EnSpire® Alpha 2390 plate reader. 
The release of TNF-α in each treatment group was normalised and expressed relative to LPS-
stimulated control group. Data recorded are mean ± SEM of at least three independent experiments 
performed in triplicate. *p ≤ 0.05 (One-way ANOVA, Bonferroni post-hoc test). 
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4.5. Discussion 
In response to injury-induced inflammation, many pro-inflammatory cytokines, in particular, IL-1β 
and TNF-α, are produced and released primarily by the macrophages. This process requires careful 
calibration and temporal orchestration to prevent dysregulation of cytokine release, which has the 
effect of worsening the inflammatory reaction. Immune-derived opioid peptides play a substantial 
role during inflammatory pain through modulation of macrophage cytokine production, highlighting 
their involvement in cytokine signalling pathways. The results presented in this chapter provide 
evidence for the modulation of human IL-1β and TNF-α release by DYN 1-17 and selected 
biotransformation fragments in LPS-activated macrophages. 
 
4.5.1. LPS induces IL-1β and TNF-α release in differentiated THP-1 cells 
LPS is known for its remarkable potency in triggering pro-inflammation cytokine production during 
innate immunity. Activation of TLR4, a specific receptor for LPS has been demonstrated to trigger 
rapid multiple intracellular signalling events in monocytes and macrophages, leading to production 
and secretion of various pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, IL-12 and IL-23 
(362, 363). These cytokines play a vital role in recruiting the effector cells to the site of infection, 
initiating and sustaining the inflammation (364). Overproduction of the cytokines, however, often 
lead to chronic inflammation.  
 
Due to the variety in experimental protocols in the literature and variability seen with LPS in 
different batch, the present study characterised the time- and concentration-dependent effects of 
LPS on the optimal release of IL-1β and TNF-α by PMA-differentiated THP-1 cells. Induction with 
LPS (1 µg/mL) for 24 h successfully released IL-1β to the optimal level for the assay, reflecting the 
concentration-dependency effect of LPS in differentiated THP-1 cells. This finding is consistent 
with data obtained previously, showing maximal accumulation of IL-1β in the culture supernatant 
and reaching a plateau level within the tested time frame after 24 h of LPS stimulation (296). While 
other studies have demonstrated that TNF-α protein peaked at 4 h and decreased gradually to 
baseline at 24 h post stimulation with 10-100 ng/mL of LPS in THP-1 cells (358, 360, 365), the 
results in the present study showed that TNF-α was optimally released by the THP-1 cells following 
LPS stimulation at 1 µg/mL for 24 h. This discrepancy could be attributed to the different 
experimental conditions including the use of PMA to differentiate monocytes to macrophages. A 
previous study has shown that PMA enhanced the response of differentiated THP-1 cells effectively 
towards LPS stimulation in comparison to undifferentiated cells. PMA induction triggers the 
accumulation of NF-κB in the cytoplasm without affecting the TNF-α gene transcription prior to the 
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stimulus, suggesting its important role in preparing the monocyte-like macrophages to respond 
immediately to infection (360). PMA has also been described to affect the up-regulation of IL-1β 
and TNF-α expression in treated cells; hence optimisation of PMA for THP-1 differentiation is 
essential to reduce the likelihood of a masking effect due to excessive usage of PMA (299). In the 
present study, the 50 nM of PMA has been previously optimised, therefore avoiding this possibility. 
Furthermore, the various sources of LPS used between these reported studies may be cause of the 
differences in their findings, indicating that different pyrogens may activate the cascade of immune 
signalling in different ways (366). The optimisation study presented here provided the groundwork 
for the current experimental design in order to elucidate the modulatory activity of DYN 1-17 and 
its biotransformation fragments on the release of IL-1β and TNF-α induced by LPS.  
 
4.5.2. The modulation of LPS-induced IL-1β and TNF-α in PMA-differentiated THP-1 
cells by DYN 1-17 and its N-terminal fragments  
DYN 1-17 and its biotransformation exhibit a differential modulation on the release of IL-1β and 
TNF-α, mediated through KOR-dependent and –independent pathways. In correlation with its prior 
NF-κB/p65 findings, the effects seen with DYN 1-7 on both cytokines release, which were almost 
completely reversed by ML-190 at 10-11 M suggests that DYN 1-7 actively interacts with KOR at 
low concentration to inhibit IL-1β and TNF-α release induced by LPS in activated macrophages. It 
is interesting to note that U50,488H, a selective KOR also exhibited similar inhibitory effects to 
DYN 1-7 in modulating IL-1β and TNF-α release. This finding broadly supports the work of 
another study in this area linking KOR activation with modulation of cytokine release. The selective 
KOR agonist U50,488H at concentrations as low as 10-10 M significantly inhibited IL-1β and TNF-
α secretion in macrophage cell line P338D1 (231). When the cells were treated with nor-BNI, a 
KOR-selective antagonist, this inhibition was reversed, confirming that U50,488H suppresses IL-1β 
and TNF-α through KOR activation (231).  
 
The differential effects shown by DYN 1-7 and DYN 1-6 on the release of LPS-induced IL-1β and 
TNF-α provide support for the differential actions of KOR activation on cytokine modulation. 
Supporting this, an earlier study has reported that ligands that are active at the same receptor site 
can produce different responses (367). In this instance, the differential effects shown by KOR 
agonists in mediating anti-nociception by acting at KOR has been reported previously. At low 
concentrations, nalorphine, a selective KOR subtype 3 agonist, significantly blocked morphine 
analgesia, however at a higher concentration, this agonist produced analgesia (368). In another 
study, U69,593, which is also a selective KOR agonist, was found to elicit a higher analgesic 
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response as compared to U50,488H (95% vs 60%) (369). The differences in signalling mechanisms 
of the KOR agonists could be due to opioid receptor heterodimerisation as shown by the synergistic 
binding of highly selective agonists by kappa-delta receptor heterodimers that further potentiates the 
signal transductions which are distinct from those of either receptor (370, 371).  
 
Furthermore, the non-peptide kappa selective ligands and the naturally occurring kappa opioid 
peptides, in this instance, U50,488H and the N-terminal fragments of DYN 1-17, respectively have 
shown differential modulation on immune functions despite sharing the common structural 
elements. Several possibilities may explain these discrepancies. Firstly, the complex structure with 
multiple stereocenters of the non-peptide KOR agonists in comparison with the KOR-associated 
peptides results in differential KOR regulation due to the different receptor conformational changes 
induced by both classes of ligands (328, 372). In addition to this, both classes of ligand may have a 
distinct regulation of calcium signalling in immune cells. Calcium signalling is one of the second 
messenger systems that are essential in opioid-mediated immune activation and regulation (373). 
Supporting this, an earlier study has reported that both dynorphin and U50,488H regulate 
intracellular calcium homeostasis differently in guinea pig cerebellar synaptomes (374). Finally, the 
kappa opioid peptides may have a tendency to bind to other opioid receptors albeit with a low 
affinity, whereas the non-peptide kappa ligands (e.g. U50,488H) selectively bind to KOR only 
(231), hence explaining the diverse immune regulatory pathways. All these possibilities may serve 
to explain the differential effects seen by both classes of KOR ligands due to their distinct 
sensitivities on KOR in modulating the release of pro-inflammatory cytokines in differentiated 
THP-1 cells following LPS stimulation. 
 
4.5.3. The modulation of LPS-induced IL-1β and TNF-α in PMA-differentiated THP-1 
cells by the intermediate and C-terminal fragments of DYN 1-17  
Among of the intermediate and C-terminal fragments, only DYN 3-14 modulated IL-1β and TNF-α, 
differentially. This result may reflect the earlier biotransformation study, in which DYN 3-14 was 
noted as being the most stable and prevalent (40). While the release of IL-1β was reduced following 
incubation with DYN 3-14 at ultra-low concentrations (10-11 to 10-17 M), DYN 3-14 further elevated 
TNF-α release induced by LPS in differentiated THP-1 cells. An earlier study has shown that DYN 
fragments at ultra-low concentrations (10-16 to 10-12 M) significantly modulated LPS-induced TNF-
α and nitric oxide by inhibiting the production of these inflammatory mediators in mouse primary 
mixed glia cultures, therefore, suggesting the involvement of a novel ultra-high-affinity receptor in 
mediating these inhibitory effects (42). A significant opioid peptide action on immune cells at ultra-
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low concentrations has also been reported in a number of experimental studies in different cell types 
(375-377).  
 
Evidence from a previous study has demonstrated opioids differential effects on cytokine release, 
showing that co-incubation of β-END and naltrindole resulted in the elevation of IL-1β production 
and the suppression of TNF-α levels in LPS-stimulated peripheral blood monocytes (349). 
Furthermore, the inverse secretion of TNF-α and IL-1β following LPS induction in isolated mouse 
macrophages (378) further describes the complexity of cytokine modulation by immune cells. A 
possible explanation for this might be that the release of IL-1β and TNF-α was measured following 
LPS stimulation in a native human monocyte-derived macrophage cell line (THP-1). There was a 
likelihood that multiple pathways were involved in producing opposing effects on cytokine release.  
 
Since LPS is a potent TLR4 ligand, it is possible that the attenuation of IL-1β release by DYN 3-14 
is mediated via TLR4 signalling pathway. The involvement of DYN 1-17 and the biotransformation 
fragments at TLR4 will be discussed further in Chapter Five. LPS-induced TNF-α production is 
regulated by a number of intracellular signal transduction pathways, including the MAPK family 
(379). LPS is able to induce ERK1 and ERK2, c-Jun N-terminal kinases (JNKs) and p38, which 
results in increased TNF-α translation (380, 381). Activation of ERK leads to transcription of c-Fos 
and activator protein-1 (AP-1) formation (382). Interestingly, several AP-1 binding regions have 
been identified on the TNF-α promoter, thus TNF-α secretion could be elicited through an AP-1 
transcription factor (378, 383). It is possible that, DYN 3-14 promotes ERK-dependent expression 
of AP-1 proteins, resulting in elevation of TNF-α levels in differentiated THP-1 cells. This, 
however, warrants further investigation.  
 
Differential effects of DYN 3-14 on both IL-1β and TNF-α release may suggest that this peptide is 
a biased antagonist at TLR4. Biased ligand refers to ligands that are able to stabilise multiple unique 
receptor confirmations, resulting in collateral activation of multiple intracellular pathways produced 
by interaction of different cellular coupling proteins (384). Another example of a biased ligand is 
the β-blocker propranolol. It is an ERK activator and at the same time inversely agonises Gs alpha 
subunit (Gsα)-mediated cAMP formation, denoting that some ligands can be agonists for some 
pathways and antagonists for others (385). The concept of biased ligand represents a novel 
approach for the development of more effective and better tolerated drugs as differential effects on 
cellular inflammatory processes may have implication clinically. 
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4.6. Conclusion 
In conclusion, LPS stimulation significantly induced the release of IL-1β and TNF-α from PMA-
differentiated THP-1 cells in a time-dependent fashion. Herein, treatment with DYN 1-17 and the 
selected biotransformation fragments (DYN 1-7, DYN 1-6 and DYN 3-14) have been shown to 
exhibit differential modulation on the release of both cytokines following LPS induction. DYN 1-7 
suppressed the release of IL-1β and TNF-α, while DYN 1-6 further elevated these cytokines, both 
involving KOR-dependent and KOR-independent pathways. Differential modulation of pro-
inflammatory cytokine release was also shown by DYN 3-14, which was concentration-dependent. 
At ultra-low concentrations (10-17 to 10-11 M), DYN 3-14 attenuated the release of IL-1β whereas at 
10-11 to 10-7 M, DYN 3-14 significantly modulated the release of TNF-α by amplifying the release 
of this cytokine, suggesting differential mechanisms involved in mediating these effects. While the 
suppressive effects of DYN 1-17 in IL-1β release is mediated through KOR, it is not clear why 
DYN 1-17 did not modulate TNF-α release. Taken together, DYN 1-17 and a select of 
biotransformation fragments (DYN 1-6, DYN 1-7 and DYN 3-14) may have particular relevance in 
the endogenous mechanisms for managing local inflammation through cytokine-dependent effects, 
hence enabling the communication between inflamed tissue and neurons, leading to functional and 
chemical changes during inflammation. 
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●    Chapter Five    ● 
Effects of DYN 1-17 and its biotransformation 
fragments on LPS-induced TLR4 signalling pathway
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5.  Chapt er  5 
5.1. Foreword 
LPS activation leads to inflammatory-driven cellular signals in immune cells; modulation of LPS-
induced TLR4 signalling may therefore suggests new pharmacological avenues for the use of 
biotransformed DYN 1-17 fragments in inflammatory-related conditions and gives an insight into 
effects on inflammatory response seen with opioids. This chapter explores the effect of DYN-17 
and its major biotransformation fragments at TLR4 following LPS stimulation using HEK-Blue™-
human TLR4 (hTLR4) cells.  
 
5.2. Introduction 
Innate immune cells such as monocytes are directed immediately to an inflamed site and are key to 
the first line of defence against invading pathogens or tissue injury (1). Recognition of TLR4 
expressed on innate immune cells results in multiple intracellular signalling cascades and the 
release of various inflammatory-related effector molecules (82). The recognition of LPS by TLR4 is 
facilitated by accessory molecules including myeloid differentiation 2 (MD2) and also CD14, that 
functions solely as a ligand-binding protein for LPS (313). The engagement of LPS with 
MD2/TLR4 complexes triggers TLR4 activation, leading to pro-inflammatory cellular signalling 
(48).  
 
There is evidence to suggest that the immunomodulatory role of opioids in both innate and adaptive 
immunity (386) is due to the presence of classical opioid receptors on both the central immune cells 
(microglia and astrocytes) and peripheral immune cells (macrophages, lymphocytes and T cells) 
(387). Nevertheless, non-opioid receptor sites have also been reported to be implicated in opioid-
induced immunomodulation. Morphine at micromolar concentrations was found to inhibit LPS-
induced interleukin-6 (IL-6) and TNF-α release associated with the attenuation of NF-κB activation 
in mouse peritoneal macrophages. This effect, however, was not reversed by naloxone, indicating 
the involvement of a non-opioid receptor mechanism (276). In addition, the inhibition of LPS-
induced NF-κB activation and resultant IL-1β release following naloxone treatment in RAW264 
cells was revealed to be mediated by L-type calcium channels (388). The enhancement of 
phagocytosis by DYN 1-17 in mouse peritoneal macrophages was reported to be dependent on 
intracellular calcium signalling (41). Furthermore, the inhibition of LPS-induced production of 
nitric oxide and TNF-α by DYN 1-8 was not blocked by the KOR antagonist nor-BNI, indicative of 
the involvement of non-opioid mechanisms in these inhibitory effects (42). 
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Removal of the amino-terminal tyrosine residue in opioid peptides yields fragments that are 
structurally “non-opioid” in nature with very low affinity for opioid receptors (209). Such fragments 
have been implicated in the modulation of immune responses through non-opioid mechanisms. For 
instance, DYN 2-17 was found to antagonise melanocortin receptors involved in controlling 
inflammatory disorders (243, 389) and to inhibit LPS-induced production of inflammatory 
cytokines in mixed glial cultures at ultra-low concentrations (42). Interestingly, DYN 6-12 
analogues were shown to potently suppress thermal oedema in a rat paw model, thereby suggesting 
that these analogues act on receptors for β1-integrins, which influence interstitial fluid pressure 
during inflammation (43).  
 
Hutchinson et al. have identified TLR4 as one of the possible sites for non-opioid receptor mediated 
mechanisms by highlighting a non-stereoselective reversal of neuropathic pain by both enantiomers 
of the opioid antagonists, naloxone and naltrexone, through inhibition of LPS-induced TLR4 
signalling (53). Moreover, morphine non-stereoselectively triggered TLR4 signalling in glial cells 
and this effect was notably blocked by (+)-naltrexone, (+)-naloxone, and (−)-naloxone, revealing an 
additional mechanistic role as TLR4 antagonists. Opioid-induced MD-2/TLR4 signalling was also 
observed in vivo using TLR4 knock-out mice (248). Further in silico docking analysis of human 
MD-2 has identified that MD-2, a potential binding site for opioids in the TLR4/MD-2 complex, 
might also involve TLR4 in the signalling pathway for opioids. This finding has been subsequently 
confirmed by structural and functional studies (390). Furthermore, in the absence of LPS, 
enantiomers of stereoisomeric opioids such as morphine and methadone still displayed significant 
TLR4 activation (248).  
 
It is therefore interesting to examine the modulatory role of DYN 1-17 and its biotransformation 
fragments, with a focus on the non-opioid fragments, in LPS-induced TLR4 activation pathway. In 
this chapter, the immunomodulatory effects of DYN 1-17 and selected biotransformation fragments 
on LPS-induced TLR4 signalling were assessed using HEK-Blue™-hTLR4 cells. HEK-Blue™ 
hTLR4 cells were designed for the monitoring of recombinant hTLR4 activation through a secreted 
embryonic alkaline phosphatase (SEAP) reporter gene. The cells were prepared by co-transfection 
of the human TLR4, MD-2 and CD14 co-receptor genes as well as a reporter plasmid expressing 
SEAP into HEK 293 cells. The SEAP reporter gene is placed under the control of IL-12 p40 
minimal promoter inducible by NF-κB and AP-1 transcription factors. Upon TLR4 stimulation with 
LPS, HEK-Blue™-hTLR4 cells activate NF-κB transcription factor and subsequently secrete 
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SEAP. The level of SEAP protein released into the culture media was used to determine the extent 
of TLR4 activation, which also represents the levels of NF-κB induction. 
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5.3. Materials and methods 
5.3.1. Materials  
All materials and chemicals were obtained from sources as detailed alphabetically (including 
catalogue number and supplier) in Appendix I and throughout the text. The desired stock 
concentrations of the DYN peptides were prepared in sterile ultrapure water (MilliQ®, Merck 
Millipore, Bayswater, Victoria, Australia). 
 
5.3.2. HEK-Blue™-hTLR4 cell culture  
A standard protocol for maintaining HEK-Blue™-hTLR4 cell line (InvivoGen, through Jomar Life 
Research, Scoresby, Victoria, Australia) was followed with slight modifications (54). Briefly, the 
cells were routinely grown and maintained in Dulbecco’s Modified Eagle’s Medium, DMEM 
supplemented with 10 % heat-inactivated FBS, 2 mM L-glutamine, 4.5 g/L glucose, 50 U/mL 
penicillin and 50 µg/mL streptomycin. This culture medium was, in addition, supplemented with 
1X HEK-Blue Selection reagent and 100 µg/mL Normocin to provide high antibiotic pressure, 
thereby ensuring persistent expression of hTLR4, MD2/CD14 and SEAP genes in the HEK-Blue™-
hTLR4 cells. The cells were split in ratios of 1:5 to 1:10 every two days or when approximately 80-
90 % confluency was reached into 75 cm2 tissue culture flasks and maintained at 37 °C in a 5 % 
humidified CO2 incubator. Cells were not used beyond passage number 20 for these experiments. 
The cell monolayer was rinsed once with 5 mL of 1X PBS and briefly incubated with PBS at 37 °C 
for 2 min. The tissue culture flask was gently tapped to dislodge any adherent cells and the detached 
cells were centrifuged at 250 x g for 4 min. Next, the supernatant was removed and the cell pellet 
was re-suspended in 5 mL of fresh culture media. For plating at specific cell densities in 96-well 
tissue culture plates, cell number was determined using a haemocytometer. Cell stocks (3-7 x 106 
cells) were res-suspended in freezing media (see Appendix 2, section 2.6) and stored frozen in 
cryotubes (1 mL/tube) at -80 °C for up to 6 months, or under liquid nitrogen for long term 
cryopreservation.  
 
5.3.3. Optimisation of LPS-induced TLR4 activation  
HEK-Blue™-hTLR4 cell inductions with LPS were performed according to the supplier’s 
recommendations with slight modification. HEK-Blue™-hTLR4 cells (2 x 105 cells/mL) were 
seeded in each well of 96-well plates (200 µL/well) and left to attach for 48 h in a humidified 
atmosphere at 37 °C under 5 % CO2. To optimise the LPS (derived from Escherichia coli, serotype 
O111:B4) concentration required to activate TLR4, a concentration-response curve for LPS-induced 
TLR4 activation was initially determined by stimulating the cells with 10-13 M to 10-6 M of LPS in 
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serum-free culture media for 24 h at 37 °C and 5 % CO2. The TLR4 signalling correlation with NF-
κB activation in the cell culture supernatant was assessed through SEAP production.  
 
5.3.4. SEAP assay 
The SEAP levels in the cell culture supernatant were determined with a colorimetric enzyme assay, 
using QUANTI-Blue™ detection reagent according to the manufacturer’s protocols. At the end of 
the treatment period, 20 µL aliquots of cell culture medium were removed and added to clear flat-
bottom 96-well plates containing 180 µL of pre-warmed detection reagent per well followed by 
incubation for 2 h at 37 °C under 5 % CO2. The optical densities were then measured at 655 nm 
wavelength using iMark™ microplate absorbance reader (Bio-Rad Laboratories, CA, USA) 
equipped with the Microplate Manager® 6 Software.  
 
5.3.5. Screening of DYN 1-17 and its biotransformation fragments on LPS-induced 
TLR4 activation  
Using an LPS submaximal concentration of 1 ng/mL, the effects of DYN 1-17 and the 
biotransformation fragments on TLR4 activation were assessed. LPS-induced cells were plated as 
described in section 5.3.2 and incubated in serum-free culture media in the presence of the 
respective peptides (DYN 1-17, DYN 1-6, DYN 1-7, DYN 1-9, DYN 1-10, DYN 1-11, DYN 2-17, 
DYN 6-12, DYN 3-14 and DYN 7-17) at concentrations of 0.1 µM, 1.0 µM, 3.0 µM and 10 µM for 
24 h at 37 °C. Additional peptides such as DYN 3-6, DYN 3-17 and DYN 4-17 were also examined 
for activity at TLR4. As positive control for this experiment, the cells were incubated with an opioid 
control, fentanyl at 0.1 µM, 1.0 µM, 3.0 µM and 10 µM under similar conditions. At the end of the 
treatment period, the SEAP level were determined accordingly (as described in section 5.3.4).  
 
5.3.6. Pharmacological inhibition of TLR4 
The concentration-inhibitory response curves of the peptides that displayed significant TLR4 
inhibition in the initial screening were compared with LPS-RS, a potent TLR4 inhibitor (10-12 to 10-
7 M). LPS-RS was initially prepared as a 5 mg/mL stock solution in endotoxin-free water and stored 
at 4 °C for up to a month or -20 °C for long term storage (6 months). The molecular weight of LPS-
RS was calculated to be 1497.8 Da. The efficacy of the respective peptides were also compared 
with LPS-RS (6.7 nM), on LPS concentration-response curves under similar conditions.  
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5.3.7. Assessment of HEK-Blue™-hTLR4 cell viability 
Cell viabilities were assessed using the MTT assay as described previously with slight 
modifications (391). Briefly, the HEK-Blue™-hTLR4 were seeded in 24-well plates (5 x 105 
cells/well) and cultured in 1 mL of culture medium containing DYN 1-17 and the biotransformation 
fragments at two concentrations (10 nM and 1 μM) for 24 h at 37 °C under 5 % CO2. Cells 
incubated with culture medium alone served as the positive control for this assay. The MTT reagent 
was added to the cell cultures (220 µL/well) to reach a final concentration of 2.5 mg/mL and further 
incubated for 2 h at 37 °C. The dark crystals formed were then dissolved by adding DMSO (1200 
µL/well) and shaken continuously on an orbital shaker (Ratek Instruments, VIC, Australia) for 20 
min. The plates were wrapped with aluminium foil to avoid direct exposure to light. Aliquots (100 
µL) from each well were transferred in duplicate into 96-well transparent microplates. Wells 
containing DMSO only in equivalent volume were used as blank. The optical density of the 
intracellular formazan, proportional to the number of viable cells present, was measured using a 
microplate reader (Bio-Rad Laboratories, CA, USA) at 590 nm. The average viable cell value after 
blank absorbance subtraction was calculated as a fraction of the average value obtained from cells 
incubated with medium alone. 
 
5.3.8. Statistical analysis 
All experiments were performed in triplicate and repeated in at least three independent experiments. 
Data are presented as mean ± SEM. GraphPad Prism® 6.07 (GraphPad Software Inc, USA) was 
used for all data analysis. Multiple comparisons between groups were analysed using one-way 
ANOVA followed by Bonferroni post-hoc test. Concentration-response curves were analysed using 
non-linear regression analysis to obtain estimates of IC50 values. P values < 0.05 were considered as 
statistically significant.  
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5.4. Results 
5.4.1. Optimisation of LPS concentration for TLR4 activation  
LPS is a prototypical TLR4 activator. In order to confirm the unique role of TLR4 in LPS signalling 
as well as to show full functionality of the cells, HEK-Blue™-hTLR4 cells were stimulated with 
LPS derived from E. coli serotype O111:B4. In this study, the optimal concentrations of LPS were 
first determined by constructing concentration-response curves as a range of concentrations, used 
for TLR4 activation in HEK-Blue™-hTLR4 cells, was evident in the literature (54, 392). LPS 
stimulation caused the cell culture medium colour shift from pink to purple/blue as detected by the 
QUANTI-Blue™ detection reagent (Figure 5.1A). The intensity of the colour change occurred in 
parallel with the increasing concentrations of LPS, representing the SEAP activity that indirectly 
correlates with NF-κB activation following TLR4 stimulation by LPS. No medium colour change 
was observed among the non-stimulated cells, describing the absence of TLR4 activation. When 
plotted using TLR4 response against log concentration with a sigmoidal fitted to the data, the 
concentration-dependent effects of LPS at TLR4 reached a maximal value at 10-6 g/mL of LPS 
(Figure 5.1B), with an EC50 value of 0.46 ± 1.05 ng/mL. LPS at 1 ng/mL was therefore chosen as 
the optimal concentration to stimulate TLR4 activation in HEK-Blue™-hTLR4 for the remainder of 
this study.  
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Figure 5.1 LPS-induced TLR4 activation. Cells were stimulated with LPS from E. coli (10-13 M 
to 10-6 M). After 24 h incubation, NF-κB-induced SEAP release in the supernatant was assessed 
using QUANTI-Blue™ and the optical density was measured spectrophotometrically at 655 nm. 
(A) A qualitative representation of LPS concentration-dependent changes in purple/blue colour 
development, indicative of increased SEAP release. The detection medium changed from pink to 
purple/blue in parallel with increasing LPS concentration. (B) LPS concentration-response curve. 
Data are represented as mean ± SEM of three independent experiments performed in triplicate. 
Non-linear regression using a sigmoidal model was used to analyse and determine EC50. 
B 
A 
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5.4.2. The effects of DYN 1-17 and its biotransformation fragments on LPS-induced 
TLR4 activation  
TLR4 selectively recognises LPS, leading to downstream inflammatory-related intracellular 
responses including translocation and translation of NF-κB transcription factors and release of pro-
inflammatory cytokines (393). Upon screening of DYN 1-17 and selected biotransformation 
fragments, only DYN 3-14 showed significant inhibition of TLR4 activation in a concentration-
dependent manner (p < 0.05) (Figure 5.2). No significant modulation of TLR4 signalling by other 
fragments and fentanyl was observed (see Appendix 3, section 3.10). Further studies demonstrated 
that DYN 3-14 displayed a lower potency than LPS-RS, (IC50=1.42 µM vs. IC50=5.09 nM, 
respectively) in inhibiting LPS-induced TLR4 activation. DYN 3-14 alone had no effect on TLR4 
signalling in the absence of LPS (see Appendix 3, section 3.11).  
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Figure 5.2 Inhibition curves for DYN 3-14 and LPS-RS on LPS-induced TLR4 activation. 
HEK-Blue™-hTLR4 reporter cell lines were stimulated with LPS 1 ng/mL and treated with DYN 
3-14 (10-8 M to 10-5 M) or LPS-RS (10-12 M to 10-7 M) for 24 h. The percentage of maximal 
response of TLR4 activation in each treatment group was normalised and expressed relative to LPS 
control group. Data are represented as mean ± SEM of at least three independent experiments in 
triplicate, IC50 values assessed using a sigmoidal model and non-linear regression. 
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In addition to these observations, the TLR4 antagonistic effects of DYN 3-14 (10 µM) and LPS-RS 
(6.7 nM) were also assessed against LPS concentration-response curves. DYN 3-14 shifted the LPS 
concentration-response curve to the right with a higher EC50 value of 0.78 ± 1.08 ng/mL (Figure 
5.3, red dashed line). LPS-RS resulted in a greater shift to the right with an EC50 value of 1.42 ± 
1.07 ng/mL (Figure 5.3, green dotted line). An F-test with a value of 74.82 rejected the null 
hypothesis, indicating that the EC50 values for each graph were different from LPS. Both DYN 3-14 
and LPS-RS achieved similar maximal inhibition of LPS induced TLR4 activation at 10 -6 g/mL, 
indicating that both are full antagonists for the TLR4 receptor complex.  
 
5.4.3. DYN 1-17 and its biotransformation fragments have no effect on the viability of 
LPS-induced HEK-Blue™-hTLR4 cells  
DYN 1-17 and the biotransformation fragments at 0.1 µM, 1 µM, 3 µM and 10 µM did not have 
any significant effects on the viability of the HEK-Blue™-hTLR4 cells stimulated by LPS (p > 
0.05).  
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Figure 5.3 Effects of DYN 3-14 and LPS-RS on LPS-induced TLR4 signalling. HEK-Blue™-
hTLR4 reporter cell lines were stimulated with LPS alone (concentrations ranging from 10-12 to 10-6 
g/mL), with combination of LPS and DYN 3-14 (10 µM) or with combination of LPS and LPS-RS 
(6.7 nM) for 24 h. The percentage of maximal response of TLR4 activation in each treatment group 
was normalised and expressed relative to LPS alone-stimulated control group. Data shown are mean 
± SEM of at least three independent experiments in triplicate. EC50 values were assessed using non-
linear regression as above.  
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5.5. Discussion 
DYN 1-17 is released by leukocytes in inflamed tissues and plays an important role in regulating 
inflammatory pain (27). The immunoregulation observed may be facilitated by a range of opioid 
and non-opioid acting fragments, produced following biotransformation of DYN 1-17 at the site of 
inflammation (40). Biotransformation resulting in the removal of the first tyrosine in opioid peptide 
sequence yields fragments that are structurally “non-opioid” in nature with very low affinities for 
opioid receptors (209). Outside of traditional opioid receptor-mediated effects, evidence of non-
opioid receptor roles for opioid peptides includes their actions at melanocortin receptors (43, 243), 
bradykinin receptors (34), NMDA receptor complex (394) and, recently, TLR4 (248). Therefore, 
the potential effects of biotransformed opioid peptides may involve a number of possible 
mechanisms. The aim of this chapter was to explore the possibility of DYN 1-17 and the 
biotransformation fragments, with a focus on non-opioid fragments (DYN 2-17, DYN 3-14, DYN 
6-12 and DYN 7-17), in modulating inflammatory responses through TLR4. Interestingly, DYN 3-
14 has been shown previously to be the most abundant fragment produced in rodent inflamed tissue 
(40), but this compound did not exhibit any KOR activity (as presented in Chapter Three and 
Chapter Four of this thesis), suggesting that this non-opioid fragment may elicit its 
immunomodulatory activity via a non-opioidergic pathway.  
 
5.5.1. LPS E. coli O111:B4 induces specific TLR4 activation  
The activation of NF-κB by LPS is fundamentally mediated through the TLR4 receptor (48, 395). A 
number of studies have reported the involvement of numerous opioids in the modulation of the 
TLR4 signalling pathway (396-398). For this reason, HEK-Blue™-hTLR4 cells were used to 
elucidate the mechanism underlying the modulation by DYN 1-17 and selected biotransformation 
fragments, as these cells overexpress TLR4 receptors. LPS from E. coli O111:B4 was used to 
stimulate the inflammatory response and this compound specifically activates TLR4 selectively 
(399), excluding the involvement of other TLRs and thus, defines the pathogen serotype specificity 
in TLR4 signalling (399).  
 
5.5.2. DYN 3-14 inhibits LPS-induced TLR4 activation in HEK-Blue™-hTLR4 cells   
This study has demonstrated that DYN 3-14 blocks LPS-induced TLR4 signalling in HEK-Blue™-
hTLR4 cells, thus providing a mechanistic insight into the inhibition of NF-κB/p65 translocation 
seen with DYN 3-14 in the differentiated THP-1 cells (Chapter Three). The selectivity of the 
modulatory effect of DYN 3-14 at TLRs other than TLR4 has not been explored. However, other 
biotransformation fragments including a range of opioid and non-opioid DYN-related peptides such 
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as DYN 2-17, DYN 6-12, DYN 7-17 and DYN 3-6 have been investigated utilising the TLR4 
overexpressed HEK cells; none of these fragments modulated TLR4 signalling, providing some 
insights into the selective nature of DYN 3-14 activity (see Appendix 3, section 3.10).  
 
The current study is the first to demonstrate the modulatory effect of DYN-related opioid peptides 
at TLR4 during inflammation. A recent study by Sauer et al. has demonstrated that β-END is 
released from monocytes dependent on calcium through stimulation with the TLR4 agonist, LPS. 
This study highlights that TLR4 potentially regulates peripheral endogenous opioid-mediated 
analgesia in inflammation (56). Opioid agents such as morphine and fentanyl have been shown to 
inhibit TLR4 signalling through non-competitive binding with LPS (54). Other studies have also 
demonstrated that the opioid antagonist, beta-funaltrexamine (β-FNA), inhibits chemokine and 
inducible nitric-oxide synthase expression in human astroglial cells through a non-opioid receptor 
mechanism (400, 401), indicating that opioids may act through a similar mechanism to that 
described above to regulate inflammatory signals. Moreover, increasing numbers of host-derived 
molecules have been proposed to be involved in disease pathogenesis via TLR4-dependent 
signalling pathways (277, 402).  
 
5.5.3. DYN 3-14 has a lower potency than LPS-RS in the inhibition of LPS-induced 
TLR4 activation     
Further examination of the concentration-effect profile of DYN 3-14 at TLR4 has shown that LPS 
induced TLR4 activation in a concentration-dependent manner. This finding is consistent with a 
previous study on LPS induction on TLR4 signalling using luciferase assay (48). Supporting this 
observation, the EC50 value obtained from the LPS-alone sigmoidal concentration-response curve 
was 0.46 ng/mL, a concentration which falls within the range of previously reported values for the 
same reporter cells (54, 403). LPS-RS, derived from Rhodobacter sphaeroides, is a potent 
competitive inhibitor of LPS at TLR4 in both human and murine cells (404). Complete inhibition of 
LPS effects on TLR4 was shown by either DYN 3-14 or LPS-RS when co-incubated in the presence 
of LPS. LPS-RS, however, exhibited greater potency in comparison to DYN 3-14 as an antagonist 
of LPS-induced TLR4 signalling. In congruence with the lower potency exhibited by DYN 3-14, 
this peptide was produced abundantly following biotransformation of DYN 1-17 in rodent inflamed 
tissue homogenate (40), hence suggesting that high local concentrations are present in the 
inflammatory milieu. In addition, DYN 3-14 at higher concentrations (10 µM) inhibited LPS-
induced TLR4 signalling in overexpressing TLR4 cells. Taken together, it can be postulated that 
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DYN 3-14 may be generated in significantly high quantities at localised sites of inflammation, 
thereby resulting in anti-inflammatory effects.  
 
5.6. Conclusion 
In conclusion, this study has shown that DYN 3-14 acts via a TLR4 post-receptor signalling 
mechanism in regulating inflammatory signals following LPS stimulation. This, thereby suggests a 
possible role for endogenous opioid peptides that are produced readily in the body during 
inflammation to promote immunomodulation in inflamed tissues, highlighting a possible new 
avenue for therapeutic intervention. DYN 3-14 has been shown to have an anti-inflammatory role in 
nature through its inhibition of NF-κB/p65 translocation and subsequent modulation of IL-1β 
release via competitive antagonism at TLR4, suggesting potential prospective use of this 
endogenous opioid fragment in treating inflammatory diseases. 
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●    Chapter Six    ● 
Biotransformation of DYN 1-17 in  
inflamed human nasal tissue
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6.  Chapt er  6 
6.1. Foreword 
DYN 1-17 is subject to metabolism by enzymatic cleavage, producing smaller fragments. Some of 
these fragments have been shown to have a regulatory role at the site at which they are metabolised. 
The work presented in this chapter aims to extend and confirm previously reported studies by 
characterising, using a validated bioanalytical liquid chromatography-mass spectrometry (LC-MS) 
method, biotransformation of DYN 1-17 in inflamed human nasal tissue and the subsequent 
generation of fragments that may be implicated in disease pathology. 
 
6.2. Introduction 
It is now well established, from a variety of studies, that, upon release from neurons or immune 
cells, DYN 1-17 is subjected to rapid metabolic degradation, producing a select group of 
metabolites that possess diverse physiological and pharmacological roles in nature. The metabolism 
of the DYN 1-17 has been studied extensively in vitro and in vivo in rats (222, 224, 405, 406) as 
well as in the rhesus monkey (223) and human blood (220, 223). Others have also examined the 
biotransformation of DYN 1-13 and its fragments in human plasma, blood (220, 221) cerebrospinal 
fluid (407) and in rat brain (408). In addition, disease has been shown to influence the metabolism 
of DYN 1-17. This is exemplified by a different range of fragments produced in a rodent model of 
Parkinson’s disease in comparison to those observed in healthy rats (224). In a recent study, DYN 
1-17 has been shown to undergo metabolic degradation in rodent inflamed tissue, producing a 
variety of smaller fragments that differ from those observed in non-inflamed tissue and blood (40). 
This finding further supports the notion that the DYN 1-17 has a potential role in inflammatory pain 
(27). It is noteworthy that, all of these studies produced diverse and unique sets of biotransformed 
fragments, thus demonstrating that metabolism of DYN 1-17 is dependent on the site at which it is 
metabolised, the presence or otherwise of disease, and other biological factors e.g. enzymes, pH and 
temperature. These factors reflect the differential enzyme-catalysed hydrolysis processes and the 
complexity of the metabolic pathways involved in biotransformation of DYN 1-17. 
 
Numerous analytical methods have been employed previously to detect and quantify constituent 
target proteins in biological matrices including immunoassays (RIA and ELISA) and LC-MS. RIA 
and ELISA are traditionally used to detect endogenous opioid peptides in plasma and tissue 
homogenates (409-411). These antibody-based approaches, however, have several limitations 
including high levels of inter-assay variability, and importantly, the lack of available specific 
antibodies for different target proteins of interest (222, 412, 413). A minor modification in the 
protein structure serving to distinguish endogenous and exogenous variants (414), may not be 
 118 
 
detected by ELISA thereby, potentially resulting in false positive or negative findings (415). The 
development of specific antibodies is additionally challenging; it is an exhaustive and laborious 
process in addition to the requirement in designing various species-specific antibody epitopes (416). 
Such factors therefore compromise the accuracy and sensitivity of these methods for analysing 
peptides in biological samples.  
 
The recent application of LC-MS offers a more precise, accurate and efficient qualitative and 
quantitative analysis of target proteins, hence its application to endogenous opioid peptides (417). 
The technique provides opportunities to analyse a wide spectrum of proteins including those with 
post-translational modifications through multiplex detection in a single experiment (413); such an 
approach is more sensitive and is also able to specifically detect peptides with the appropriate 
molecular masses. A number of earlier studies on opioid peptide metabolism have utilised LC-MS 
coupled with matrix-assisted laser desorption/ionisation (MALDI) or electrospray ionisation (ESI) 
that allows ‘soft ionisation’ of peptides without the propensity of peptide fragmentation, hence 
providing a more accurate molecular mass of the target peptides (40, 418, 419). The label- and gel-
free quantitation of the LC-MS method provides a greater specificity and sensitivity with less inter- 
and intra-variation between assays, thereby reducing the possibility of false positive findings (420). 
Moreover, this method also demonstrates a highly reproducible approach to peptide sequencing and 
the identification of various fragments according to their molecular mass (222). The multiplexing 
capability of this analytical method and the modest instrument time required per sample in 
producing consistent and reliable data further outline the robustness of LC-MS as a useful tool for 
elucidating peptide metabolism and performing metabolic pathway analysis in various complex 
biological matrices (416). 
 
The effects of DYN 1-17 and its biotransformation fragments on the modulation of inflammatory 
signals have been presented in Chapters Three, Four and Five; the study presented here aims to 
extend previous findings of DYN 1-17 metabolic degradation in rodent inflamed tissue by further 
characterising and defining the biotransformation of this endogenous peptide in the context of 
inflammatory disease in human tissue. Employing a similar methodology to that of the previous 
biotransformation study of DYN 1-17 by Morgan et al. (40), this study is the first to examine the 
DYN 1-17 degradation profile in inflamed human tissue. The obtained fragmentation pattern will 
provide an overview of the possible physiological and disease-related metabolic processing of 
endogenous opioid peptides, thereby revealing information on the pharmacological activities of 
DYN 1-17 and its specific biotransformation fragments in human disease.  
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6.3. Materials and methods  
6.3.1. Materials  
Details of all materials and chemicals (including catalogue number and supplier) were obtained 
from sources as listed alphabetically in Appendix I and throughout the text. High-purity water was 
prepared in-house using a Millipore Milli-Q system (Milford, USA). Water and solvents used for 
the mobile phases were filtered through a Nylon 0.45 μm, 47 mm membrane filter (Sigma Aldrich, 
NSW, Australia). 
 
6.3.2. Ethics statement  
The study was conducted using a human subject research protocol after approval by the 
Greenslopes Research and Ethics Committee, Greenslopes Private Hospital and Human Research 
Ethics Committee, the University of Queensland. All patients were provided with written informed 
consent for the collection of samples and subsequent analysis.  
 
6.3.3. Nasal biopsy 
All procedures were performed under local nasal anaesthesia by experienced otolaryngologists at 
the Greenslopes Private Hospital. The inflamed nasal tissue biopsies were taken from the nasal 
cavity/sinuses as part of the elective septoplasty with or without reduction of turbinates surgery, 
endoscopic sinus surgery or trans-sphenoidal pituitary surgery and transported immediately to 
Pharmacy Australia Centre of Excellence (PACE) laboratory. Large biopsies were cut into smaller 
pieces (0.5 x 0.5 mm) before being stored in a -80 °C freezer in 0.32 M aqueous sucrose solution 
until homogenisation. 
 
6.3.4. Fragmentation of DYN 1-17 in inflamed human nasal tissue homogenates 
The nasal biopsy tissues were homogenised with 10 mM PBS (pH 7.4) or 10 mM MES (pH 5.5) 
buffers at a ratio of 1 g tissue in 10 mL buffer using an ultrasonic processor attached to a 6 mm 
probe (Vibra-Cell™ VC130, Sonics, USA). The homogenised samples were then centrifuged at 
1600 g for 10 min at 4 °C and the resulting supernatant was incubated with DYN 1-17 to a final 
concentration of 150 µM in a temperature controlled room (37 °C) for periods up to 120 min. 
During the incubation periods, 100 µL of sample was removed at different time intervals (0, 2, 5, 
10, 15, 20, 30, 45, 60, 90 and 120 min) and vortex mixed with 200 µL of acetonitrile for 1 min to 
halt the enzymatic reaction. The samples were then brought to room temperature and incubated for 
at least 20 min to allow protein precipitation and centrifuged at 12,500 g for 15 min at 25 °C. The 
resultant supernatant was collected in a new microcentrifuge tube, placed on a heating block at 37 
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°C and evaporated to dryness under a gentle stream of nitrogen. After evaporation, residues were 
reconstituted with 75 μL of Milli-Q water, vortex mixed for 30 sec and transferred to auto-sampler 
vials for analysis. To prevent adsorption, all samples containing peptides were stored in 
polypropylene containers.  
 
6.3.5. LC-MS 
A previously validated method for the quantification of DYN 1-17 in inflamed tissue was employed 
in this study (40, 419). The chromatographic separation was performed on a Jupiter® C4, 300 Å 
(150 × 4.6 mm, 5 μm) reversed phase analytical column (Phenomenex, Lane Cove, NSW, 
Australia) fitted with a SecurityGuard™ cartridge system containing a C4 (4 × 2.0 mm) pre-column 
(Phenomenex, NSW, Australia) and coupled to an Agilent 1100 series HPLC system consisting of 
an Agilent LC binary pump, an Agilent (Agilent Technologies, CA, USA) 1100 well plate auto-
sampler, degasser and column compartment; the latter was maintained at 12 °C. The separations 
were performed at a flow rate of 200 µL/min using a binary solvent mixture consisting of 0.1 % 
formic acid in water (A) and 0.1 % of formic acid in acetonitrile (B). Following a 10 min period of 
column equilibration with 0 % B, the sample was injected (20 μL). After injection, isocratic elution 
was maintained at 0 % B for 3 min and then changed from 0 % B to 50 % B over the next 30 min. 
Subsequently, the composition of the mobile phase was changed to 100 % B within the next 5 min 
and remained at the same gradient over the next 2 min. The mobile phase was then returned to the 
starting composition of 0 % B within the next 3 min and the column was re-equilibrated for 10 min 
before the next sample was injected. The total run time including column equilibration was 53 min.  
 
Identification and characterisation of biotransformed fragments of DYN 1-17 was performed using 
API 3000 triple quadrupole mass spectrometry (Applied Biosystems, CA, USA) equipped with ESI 
set in the positive ion mode. The mass spectrometer ion spray (IS) voltage, declustering potential 
(DP), focusing potential (FP), and entrance potential (EP) were set at 4200, 30, 200 and 10 V, 
respectively as previously optimised (40, 419). The total ion current (TIC) mode (MS1/Q1) and 
MS2 scan mode were used to detect the resultant fragments and obtain the structural information, 
respectively. Analyst™ version 1.6.2 software was used for data acquisition and processing. 
Detection of fragments from the mass spectra were predicted based on their mass/charge (m/z) 
values, calculated using Peptide Sequence Fragmentation Modelling tool in a molecular weight 
calculator software (Monroe M., Washington, USA 
http://www.alchemistmatt.com/resume/mwtoverview.html). 
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6.3.6. Mean residence time (MRT) 
To determine the average time of a particular fragment residing in specific milieu, the MRT for all 
observed fragments were calculated based on the following equation (421):  
 
 
 
Both area under the first moment of the molecule concentration-time curve (AUMC) and area under 
the concentration-time curve (AUC) were expressed accordingly as below:  
 
 
 
 
 defines area under the analyte peak on the mass chromatogram and  represents incubation time 
boundaries.  
 
6.3.7. Peptide stability  
To determine the stability of DYN 1-17, DYN 1-6, DYN 1-7, DYN 1-9 and DYN 3-14 in the 
AlphaLISA and TLR4 signalling assays, these peptides were incubated with THP-1 cells and HEK-
Blue™-hTLR cells suspended in the culture medium at the highest concentrations of cells used (4 x 
104 cells/well). The treated cells were incubated for 1 h and 24 h and the culture supernatants were 
collected for peptide analysis using LC-MS. A protein precipitation method was used for protein 
extraction and sample clean-up. Briefly, the culture supernatants (100 µL) were vortex mixed with 
acetonitrile (200 µL) for a minute (to terminate the enzymatic reaction) followed by at least a 20-
min incubation at room temperature to allow protein precipitation. Next, the samples were 
centrifuged at 12,500 g for 15 min at 25 °C. The resultant supernatant was collected and placed on a 
heating block at 37 °C and evaporated to dryness under a gentle stream of nitrogen. The residues 
were then reconstituted with 75 μL of Milli-Q water, vortex mixed for 30 sec and transferred to 
auto-sampler vials for analysis. 
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6.4. Results 
6.4.1. Biotransformation of DYN 1-17 in inflamed human nasal tissue at pH 7.4 
In this study, the incubation of DYN 1-17 with inflamed tissue was performed ex vivo at 37 °C and 
pH 7.4. Intact DYN 1-17 (Figure 6.1) was observed at a retention time of 19.4 min with the 
following mass/charge (m/z) ratios: 1+ 2149.3; 2+ 1074.8; 3+ 716.8; 4+ 538.0; 5+ 430.8 and 6+ 
359.3. DYN 1-17 was rapidly metabolised into smaller fragments at 30 min incubation time. The 
decline in the peak intensity of DYN 1-17 occurs in concert with the formation of smaller peptide 
fragments. A total of 14 different biotransformation fragments were detected throughout the 
experiment and the resultant chromatograms corresponding to the fragments detected at 30 and 120 
min following the incubation at pH 7.4 (Figure 6.2). As shown in Figure 6.2, the following DYN 1-
17 fragments were generated at 30 min post-incubation: DYN 13-17, co-eluting with DYN 3-15 
(peak 1), DYN 2-8 (peak 2), DYN 9-17 co-eluting with DYN 11-17 (peak 3), DYN 7-17 (peak 4), 
DYN 8-17, DYN 12-17 and DYN 7-14 (peak 5) that co-elute, DYN 1-7 (peak 6), DYN 1-11 (peak 
7) and DYN 1-6 (peak 8). DYN 1-15, that co-elutes with DYN 3-14 (peak 9), were observed at 
19.98 min post-incubation. The cleavage patterns of DYN 1-17 biotransformation observed at pH 
7.4 together with their respective m/z values are given in Table 6.1. The mass spectra of each 
detected fragment are provided in Appendix 3, section 3.14. Some expected fragments (as indicated 
by their calculated m/z values) of DYN 1-17 were not present or were below the limit of detection 
(see Table 6.1). When DYN 1-17 was incubated alone in PBS buffer (pH 7.4) for a 2 h period, no 
significant reduction in peak intensity for DYN 1-17 was seen, indicating that non-enzymatic 
degradation was not involved in the incubations of DYN 1-17 at pH 7.4 (see Appendix 3, section 
3.13B). 
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Figure 6.1 Identification of DYN 1-17 at pH 7.4. TIC chromatogram and mass spectrum of DYN 
1-17 detected at 0 min during incubation at 37 °C with inflamed human nasal tissue at pH 7.4.  
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Figure 6.2 TIC chromatograms of DYN 1-17 biotransformation fragments at pH 7.4. The 
peaks represent biotransformed fragments detected (A) 30 min and (B) 120 min post-incubation of 
DYN 1-17 at 37 °C with inflamed human nasal tissue at pH 7.4 (peak 1: DYN 13-17,DYN 3-15; 
peak 2: DYN 2-8; peak 3: DYN 9-17, DYN 11-17; peak 4: DYN 7-17; peak 5: DYN 8-17, DYN 12-
17, DYN 7-14; peak 6: DYN 1-7; peak 7: DYN 1-11; peak 8: DYN 1-6 and peak 9: DYN 1-15, DYN 
3-14). 
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Table 6.1: The cleavage patterns of DYN 1-17 biotransformation fragments at pH 7.4. These fragments were produced following incubation of 
DYN 1-17 at 37 °C with homogenised human inflamed tissue at pH 7.4 for 120 min and their respective m/z values. 
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6.4.2. Biotransformation of DYN 1-17 in inflamed human nasal tissue at pH 5.5 
The chromatogram and mass spectrum shown in Figure 6.3 represent DYN 1-17 detected at 0 min 
incubation with inflamed nasal tissue at pH 5.5. The retention time for detection was around 19.4 
min with the following mass/charge (m/z) ratios: 1+ 2149.3; 2+ 1074.8; 3+ 716.8; 4+ 537.7; 5+ 
430.4 and 6+ 359.3, similar to those observed at pH 7.4. After 90 min incubation under the same 
conditions, DYN 1-17 was essentially completely biotransformed into smaller fragments; the peak 
for DYN 1-17 being absent in the chromatogram. Figure 6.4 corresponds to the chromatograms of 
the peptide fragments observed after 20 min and 120 min incubations of DYN 1-17. The following 
DYN 1-17 fragments: DYN 13-17 and DYN 3-15 (peak 1), DYN 11-17 and DYN 9-17 (peak 2), 
DYN 7-17 and DYN 9-15 (peak 3), DYN 8-17 (peak 4), DYN 1-7 (peak 5), DYN 1-11 (peak 6), 
DYN 1-6 (peak 7), DYN 2-17 (peak 8), DYN 1-10 (peak 9), DYN 1-15 (peak 10), DYN 3-14 (peak 
11), DYN 1-5 (peak 12), DYN 2-8 (peak 13), DYN 9-16 (peak 14) and DYN 2-10 (peak 15). Other 
fragments detected at different incubation times were DYN 7-15 (post 15 min incubation), DYN 
12-17 (post 30 min incubation), DYN 8-13 and DYN 7-14 (post 60 min incubation), resulting in a 
total of 22 peptide fragments of DYN 1-17. A mass spectrum for each detected fragment is 
provided in Appendix 3, section 3.15. A summary of the detected fragments and their m/z values is 
shown in Table 6.2. To confirm that enzymes present in inflamed tissues are responsible for the 
degradation of DYN 1-17 into different fragments, DYN 1-17 was added to MES buffer without the 
presence of homogenised inflamed tissue followed by a 120-min incubation time. The results 
demonstrated that no fragments were detected, confirming that the hydrolytic cleavage of DYN 1-
17 was due to enzymes present in the inflamed tissue and not due to the acidic pH (see Appendix 3, 
section 3.13A). 
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Figure 6.3 Identification of DYN 1-17 at pH 5.5. TIC chromatogram and mass spectrum of DYN 
1-17 detected at 0 min following incubation at 37 °C with inflamed human nasal tissue at pH 5.5.  
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Figure 6.4 TIC chromatograms of DYN 1-17 biotransformation fragments at pH 5.5. The 
peaks represent biotransformed fragments detected at (A) 20 min and (B) 120 min post-incubation 
of DYN 1-17 at 37 °C with inflamed human nasal tissue at pH 5.5 (peak 1: DYN 13-17, DYN 3-15; 
peak 2: DYN 11-17, DYN 9-17; peak 3: DYN 7-17, DYN 9-15; peak 4: DYN 8-17; peak 5: DYN 1-7; 
peak 6: DYN 1-11; peak 7: DYN 1-6; peak 8: DYN 2-17; peak 9: DYN 1-10; peak 10: DYN 1-15; 
peak 11: DYN 3-14; peak 12: DYN 1-5; peak 13: DYN 2-8; peak 14: DYN 9-16 and peak 15: DYN 
2-10).  
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Table 6.2: The cleavage patterns of DYN 1-17 biotransformation fragments at pH 5.5. These fragments were produced following incubation of 
DYN 1-17 at 37 °C with homogenised human inflamed tissue at pH 5.5 for 120 min and their respective m/z values.  
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6.4.3. Metabolism profile of DYN 1-17 and its major fragments in inflamed human 
nasal tissue at pH 7.4 and pH 5.5 
Biotransformation of DYN 1-17 produced a range of fragments as a result of enzymatic hydrolysis. 
To determine the metabolism profile of DYN 1-17 in the inflamed human nasal homogenates at 
different pH, the peak intensity for DYN 1-17 in the chromatogram at each time point was 
estimated. Figure 6.5 shows the comparative hydrolysis of intact DYN 1-17 at pH 7.4 and pH 5.5, 
indicating that under similar experimental conditions, DYN 1-17 revealed reduced metabolism at 
pH 5.5 in comparison to pH 7.4. The different starting points for both pH values may be related to 
the ionisation ability of DYN 1-17 in the MS due to incubation in different buffers. The production 
of the N-terminal fragments at different pH conditions over the 2 h incubation period is shown in 
Figure 6.6. The concentration of each fragment is represented by the peak intensity. With an 
exception of DYN 1-5, the peak intensities for the N-terminal fragments (DYN 1-6, DYN 1-7, DYN 
1-10, DYN 1-11 and DYN 1-15) at both pH values increased substantially in the early time points 
of the incubation followed by a gradual decline, denoting that these fragments were generated and 
subsequently, further metabolised. The maximum peak levels of DYN 1-6, DYN 1-7, DYN 1-10, 
DYN 1-11 and DYN 1-15 at both pH were seen between 10-20 min, indicating that these fragments 
were produced and metabolised rapidly in comparison to DYN 1-5 (maximum peak level was at 60 
min). DYN 1-5 was produced and metabolised rather slowly in comparison to the other N-terminal 
fragments (Figure 6.6 B).  
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Figure 6.5 The effect of pH on the time course of DYN 1-17 hydrolytic metabolism at 37 °C 
following incubation with inflamed human nasal tissue. The peak intensity of DYN 1-17 was 
determined at each time point at pH 5.5 and pH 7.4. 
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Figure 6.6 The metabolism profile of the N-terminal fragments of DYN 1-17 over a 2 h period 
following incubation with inflamed human nasal tissue. DYN 1-17 was incubated at 37 °C with 
inflamed human nasal tissue at pH 7.4 and pH 5.5 over 120 min. The peak intensities of the main N-
terminal fragments at (A) pH 7.4 and (B) pH 5.5 were determined at each time point and plotted. 
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Similarly, the intermediate and C-terminal fragments of DYN 1-17 also exhibited slower 
metabolism at both pH (Figure 6.7 and Figure 6.8, respectively), suggesting that the fragments were 
more resistant towards enzymatic degradation in comparison to the N-terminal fragments. At the 
end of the incubation period, the peak intensities of the intermediate and the C-terminal fragments 
at both pH conditions either declined gradually or remained relatively constant. DYN 3-14, 
however, interestingly showed a gradual increase in its peak intensity throughout the incubation 
period and hence likely concentration in the inflamed tissue at pH 5.5.  
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Figure 6.7 The pH-dependent production and degradation of the intermediate fragments of 
DYN 1-17 within inflamed human nasal tissue. DYN 1-17 was incubated at 37 °C with inflamed 
human nasal tissue at pH 7.4 and pH 5.5 over 120 min. The peak intensities of major intermediate 
fragments at (A) pH 7.4 and (B) pH 5.5 were determined at each time point and plotted. 
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Figure 6.8 The pH-dependent production and degradation of the C-terminal fragments of 
DYN 1-17 within inflamed human nasal tissue. DYN 1-17 was incubated at 37 °C with inflamed 
human nasal tissue at pH 7.4 and pH 5.5 over 120 min. The peak intensities of major C-terminal 
fragments at (A) pH 7.4 and (B) pH 5.5 were determined at each time point and plotted. 
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The metabolism profile of each fragment, shown in the Figures noted above, demonstrates a close 
association with their respective MRT values. In essence, the MRT value represents the average 
time that a molecule of a particular compound will reside in a specific system. A longer residence 
time, denoted by a higher MRT value, indicates that such fragments have a greater resistance to 
metabolism (hydrolysis). In this study, the MRT value for each fragment was plotted as shown in 
Figure 6.9. These data were in accordance with the formation and metabolism profiles of the 
fragments following incubation in the inflamed human nasal tissue homogenates. The results 
demonstrated that majority of these fragments, particularly the intermediate and the C-terminal 
fragments at pH 5.5 possessed higher MRT values in the human inflamed tissue incubation. 
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Figure 6.9 The mean residence time (MRT) of DYN 1-17 and its fragments. The opened and closed columns represent MRT for each fragment at 
pH 7.4 and pH 5.5, respectively. 
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6.4.4. The stability of DYN 1-17 and selected biotransformation fragments in cell 
culture protocol  
As shown above, DYN 1-17 and a number of its biotransformation fragments are predisposed to 
degradation. Hence, the stabilities of DYN 1-17 and selected biotransformation peptide fragments 
(DYN 1-6, DYN 1-7, DYN 1-9 and DYN 3-14) used in treating THP-1 and HEK-Blue™ hTLR4 
cells in the previous chapters were evaluated. The cells were treated with the peptides for an hour 
and 24 h; the results are summarised in Table 6.3. Following a 1-h incubation in THP-1 cells, some 
biotransformation was observed with these fragments however, no significant hydrolysis was seen 
with DYN 3-14. At the end of a 24-hr incubation period, all of the tested fragments were still 
present in the cell culture although in reduced amounts. DYN 3-14 incubated in HEK-Blue™ 
hTLR4 cells demonstrated a reduced degradation at 24 h when compared to its incubation with 
THP-1 cells, with around 60% of the fragment remaining after 24 h.  
 
Table 6.3 Stabilities of DYN 1-17 and selected biotransformation fragments in cell cultures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide 
Percentage of remaining peptides (%) 
THP-1 cells HEK-Blue™ hTLR4 cells 
1 h 24 h 1 h 24 h 
DYN 1-17  85.60 7.75 
  
DYN 1-6 54.20 11.60 
  
DYN 1-7 43.10 14.10 
  
DYN 1-9  50.80 27.40 
  
DYN 3-14 93.40 12.10 90.90 57.20 
 139 
 
6.5. Discussion 
The main focus of the studies presented in this chapter is to characterise and compare the 
biotransformation pattern of DYN 1-17 in inflamed human tissue, specifically that from subjects 
with CRS to a previous study on the biotransformation of DYN 1-17 in inflamed rodent paw tissue 
homogenates (40). CRS is a significant public health problem, resulting in large financial burden on 
society over the years. CRS is characterised by a persistent inflammatory condition of the sinonasal 
mucosa linings (254). The tissue biopsies collected from the human subjects with CRS have been 
reported histologically to contain various inflammatory cells such as macrophages, monocytes and 
eosinophils (255). These cells release multiple inflammatory cytokines, degradative enzymes and 
acids at the injured area and eventually activating the matrix metalloproteinases that directly alter 
the intracellular composition (422). 
 
6.5.1. Biotransformation of DYN 1-17 in human inflamed nasal tissue produces a 
variety of smaller fragments 
Using similar sample preparation methodology and mass spectrometry instrumentation as 
previously described (40), incubation of DYN 1-17 in the human inflamed nasal tissue resulted in a 
similar range of fragments from those found in incubations with rodent inflamed paw tissue 
including DYN 8-13, DYN 9-17, DYN 11-17, DYN 13-17, DYN 7-17, DYN 7-15, DYN 12-17, 
DYN 1-7, DYN 1-11, DYN 2-10, DYN 1-6, DYN 2-17, DYN 3-14, DYN 2-8 and DYN 1-15 (40). 
These workers, did not however, detect DYN 3-15, DYN 9-15, DYN 7-14, DYN 9-16 and DYN 1-
5 in the rodent inflamed tissue homogenates (40). It is suggested that the differences seen in the 
cleavage sites following the metabolism of DYN 1-17 in this study from those observed previously 
may result from the use of different systems i.e. human nasal tissue vs. rodent paw tissues. It has 
been known that several factors such as the magnitude of morphological variations, anatomical 
areas and immunogenic responses can differ markedly among species (423-425). Samples taken 
from humans have been noted to differ from animals in term of isoform composition as well as 
expression and catalytic activities of the metabolising enzymes (426). In an earlier study, purified 
CYP enzymes in pooled human serum were found to possess reduced stability compared to that in 
bovine serum albumin, indicative of the variations existing between human and animals species 
(427). Furthermore, the complexity of human disease may affect the cellular compositions of the 
rodent and human inflamed tissues, resulting in the differences seen in the molecular responses 
(428-430). Hence, in relation to this study, the sources of the inflamed tissue will likely play a 
determinant role in delineating the biotransformation pattern of DYN 1-17.  
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Several enzymes have been implicated in the metabolism of DYN 1-17. Despite the different source 
of the tissues used, the common predominant loci of enzymatic cleavage such as Tyr1-Gly2 and 
Arg6-Arg7 were again observed, reflecting the similarities of hydrolytic degradative enzymes 
present in the human and rodent inflamed tissues. Consistent with previous studies, dynorphin-
converting enzyme, isolated from the spinal cord, is responsible for cleaving at the Arg6-Arg7 site, 
yielding DYN 1-6 and DYN 7-17. In addition to these fragments, trace levels of DYN 1-7 and DYN 
8-17 were observed as well (431). The removal of the N-terminal residue of DYN 1-17 by 
aminopeptidases, thereby produces DYN 2-17, a major metabolite found in blood (223) and a 
compound that may potentially be involved in the modulation of NMDA receptor activity (432). 
Other processing enzymes that have been reported previously are proprotein convertase 2, 
carboxypeptidase E and metallopeptidases (222). Thus, the range of fragmentation routes observed 
in this study highlights the differential involvement of a number of enzymes in inflammatory 
conditions, implying linkages to particular disease states. 
 
A body of growing body of evidence has reported that injury and disease status causes disruptions 
in the biogenesis and processing of dynorphinergic system (433-438). For instance, a previous 
biotransformation study of DYN 1-17 in animal model of Parkinson’s disease has demonstrated that 
the metabolites produced in the striatum of the 6-OHDA-induced lesion of hemiparkinsonian rats 
differed from those observed in the healthy striatum (224). Under disease conditions, the production 
levels of DYN 1-17 exceeded the physiological range as well (435). It is evident in the present 
study that the non-opioid fragments of DYN 1-17 were produced in greater concentrations 
especially at pH 5.5 (an indicator of an inflamed milieu) in comparison to the N-terminal fragments, 
coinciding with the Morgan et al. study (40). This suggests that pathophysiological mechanisms of 
a disease may disturb the usual processing pathways of DYN, resulting in an increased number of 
non-opioid ligands that may act through multiple independent pathways involving non-opioid 
mechanisms. It has been previously demonstrated that the C-terminal fragment, DYN 2-17, elicited 
excitotoxic actions upon activation of glutamate receptors, which may worsen the pathological 
conditions of the demyelinating diseases of CNS (439). Furthermore, dynorphins have been shown 
to reduce the viability of neuronal or non-neuronal cells, implying the presence of cytotoxic effects 
through intracellular protein-protein interactions (440). In contrast to the above evidence, many 
other non-opioid derivatives have been described to have beneficial effects in immunomodulation 
(41, 43). Such discrepancies may be due to several factors such as the types of cells involved, the 
nature of processing enzymes during the disease progression and the time of insult (435). 
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6.5.2. DYN 3-14 and DYN 1-5 are the major hydrolysis fragments produced during 
biotransformation of DYN 1-17 in human inflamed nasal tissue 
One of the noteworthy findings, comparatively similar to the previous study by Morgan et al. (40), 
was the abundant production of an intermediate fragment, DYN 3-14 in the inflamed tissue. This 
observation was in accord with the effects shown by this particular fragment in the earlier chapters 
of this thesis. DYN 3-14 demonstrated significant inhibition of the LPS-induced TLR4 signalling 
pathway by attenuating NF-κB/p65 nuclear translocation and modulation of IL-1β and TNF-α 
release. These findings indicate that DYN 3-14 is a potential TLR4 antagonist that alters cellular 
signalling in response to LPS and cytokine release, implicating a role for biotransformed 
endogenous opioid peptides in immunomodulation. 
 
In the present study, the N-terminal fragments were rapidly generated and then metabolised at the 
earlier analysis time points, in a manner similar to those previously reported (40, 224). Interestingly, 
among of these fragments, DYN 1-5, also known leu-enkephalin, was consistently produced 
throughout the incubation period at relatively high concentrations. This pentapeptide was however 
observed only in inflamed tissue homogenate at pH 5.5 with insignificant trace level seen at pH 7.4. 
This finding indicates that the acidic environment produced during inflammation triggers the 
processing of DYN 1-17 by unknown enzymatic degradation pathways, yielding DYN 1-5, a 
compound that may possess important biological activities in CRS. Mounting evidence has reported 
the possible involvement of this opioid peptide in the process of immunoregulation (441), in 
addition to its role in pain perception (140). For instance, a recent in vitro study has demonstrated 
that nitrated leu-enkephalin, induced by activated human neutrophils, has a regulatory function in 
promoting the efficiency of inflammatory response (442). Previously, leu-enkephalin has been 
demonstrated to modulate mouse splenocyte cell migration (443) as well as the phenotype of NK 
cells and their cytolytic functions in vivo (444). A significant level of leu-enkephalin was also 
detected in nerve tissues and may represent an inhibitory control mechanism in arthritic rats (445). 
Taken together, this suggests that DYN 1-5 may exert an immunoregulatory action in CRS which 
warrants further investigation. 
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6.6. Conclusion 
In this study, the biotransformation of DYN 1-17 studied in human inflamed tissue homogenate 
collected from patients with CRS revealed an array of biotransformation products different from 
those observed previously in rat inflamed paw tissue homogenate. Of these fragments, DYN 3-14 
along with DYN 1-5 were the major hydrolysis fragments with higher peak intensity, produced  in 
inflamed human nasal tissue at pH 5.5 until the end of the incubation period. This suggests that 
these fragments may possess important roles in immunoregulation and therefore, may be useful as 
potential therapeutic agents for CRS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 143 
 
 
 
 
 
 
 
 
 
 
 
 
 
●    Chapter Seven    ● 
Summary and conclusion 
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7.  Chapt er  7 
7.1. Summary  
Inflammatory pain is the painful sensation which occurs during inflammation. During inflammatory 
response, the production of active inflammatory mediators is triggered by the microbial products or 
the host proteins. The initiation of inflammation results in cascade of events including swelling 
within the injured tissues and concomitant activation of nociceptors (446, 447). Endogenous opioid 
peptides are primarily known to modulate pain through their interaction with opioid receptors in the 
CNS and peripheral nervous system (PNS). The presence of opioid receptors outside the CNS (e.g. 
the peripheral nervous tissues), has, however, expanded the perspective that, opioid-induced 
analgesia is not restricted entirely to central mechanism of action, but it may also be modulated in 
the periphery and even that at the extremities of the PNS (3, 133, 448). The opioid receptors are 
also expressed on immune cells, suggesting that opioids have a direct effect on immune function in 
host defence and immunity (211). A substantial body of literature evidence over the past decades 
has shown that the immune-derived opioid peptides produce significant inhibition of inflammatory 
pain upon their interaction with opioid receptors expressed on the terminals of peripheral sensory 
neurons in inflamed tissue (10, 11, 78, 142). 
 
Recent research has shown that, upon release by the immune cells at the site of inflammation, the 
endogenous opioid DYN 1-17 is rapidly metabolised and yields a unique set of metabolites, 
comprising both opioid and non-opioid fragments (40). Evidence has revealed that some of these 
major biotransformation fragments play a role in immunomodulation through opioid and non-opioid 
pathways (34, 41-43, 243, 394). Nevertheless, the underlying intracellular signalling mechanisms of 
these immunomodulatory effects remained unclear. The overall aim of this research was to identify 
and to gain some mechanistic insights into the immune-modulation properties of DYN 1-17 and 
selected biotransformation fragments on major inflammatory signalling pathways.  
 
Previous chapters in this thesis outline a number of significant findings from the research 
undertaken. Firstly, DYN 1-17 and the biotransformation fragments significantly inhibited the NF-
κB/p65 nuclear translocation induced by the LPS. DYN 1-7 had a greater inhibitory effect on this 
signal transduction pathway when compared to the parent compound (DYN 1-17). Secondly, DYN 
1-17 and selected N-terminal fragments (i.e. DYN 1-6, DYN 1-7 and DYN 1-9) mediated this 
inhibitory effect through activation of KOR in differentiated THP-1 cells, highlighting the presence 
of functional KOR in human macrophages and its potential role in a coordinated regulation of 
immune and neural function.  
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Another hypothesis tested in this thesis was the assessment of the effects of DYN 1-17 and its major 
biotransformation fragments on the LPS-induced release of pro-inflammatory IL-1β and TNF-α in 
macrophages. During the inflammatory response, pro-inflammatory cytokines are released at sites 
of inflammation. These cytokines are regulated primarily at the transcriptional level mainly via NF-
κB signalling pathway (268) and play an important role in the activation and development of 
immune response (349). Following LPS induction, DYN 1-17 and several fragments (i.e. DYN 1-7, 
DYN 1-6 and DYN 3-14) exhibit differential modulation of both IL-1β and TNF-α release, 
mediated through KOR-dependent or KOR-independent pathways. The divergent effects seen with 
DYN 1-7 and DYN 1-6 fragments on the release of both cytokines provide additional evidence with 
respect to differential KOR activation on cytokine modulation and highlight the unique properties 
of these fragments in opioid action. It is possible that multiple pathways were involved in producing 
opposing effects on cytokine release, implying the complexity of cytokine modulation by immune 
cells.  
 
The overall effects of DYN 1-17 and its fragments on NF-κB/p65 nuclear translocation and the 
release of pro-inflammatory cytokines (IL-1β and TNF-α) were summarised in Table 7.1.  
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Table 7.1 Effects of DYN 1-17 and its biotransformation fragments on LPS-induced NF-κB/p65 nuclear translocation and the release of pro-
inflammatory cytokines in differentiated THP-1 cells. The concentrations denote the peptides concentration used in the respective assays. 
 
 
 
Peptides  
NF-κB/p65 
nuclear 
translocation 
 
IL-1β release 
 
TNF-α release 
Inhibition at 
10 nM  
10-17 M 10-15 M 10-13 M 10-11 M 10-9 M 10-7 M 10-17 M 10-15 M 10-13 M 10-11 M 10-9 M 10-7 M 
DYN 1-17 *       ↓ ↓ ↓*       ↔ ↔ ↔ 
DYN 1-6 *       ↑ ↑* ↑       ↔ ↑ ↑* 
DYN 1-7 *       ↓* ↓ ↓       ↓* ↓* ↓ 
DYN 1-9 *       ↔ ↔ ↔       ↔ ↔ ↔ 
DYN 1-10         ↔ ↔ ↔       ↔ ↔ ↔ 
DYN 1-11        ↔ ↔ ↔       ↔ ↔ ↔ 
DYN 3-14   ↓ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↔ ↑ ↑ ↑ 
DYN 6-12        ↔ ↔ ↔       ↔ ↔ ↔ 
DYN 2-17         ↔ ↔ ↔       ↔ ↔ ↔ 
DYN 7-17        ↔ ↔ ↔       ↔ ↔ ↔ 
*The inhibition of NF-κB/p65 nuclear translocation by the peptides was significantly antagonised by ML-190 (p ≤ 0.05).   
↓ = inhibit, ↑ = enhance, ↔ = no changes, = yes 
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LPS (derived from E. coli O111:B4) is a potent TLR4 activator, leading to the transcriptional 
activation of NF-κB protein and the downstream release of pro-inflammatory cytokines (48). A 
number of exogenous opioids have been demonstrated previously to modulate TLR4 activity (53, 
397). Prior to the research reported in this thesis, the role of endogenous opioids, particularly the 
dynorphins, as an immune modulator at TLR4, had not been assessed. One of the central findings to 
emerge from this thesis is the involvement of DYN 3-14 in the TLR4 signalling pathway. DYN 3-
14, produced following biotransformation of DYN 1-17 in inflamed tissue, is structurally “non-
opioid” in nature with very low affinity for opioid receptors due to the absence of the N-terminal 
tyrosine residue in the peptide chain (209). Despite the potency of DYN 3-14 on the inhibition of 
LPS-induced TLR4 signalling in the HEK-Blue™-hTLR4 cells being less than a potent, 
commercially available, TLR4 antagonist (LPS-RS), this finding has provided a mechanistic insight 
into the inhibition of NF-κB/p65 translocation and modulation of IL-1β and TNF-α release, 
following incubation of LPS-induced, differentiated THP-1 cells with DYN 3-14. These findings 
describe a potential role for DYN 3-14 as an antagonist at TLR4 and its involvement in the 
regulation of inflammatory signals through a non-opioid mechanism in inflammation.  
 
This thesis also aimed to explore the biotransformation of DYN 1-17 in human inflamed tissue 
homogenates and compare the generated fragments with those obtained in previous studies (40). 
The data in this thesis has presented a similar range of fragments following the incubation of DYN 
1-17 with both rodent inflamed paw and human inflamed nasal tissues, suggesting that similar 
processing enzymes are present in the homogenates from both inflamed tissues. Intriguingly, further 
observation also showed the significant production of DYN 3-14 at pH 5.5 which resembles the 
naturally occurring inflammatory environment, up until the end of the incubation period, similar to 
findings presented in Morgan et al. (40). This indicates that this particular intermediate fragment 
was produced abundantly in the inflamed tissue, thereby, highlighting a rationale for its activity 
during an inflammatory response. This finding complements earlier findings in this thesis, 
demonstrating that DYN 3-14 significantly inhibits NF-κB/p65 nuclear translocation and modulates 
the release of IL-1β and TNF-α in LPS-activated human macrophages through the TLR4 signalling 
pathway. In addition, this study also revealed that DYN 1-5 and DYN 3-15 which was produced in 
significant amount following the enzymatic degradation, highlighting that these fragments may 
possess an important immune modulator role during CRS. Taken together, this study confirms 
previous findings and contributes additional evidence that suggests disease pathophysiology may 
influence the biotransformation of DYN 1-17. 
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7.2. Study limitations 
The findings in this thesis are subject to several limitations that need to be acknowledged.  
 
 The immunomodulatory effects of DYN 1-17 and its biotransformation fragments were only 
assessed in the macrophage-like THP-1 cells. In the context of innate immunity, neutrophils 
have also been recognised as the first line of defence besides macrophages. In fact, 
neutrophils are the first responders that rapidly extravasate from the circulation into sites of 
infection or sterile tissue injury. These cells are responsible for initiating inflammatory 
reactions that is later managed by macrophages (449).  
 
 Although THP-1 cells are established as an in vitro cell model for immune modulation 
approach, unexpected up-regulation of certain genes during the differentiation process of 
THP-1 cells may affect the sensitivity of LPS towards stimuli and the downstream 
inflammatory response (299, 360). The propagation of THP-1 macrophages under controlled 
conditions also may result in different sensitivities and responses as opposed to the peripheral 
blood mononuclear cells in their natural environment (293). Hence, definite conclusions on 
the immunomodulatory functions of DYN 1-17 and its biotransformation fragments on 
inflammatory signalling pathways are only a partial perspective without in vivo validation.  
 
 Several studies have suggested that all TLRs involve in NF-κB activation, expressing of 
various inflammatory cytokine genes via multiple signalling pathways [reviewed in (450)]. 
However, the immunomodulation of DYN 3-14 were only examined in HEK cells 
overexpressing TLR4, excluding other TLRs involvement. Therefore, the claimed inhibitory 
effects of this fragment were only limited to TLR4-mediated NF-κB signalling pathway.  
 
 The biotransformation of DYN 1-17 in inflamed human nasal tissue analysed by LC-MS was 
only carried out qualitatively by characterising the major resultant fragments without 
determining the actual concentration of these fragments in the inflamed tissue homogenates.  
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7.3. Future directions 
Further research leading from these studies is required to better understand the immunomodulation 
of DYN 1-17 and its biotransformation fragments on inflammatory signalling pathways. Future 
studies could focus on:  
 
 Investigating the immunomodulatory effects of DYN 1-17 and its major biotransformation 
fragments in human neutrophils and the underlying intracellular signalling mechanisms 
contributing to these effects. Neutrophils have been shown previously to modulate the 
phenotype and cytokine profile expression of macrophages, thereby regulating the innate 
immune response (451).  
 
 Exploring the involvement of other opioid receptors such as DOR in mediating the effects of 
DYN 1-17 and biotransformation fragments in the LPS-induced NF-κB/p65 signalling 
pathway. Evidence has shown that shorter peptides have activity at DOR (452), this may 
therefore provide an indication of other potential sites of action for the biotransformation 
fragments.  
 
 Assessing the effects of DYN 1-17 and its biotransformation fragments in other signal 
transduction pathways, including the MAPK pathways, as these protein kinases have been 
demonstrated to play a role in the regulation of inflammatory mediators at the levels of 
transcription and translation (453).  
 
 Examining the involvement of DYN 1-17 and its fragments (especially the intermediate and 
C-terminal fragments) at other non-opioid sites of action such as other TLRs, bradykinin and 
NMDA receptors. The involvement of opioid peptides outside the traditional opioid receptor-
mediated pathways is evident from the literature (34, 243, 394). A recent pilot study by one of 
our collaborator has shown some encouraging findings on the functional interactions between 
sodium channels and opioids (i.e. DYN 1-17 and β-END fragments) (unpublished data). 
Therefore, investigating the effects of these fragments in the regulation of the voltage-gated 
sodium channels activity could be future direction. 
 
 Evaluating the immunomodulatory function, particularly the anti-inflammatory properties, of 
potentially beneficial fragments such as DYN 3-14 and DYN 1-7 in animal model of 
nociception and inflammation. Several in vivo animal models that are commonly used in 
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laboratory practice include carrageenan-induced rat paw oedema model, ultraviolet erythema 
in guinea pigs, oxazolone-induced ear oedema in mice, and rat adjuvant-induced arthritis 
model (454).  
 
 Quantifying the concentrations of the major resultant fragments produced following 
biotransformation of DYN 1-17 in inflamed human nasal tissue using appropriate standards as 
reference to these fragments. It would be interesting to investigate the biotransformation of 
DYN 1-17 in other human inflammatory-related disease conditions such as rheumatoid 
arthritis or burns/trauma, to better understand the possible link between disease aetiology and 
the biotransformation patterns of the opioid peptides.  
 
7.4. Conclusion 
In summary, this thesis highlight the pharmacological differences that exist between the DYN 1-17 
and its biotransformation fragments on inflammatory signalling pathways, mediated through opioid- 
and non-opioid-dependent pathways. Furthermore, the effects seen with DYN 1-17 in inflammation 
may not be solely dependent on the parent molecule but may also be attributed to the modulatory 
effects exerted by the major biotransformation fragments. These findings highlight the potential 
usefulness of these fragments as possible human-directed therapeutic agents in managing 
inflammatory-related diseases and may provide insights into potential new therapeutic strategies in 
inflammatory pain. 
 
151 
 
8.  Ref er ences 
BIBLIOGRAPHY 
 
1. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428-
35. 
2. Straub RH, Schradin C. Chronic inflammatory systemic diseases: an evolutionary trade-off 
between acutely beneficial but chronically harmful programs. Evol Med Public Health. 
2016;2016(1):37-51. 
3. Stein C. Targeting pain and inflammation by peripherally acting opioids. Front Pharmacol. 
2013;4:123. 
4. Stein C, Küchler S. Targeting inflammation and wound healing by opioids. Trends 
Pharmacol Sci. 2013;34(6):303-12. 
5. Liang X, Liu R, Chen C, Ji F, Li T. Opioid system modulates the immune function: a review. 
Transl Perioper Pain Med. 2016;1(1):5-13. 
6. Zöllner C, Stein C. Opioids. In: Stein C, editor. Analgesia. Berlin, Heidelberg: Springer 
Berlin Heidelberg; 2007. p. 31-63. 
7. Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of 
palliative care patients. J Pain Palliat Care Pharmacother. 2007;21(1):15-25. 
8. Stein C. Opioid receptors on peripheral sensory neurons Madame Curie Bioscience Database 
2000-2013 [Internet]. 2013 12/09/2016. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK6242/. 
9. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid 
complications and side effects. Pain Physician. 2008;11(Suppl 2):S105-20. 
10. Stein C, Millan MJ, Shippenberg TS, Peter K, Herz A. Peripheral opioid receptors mediating 
antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. 
J Pharmacol Exp Ther. 1989;248(3):1269-75. 
11. Iwaszkiewicz KS, Schneider JJ, Hua S. Targeting peripheral opioid receptors to promote 
analgesic and anti-inflammatory actions. Front Pharmacol. 2013;4:132. 
12. Sehgal N, Smith HS, Manchikanti L. Peripherally acting opioids and clinical implications for 
pain control. Pain Physician. 2011;14(3):249-58. 
13. Stein C, Lang LJ. Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol. 
2009;9(1):3-8. 
14. Baddack-Werncke U, Busch-Dienstfertig M, Gonzalez-Rodriguez S, Maddila SC, Grobe J, 
Lipp M, et al. Cytotoxic T cells modulate inflammation and endogenous opioid analgesia in 
chronic arthritis. J Neuroinflammation. 2017;14(1):30. 
 152 
 
15. Basso L, Boue J, Bourreille A, Dietrich G. Endogenous regulation of inflammatory pain by 
T-cell-derived opioids: when friend turns to foe. Inflamm Bowel Dis. 2014;20:1870-7. 
16. Basso L, Boué J, Mahiddine K, Blanpied C, Robiou-du-Pont S, Vergnolle N, et al. 
Endogenous analgesia mediated by CD4+ T lymphocytes is dependent on enkephalins in 
mice. J Neuroinflammation. 2016;13(1):132. 
17. Boué J, Basso L, Cenac N, Blanpied C, Rolli-Derkinderen M, Neunlist M, et al. Endogenous 
regulation of visceral pain via production of opioids by colitogenic CD4(+) T cells in mice. 
Gastroenterol. 2014;146:166-75. 
18. Boué J, Blanpied C, Brousset P, Vergnolle N, Dietrich G. Endogenous opioid-mediated 
analgesia is dependent on adaptive T cell response in mice. J Immunol. 2011;186:5078-84. 
19. Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schäfer M, Loeffler JP, et al. Immune cell-derived 
beta-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest. 
1997;100(1):142-8. 
20. Gavériaux-Ruff C, Nozaki C, Nadal X, Hever XC, Weibel R, Matifas A, et al. Genetic 
ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and 
abolishes opioid analgesia. Pain. 2011;152:1238-48. 
21. Labuz D, Celik MÖ, Zimmer A, Machelska H. Distinct roles of exogenous opioid agonists 
and endogenous opioid peptides in the peripheral control of neuropathy-triggered heat pain. 
Sci Rep. 2016;6:32799. 
22. Maddila SC, Busch-Dienstfertig M, Stein C. B lymphocytes express POMC mRNA, 
processing enzymes and β-endorphin in painful inflammation. J Neuroimmune Pharmacol. 
2017;12(1):180-6. 
23. Minett MS, Pereira V, Sikandar S, Matsuyama A, Lolignier S, Kanellopoulos AH, et al. 
Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium 
channel Nav1.7. Nat Commun. 2015;6:8967. 
24. Mousa SA, Zhang Q, Sitte N, Ji R, Stein C. Beta-endorphin-containing memory-cells and 
mu-opioid receptors undergo transport to peripheral inflamed tissue. J Neuroimmunol. 
2001;115(1-2):71-8. 
25. Pannell M, Labuz D, Celik MÖ, Keye J, Batra A, Siegmund B, et al. Adoptive transfer of 
M2 macrophages reduces neuropathic pain via opioid peptides. J Neuroinflammation. 
2016;13(1):262. 
26. Stein C, Machelska H. Modulation of peripheral sensory neurons by the immune system: 
implications for pain therapy. Pharmacol Rev. 2011;63(4):860-81. 
 153 
 
27. Cabot PJ, Carter L, Schäfer M, Stein C. Methionine-enkephalin and dynorphin A release 
from immune cells and control of inflammatory pain. Pain. 2001;93(3):207-12. 
28. Schäfer M, Carter L, Stein C. Interleukin-1beta and corticotropin-releasing factor inhibit 
pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci U S A. 
1994;91(10):4219-23. 
29. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa-
opioid receptor. Science. 1982;215(4531):413-5. 
30. Hassan AH, Pzewlocki R, Herz A, Stein C. Dynorphin, a preferential ligand for kappa-
opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the 
rat. Neurosci Lett. 1992;140(1):85-8. 
31. Alt A, Mansour A, Akil H, Medzihradsky F, Traynor JR, Woods JH. Stimulation of 
guanosine-5'-O-(3-[35S]thio) triphosphate binding by endogenous opioids acting at a cloned 
mu-receptor. J Pharmacol Exp Ther. 1998;286(1):282-8. 
32. Zhang Q, Schäfer M, Elde R, Stein C. Effects of neurotoxins and hindpaw inflammation on 
opioid receptor immunoreactivities in dorsal root ganglia. Neuroscience. 1998;85(1):281-91. 
33. Guerrini R, Calo G, Rizzi A, Bigoni R, Rizzi D, Regoli D, et al. Structure-activity 
relationships of nociceptin and related peptides: comparison with dynorphin A. Peptides. 
2000;21(7):923-33. 
34. Lai J, Luo M-c, Chen Q, Porreca F. Pronociceptive actions of dynorphin via bradykinin 
receptors. Neurosci Lett. 2008;437(3):175-9. 
35. Kanemitsu Y, Hosoi M, Zhu PJ, Weight FF, Peoples RW, McLaughlin JS, et al. Dynorphin 
A inhibits NMDA receptors through a pH-dependent mechanism. Mol Cell Neurosci. 
2003;24(3):525-37. 
36. Gein SV. Dynorphins in regulation of immune system functions. Biochemistry (Mosc). 
2014;79(5):397-405. 
37. Stein C, S. K. Non-analgesic effects of opioids: peripheral opioid effects on inflammation 
and wound healing. Curr Pharm Des. 2012;18(37):6053-69. 
38. Safavi A, Hersh LB. Degradation of dynorphin-related peptides by the puromycin-sensitive 
aminopeptidase and aminopeptidase M. J Neurochem. 1995;65(1):389-95. 
39. Schreiter A, Gore C, Labuz D, Fournie-Zaluski MC, Roques BP, Stein C, et al. Pain 
inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed 
tissue. FASEB J. 2012;26(12):5161-71. 
 154 
 
40. Morgan M, Herath HM, Cabot PJ, Shaw PN, Hewavitharana AK. Dynorphin A 1-17 
biotransformation in inflamed tissue, serum and trypsin solution analysed by liquid 
chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2012;404(10):3111-21. 
41. Ichinose M, Asai M, Sawada M. Enhancement of phagocytosis by dynorphin A in mouse 
peritoneal macrophages. J Neuroimmunol. 1995;60(1-2):37-43. 
42. Kong LY, McMillian MK, Hudson PM, Jin L, Hong JS. Inhibition of lipopolysaccharide-
induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in 
mixed glia cultures. J Pharmacol Exp Ther. 1997;280(1):61-6. 
43. Wei ET, Thomas HA, Gjerde EA, Reed RK, Burov SV, Korolkov VI, et al. Dynorphin A (6-
12) analogs suppress thermal edema. Peptides. 1998;19(4):767-75. 
44. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. 
Cold Spring Harb Perspect Biol. 2009;1(4):a000034. 
45. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6(3):203-8. 
46. Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, et al. 
Identification of known drugs that act as inhibitors of NF-kappaB signaling and their 
mechanism of action. Biochem Pharmacol. 2010;79(9):1272-80. 
47. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health 
and disease. J Mol Med (Berl). 2004;82(7):434-48. 
48. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates 
lipopolysaccharide-induced signal transduction. J Biol Chem. 1999;274(16):10689-92. 
49. Sharif O, Bolshakov VN, Raines S, Newham P, Perkins ND. Transcriptional profiling of the 
LPS induced NF-kappaB response in macrophages. BMC Immunol. 2007;8:1. 
50. Zhang G, Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically 
conserved paradigm in innate immunity. J Clin Invest. 2001;107(1):13-9. 
51. Kuper C, Beck FX, Neuhofer W. Toll-like receptor 4 activates NF-kappaB and MAP kinase 
pathways to regulate expression of pro-inflammatory COX-2 in renal medullary collecting 
duct cells. Am J Physiol Renal Physiol. 2012;302(1):F38-46. 
52. Andreakos E, Sacre SM, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, et al. Distinct 
pathways of LPS-induced NF-kappaB activation and cytokine production in human myeloid 
and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood. 
2004;103(6):2229-37. 
53. Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, et al. Non-
stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of 
Toll-like receptor 4 (TLR4). Eur J Neuro. 2008;28(1):20-9. 
 155 
 
54. Stevens CW, Aravind S, Das S, Davis RL. Pharmacological characterization of LPS and 
opioid interactions at the Toll-like receptor 4. Br J Pharmacol. 2013;168(6):1421-9. 
55. Wang X, Zhang Y, Peng Y, Hutchinson MR, Rice KC, Yin H, et al. Pharmacological 
characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as 
antagonists of Toll-like receptor 4. Br J Pharmacol. 2016;173(5):856-69. 
56. Sauer RS, Hackel D, Morschel L, Sahlbach H, Wang Y, Mousa SA, et al. Toll like receptor 
(TLR)-4 as a regulator of peripheral endogenous opioid-mediated analgesia in inflammation. 
Mol Pain. 2014;10:10. 
57. Heidland A, Klassen A, Rutkowski P, Bahner U. The contribution of Rudolf Virchow to the 
concept of inflammation: what is still of importance? J Nephrol. 2006;19(Suppl 10):S102-9. 
58. Budd K, Shipton EA. Acute pain in the immune system and opioimmunosuppression. Acute 
Pain. 2004;6(3):123-35. 
59. Reeh PW, Steen KH. Tissue acidosis in nociception and pain. Prog Brain Res. 
1996;113:143-51. 
60. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc 
Biol. 2011;31(5):986-1000. 
61. Hua S, Cabot PJ. Mechanisms of peripheral immune-cell-mediated analgesia in 
inflammation: clinical and therapeutic implications. Trends Pharmacol Sci. 2010;31(9):427-
33. 
62. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413(6852):203-
10. 
63. Coutaux A, Adam F, Willer JC, Le Bars D. Hyperalgesia and allodynia: peripheral 
mechanisms. Joint Bone Spine. 2005;72(5):359-71. 
64. Rittner HL, Machelska H, Stein C. Leukocytes in the regulation of pain and analgesia. J 
Leukoc Biol. 2005;78(6):1215-22. 
65. Rittner HL, Stein C. Involvement of cytokines, chemokines and adhesion molecules in 
opioid analgesia. Eur J Pain. 2005;9(2):109-12. 
66. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walters P. Innate Immunity. New York: 
Garland Science; 2002. Available from: http://www.ncbi.nlm.nih.gov/books/NBK26846/. 
67. Davis MM. A prescription for human immunology. Immunity. 2008;29(6):835-8. 
68. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 
2010;16(11):1267-76. 
 156 
 
69. Suzuki A, Suzuki R, Furuno T, Teshima R, Nakanishi M. N-cadherin plays a role in the 
synapse-like structures between mast cells and neurites. Biol Pharm Bull. 2004;27(12):1891-
4. 
70. Rudick CN, Bryce PJ, Guichelaar LA, Berry RE, Klumpp DJ. Mast cell-derived histamine 
mediates cystitis pain. PLoS One. 2008;3(5):e2096. 
71. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, et al. Mast cell-
dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. 
Gastroenterol. 2007;132(1):26-37. 
72. Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced 
hyperalgesia. Eur J Neurosci. 1994;6(12):1903-12. 
73. Cui JG, Holmin S, Mathiesen T, Meyerson BA, Linderoth B. Possible role of inflammatory 
mediators in tactile hypersensitivity in rat models of mononeuropathy. Pain. 2000;88(3):239-
48. 
74. Binshtok AM, Wang H, Zimmermann K, Amaya F, Vardeh D, Shi L, et al. Nociceptors are 
interleukin-1beta sensors. J Neurosci. 2008;28(52):14062-73. 
75. Liu T, van Rooijen N, Tracey DJ. Depletion of macrophages reduces axonal degeneration 
and hyperalgesia following nerve injury. Pain. 2000;86(1-2):25-32. 
76. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain 
Res Rev. 2006;51(2):240-64. 
77. Gaboury JP, Johnston B, Niu XF, Kubes P. Mechanisms underlying acute mast cell-induced 
leukocyte rolling and adhesion in vivo. J Immunol. 1995;154(2):804-13. 
78. Rittner HL, Brack A, Stein C. Pain and the immune system. Br J Anaesth. 2008;101(1):40-4. 
79. Perretti M, Ahluwalia A, Flower RJ, Manzini S. Endogenous tachykinins play a role in IL-1-
induced neutrophil accumulation: involvement of NK-1 receptors. Immunology. 
1993;80(1):73-7. 
80. Kramer HH, He L, Lu B, Birklein F, Sommer C. Increased pain and neurogenic 
inflammation in mice deficient of neutral endopeptidase. Neurobiol Dis. 2009;35(2):177-83. 
81. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 
2010;140(6):805-20. 
82. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. 
Clin Microbiol Rev. 2009;22(2):240-73. 
83. Peltier DC, Simms A, Farmer JR, Miller DJ. Human neuronal cells possess functional 
cytoplasmic and Toll-like receptor-mediated innate immune pathways influenced by 
phosphatidylinositol-3 kinase signaling. J Immunol. 2010;184(12):7010-21. 
 157 
 
84. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-32. 
85. Liu T, Gao YJ, Ji RR. Emerging role of Toll-like receptors in the control of pain and itch. 
Neurosci Bull. 2012;28(2):131-44. 
86. Boaru SG, Borkham-Kamphorst E, Tihaa L, Haas U, Weiskirchen R. Expression analysis of 
inflammasomes in experimental models of inflammatory and fibrotic liver disease. J 
Inflamm (Lond). 2012;9(1):49. 
87. Chen S, Sun B. Negative regulation of NLRP3 inflammasome signaling. Protein Cell. 
2013;4(4):251-8. 
88. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev 
Immunol. 2009;27:229-65. 
89. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, et al. The NLR gene 
family: a standard nomenclature. Immunity. 2008;28(3):285-7. 
90. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering 
activation of inflammatory caspases and processing of proIL-1. Mol Cell. 2002;10(2):417-
26. 
91. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and 
associated diseases. Annu Rev Immunol. 2011;29:707-35. 
92. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev 
Immunol. 2013;13(6):397-411. 
93. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb 
Perspect Biol. 2009;1(6):a001651. 
94. Lenardo MJ, Baltimore D. NF-kappaB: a pleiotropic mediator of inducible and tissue-
specific gene control. Cell. 1989;58(2):227-9. 
95. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell 
Biol. 2001;11(9):372-7. 
96. Hayden MS, Ghosh S. NF-kappaB in immunobiology. Cell Res. 2011;21(2):223-44. 
97. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 
2006;25(51):6680-4. 
98. Vela JM, Molina-Holgado E, Arevalo-Martin A, Almazan G, Guaza C. Interleukin-1 
regulates proliferation and differentiation of oligodendrocyte progenitor cells. Mol Cell 
Neurosci. 2002;20(3):489-502. 
99. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-
1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer 
Metastasis Rev. 2006;25(3):387-408. 
 158 
 
100. Eder C. Mechanisms of interleukin-1beta release. Immunobiology. 2009;214(7):543-53. 
101. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin-1beta in 
inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4(1):34-42. 
102. Simi A, Tsakiri N, Wang P, Rothwell NJ. Interleukin-1 and inflammatory 
neurodegeneration. Biochem Soc Trans. 2007;35:1122-6. 
103. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-
1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-52. 
104. Norman J, Franz M, Messina J, Riker A, Fabri PJ, Rosemurgy AS, et al. Interleukin-1 
receptor antagonist decreases severity of experimental acute pancreatitis. Surgery. 
1995;117(6):648-55. 
105. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, et al. The 
grateful dead: damage-associated molecular pattern molecules and reduction/oxidation 
regulate immunity. Immunol Rev. 2007;220:60-81. 
106. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and 
IL-1 and IL-18 processing during infection. Trends Immunol. 2011;32(3):110-6. 
107. Halban PA, Irminger JC. Sorting and processing of secretory proteins. Biochem J. 
1994;299(1):1-18. 
108. Perregaux D, Gabel CA. Interleukin-1beta maturation and release in response to ATP and 
nigericin. Evidence that potassium depletion mediated by these agents is a necessary and 
common feature of their activity. J Biol Chem. 1994;269(21):15195-203. 
109. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. Rapid 
secretion of interleukin-1beta by microvesicle shedding. Immunity. 2001;15(5):825-35. 
110. Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to 
osmotic lysis of infected host macrophages. Cell Microbiol. 2006;8(11):1812-25. 
111. Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1 secretion. Cytokine 
Growth Factor Rev. 2011;22(4):189-95. 
112. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and 
inflammatory hyperalgesia: the contribution of tumour necrosis factor-alpha. Br J 
Pharmacol. 1997;121(3):417-24. 
113. Leung L, Cahill CM. TNF- and neuropathic pain - a review. J Neuroinflammation. 
2010;7:27. 
114. Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev 
Eukaryot Gene Expr. 2010;20(2):87-103. 
 159 
 
115. Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. 
Minerva Gastroenterol Dietol. 2010;56(2):233-43. 
116. Seymour HE, Worsley A, Smith JM, Thomas SHL. Anti-TNF agents for rheumatoid 
arthritis. Br J Clin Pharmacol. 2001;51(3):201-8. 
117. Hackel D, Brack A, Rittner HL. Chapter 19 - Leukocytes as Mediators of Pain and 
Analgesia. In: Barry GA, editor. NeuroImmune Biology. 9: Elsevier; 2010. p. 237-50. 
118. Grell M. Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and 
membrane-expressed TNF. J Inflamm. 1995;47(1-2):8-17. 
119. Naude PJ, den Boer JA, Luiten PG, Eisel UL. Tumor necrosis factor receptor cross-talk. 
FEBS J. 2011;278(6):888-98. 
120. Leister KP, Huang R, Goodwin BL, Chen A, Austin CP, Xia M. Two high-throughput 
screen assays for measurement of TNF-alpha in THP-1 cells. Curr Chem Genomics. 
2011;5:21-9. 
121. Cabal-Hierro L, Rodríguez M, Artime N, Iglesias J, Ugarte L, Prado MA, et al. TRAF-
mediated modulation of NF-B and JNK activation by TNFR2. Cell Signal. 
2014;26(12):2658-66. 
122. Siegmund D, Kums J, Ehrenschwender M, Wajant H. Activation of TNFR2 sensitizes 
macrophages for TNFR1-mediated necroptosis. Cell Death Dis. 2016;7:e2375. 
123. Erickson SL, de Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, et al. 
Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF 
receptor-2-deficient mice. Nature. 1994;372(6506):560-3. 
124. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest. 
2010;120(11):3779-87. 
125. Basbaum AI, Fields HL. Endogenous pain control mechanisms: review and hypothesis. Ann 
Neurol. 1978;4(5):451-62. 
126. Cui M, Feng Y, McAdoo DJ, Willis WD. Periaqueductal gray stimulation-induced inhibition 
of nociceptive dorsal horn neurons in rats is associated with the release of norepinephrine, 
serotonin, and amino acids. J Pharmacol Exp Ther. 1999;289(2):868-76. 
127. Machelska H, Stein C. Pain control by immune-derived opioids. Clin Exp Pharmacol 
Physiol. 2000;27(7):533-6. 
128. Carlton SM, Du J, Davidson E, Zhou S, Coggeshall RE. Somatostatin receptors on 
peripheral primary afferent terminals: inhibition of sensitized nociceptors. Pain. 
2001;90(3):233-44. 
 160 
 
129. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug 
Targets. 2009;8(6):403-21. 
130. Simon EJ. Opioid receptors and endogenous opioid peptides. Med Res Rev. 1991;11(4):357-
74. 
131. Mansour A, Hoversten MT, Taylor LP, Watson SJ, Akil H. The cloned mu, delta and kappa 
receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. 
Brain Res. 1995;700(1-2):89-98. 
132. Taub DD. Neuroendocrine interactions in the immune system. Cell Immunol. 2008;252(1-
2):1-6. 
133. Machelska H, Schopohl JK, Mousa SA, Labuz D, Schäfer M, Stein C. Different mechanisms 
of intrinsic pain inhibition in early and late inflammation. J Neuroimmunol. 2003;141(1-
2):30-9. 
134. Hua S. Neuroimmune interaction in the regulation of peripheral opioid-mediated analgesia in 
inflammation. Front Immunol. 2016;7:293. 
135. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med. 
1995;332(25):1685-90. 
136. Lyons PD, Blalock JE. Pro-opiomelanocortin gene expression and protein processing in rat 
mononuclear leukocytes. J Neuroimmunol. 1997;78(1-2):47-56. 
137. Hook VY, Tezapsidis N, Hwang SR, Sei C, Byrne M, Yasothornsrikul S. Alpha1-anti-
chymotrypsin-like proteins I and II purified from bovine adrenal medulla are enriched in 
chromaffin granules and inhibit the pro-enkephalin processing enzyme "prohormone thiol 
protease". J Neurochem. 1999;73(1):59-69. 
138. Boué J, Blanpied C, Djata-Cabral M, Pelletier L, Vergnolle N, Dietrich G. Immune 
conditions associated with CD4+ T effector-induced opioid release and analgesia. Pain. 
2012;153:485-93. 
139. Brack A, Rittner HL, Machelska H, Shaqura M, Mousa SA, Labuz D, et al. Endogenous 
peripheral antinociception in early inflammation is not limited by the number of opioid-
containing leukocytes but by opioid receptor expression. Pain. 2004;108(1-2):67-75. 
140. Przewłocki R, Przewłocka B. Opioids in chronic pain. Eur J Pharmacol. 2001;429(1–3):79-
91. 
141. Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M, Schäfer M, et al. Opioid peptide-
expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition 
of inflammatory pain. Anesthesiology. 2001;95(2):500-8. 
 161 
 
142. Cabot PJ. Immune-derived opioids and peripheral antinociception. Clin Exp Pharmacol 
Physiol. 2001;28(3):230-2. 
143. LaMendola J, Martin SK, Steiner DF. Expression of PC3, carboxypeptidase E and 
enkephalin in human monocyte-derived macrophages as a tool for genetic studies. FEBS 
Lett. 1997;404(1):19-22. 
144. Stein C, Schäfer M, Machelska H. Attacking pain at its source: new perspectives on opioids. 
Nat Med. 2003;9(8):1003-8. 
145. Brack A, Rittner HL, Machelska H, Leder K, Mousa SA, Schäfer M, et al. Control of 
inflammatory pain by chemokine-mediated recruitment of opioid-containing 
polymorphonuclear cells. Pain. 2004;112(3):229-38. 
146. Machelska H, Cabot PJ, Mousa SA, Zhang Q, Stein C. Pain control in inflammation 
governed by selectins. Nat Med. 1998;4(12):1425-8. 
147. Mousa SA, Machelska H, Schäfer M, Stein C. Co-expression of beta-endorphin with 
adhesion molecules in a model of inflammatory pain. J Neuroimmunol. 2000;108(1-2):160-
70. 
148. Rittner HL, Lux C, Labuz D, Mousa SA, Schäfer M, Stein C, et al. Neurokinin-1 receptor 
antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral 
antinociception. Anesthesiology. 2007;107(6):1009-17. 
149. Schäfer M. Cytokines and peripheral analgesia. Adv Exp Med Biol. 2003;521:40-50. 
150. Mousa SA, Bopaiah CP, Richter JF, Yamdeu RS, Schäfer M. Inhibition of inflammatory 
pain by CRF at peripheral, spinal and supraspinal sites: involvement of areas coexpressing 
CRF receptors and opioid peptides. Neuropsychopharmacology. 2007;32(12):2530-42. 
151. Likar R, Schäfer M, Paulak F, Sittl R, Pipam W, Schalk H, et al. Intra-articular morphine 
analgesia in chronic pain patients with osteoarthritis. Anesth Analg. 1997;84(6):1313-7. 
152. Mousa SA, Schäfer M, Mitchell WM, Hassan AH, Stein C. Local up-regulation of 
corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb 
inflammation. Eur J Pharmacol. 1996;311(2-3):221-31. 
153. Binder W, Mousa SA, Sitte N, Kaiser M, Stein C, Schäfer M. Sympathetic activation 
triggers endogenous opioid release and analgesia within peripheral inflamed tissue. Eur J 
Neurosci. 2004;20(1):92-100. 
154. Hassan AH, Ableitner A, Stein C, Herz A. Inflammation of the rat paw enhances axonal 
transport of opioid receptors in the sciatic nerve and increases their density in the inflamed 
tissue. Neuroscience. 1993;55(1):185-95. 
 162 
 
155. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor 
signaling. Annu Rev Pharmacol Toxicol. 2000;40:389-430. 
156. Wilding TJ, Womack MD, McCleskey EW. Fast, local signal transduction between the mu-
opioid receptor and Ca2+ channels. J Neurosci. 1995;15(5 Pt 2):4124-32. 
157. Wiley JW, Moises HC, Gross RA, Macdonald RL. Dynorphin A-mediated reduction in 
multiple calcium currents involves a Gα-subtype G protein in rat primary afferent neurons. J 
Neurophysiol. 1997;77(3):1338-48. 
158. Miyake M, Christie MJ, North RA. Single potassium channels opened by opioids in rat locus 
ceruleus neurons. Proc Natl Acad Sci U S A. 1989;86:3419-22. 
159. North RA, Williams JT, Surprenant A, Christie MJ. Mu and delta receptors belong to a 
family of receptors that are coupled to potassium channels. Proc Natl Acad Sci U S A. 
1987;84(15):5487-91. 
160. Yonehara N, Takiuchi S. Involvement of calcium-activated potassium channels in the 
inhibitory prejunctional effect of morphine on peripheral sensory nerves. Regul Pept. 
1997;68(3):147-53. 
161. Akins PT, McCleskey EW. Characterization of potassium currents in adult rat sensory 
neurons and modulation by opioids and cyclic AMP. Neuroscience. 1993;56(3):759-69. 
162. Fan SF, Crain SM. Dual regulation by mu-, delta- and kappa-opioid receptor agonists of K+ 
conductance of DRG neurons and neuroblastoma X DRG neuron hybrid F11 cells. Brain 
Res. 1995;696(1-2):97-105. 
163. Gold MS, Reichling DB, Shuster MJ, Levine JD. Hyperalgesic agents increase a 
tetrodotoxin-resistant Na+ current in nociceptors. Proc Natl Acad Sci U S A. 
1996;93(3):1108-12. 
164. Ingram SL, Williams JT. Modulation of the hyperpolarization-activated current (Ih) by 
cyclic nucleotides in guinea-pig primary afferent neurons. J Physiol. 1996;492 97-106. 
165. Zöllner C, Shaqura MA, Bopaiah CP, Mousa S, Stein C, Schäfer M. Painful inflammation-
induced increase in μ-opioid receptor binding and G-protein coupling in primary afferent 
neurons. Mol Pharmacol. 2003;64(2):202-10. 
166. Ji RR, Zhang Q, Law PY, Low HH, Elde R, Hokfelt T. Expression of mu-, delta-, and 
kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-
induced inflammation. J Neurosci. 1995;15(12):8156-66. 
167. Sharp BM, Roy S, Bidlack JM. Evidence for opioid receptors on cells involved in host 
defense and the immune system. J Neuroimmunol. 1998;83(1-2):45-56. 
 163 
 
168. Antonijevic I, Mousa S, Schäfer M, Stein C. Perineurial defect and peripheral opioid 
analgesia in inflammation. J Neurosci. 1995;15(1):165-72. 
169. Selley DE, Breivogel CS, Childers SR. Modification of G protein-coupled functions by low-
pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by 
decreased inactivation of G proteins. Mol Pharmacol. 1993;44(4):731-41. 
170. Vetter I, Kapitzke D, Hermanussen S, Monteith GR, Cabot PJ. The effects of pH on beta-
endorphin and morphine inhibition of calcium transients in dorsal root ganglion neurons. J 
Pain. 2006;7(7):488-99. 
171. Przewlocki R, Hassan AH, Lason W, Epplen C, Herz A, Stein C. Gene expression and 
localization of opioid peptides in immune cells of inflamed tissue: functional role in 
antinociception. Neuroscience. 1992;48(2):491-500. 
172. Stein C, Hassan AH, Lehrberger K, Giefing J, Yassouridis A. Local analgesic effect of 
endogenous opioid peptides. Lancet. 1993;342(8867):321-4. 
173. Hewitt DJ, McDonald M, Portenoy RK, Rosenfeld B, Passik S, Breitbart W. Pain syndromes 
and etiologies in ambulatory AIDS patients. Pain. 1997;70(2):117-23. 
174. Carr DJ, Rogers TJ, Weber RJ. The relevance of opioids and opioid receptors on 
immunocompetence and immune homeostasis. Proc Soc Exp Biol Med. 1996;213(3):248-57. 
175. Stein C, Hassan AH, Przewlocki R, Gramsch C, Peter K, Herz A. Opioids from 
immunocytes interact with receptors on sensory nerves to inhibit nociception in 
inflammation. Proc Natl Acad Sci U S A. 1990;87(15):5935-9. 
176. Lipp J. Possible mechanisms of morphine analgesia. Clin Neuropharmacol. 1991;14(2):131-
47. 
177. Heinl C, Drdla-Schutting R, Xanthos DN, Sandkuhler J. Distinct mechanisms underlying 
pronociceptive effects of opioids. J Neurosci. 2011;31(46):16748-56. 
178. Machelska H, Stein C. Leukocyte-derived opioid peptides and inhibition of pain. J 
Neuroimmune Pharmacol. 2006;1(1):90-7. 
179. Gutstein H, Akil H. Opioid Analgesics. In: Brunton L, Lazo J, Parker K, editors. Goodman 
& Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 
2006. p. 547–90. 
180. Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva 
Anestesiol. 2005;71(7-8):461-70. 
181. Likar R, Koppert W, Blatnig H, Chiari F, Sittl R, Stein C, et al. Efficacy of peripheral 
morphine analgesia in inflamed, non-inflamed and perineural tissue of dental surgery 
patients. J Pain Symptom Manage. 2001;21(4):330-7. 
 164 
 
182. Stein C, Machelska H, Binder W, Schäfer M. Peripheral opioid analgesia. Curr Opin 
Pharmacol. 2001;1(1):62-5. 
183. Kalso E, Smith L, McQuay HJ, Andrew Moore R. No pain, no gain: clinical excellence and 
scientific rigour-lessons learned from IA morphine. Pain. 2002;98(3):269-75. 
184. Vadivelu N, Mitra S, Hines RL. Peripheral opioid receptor agonists for analgesia: a 
comprehensive review. J Opioid Manag. 2011;7(1):55-68. 
185. Stein  C, Comisel  K, Haimerl  E, Yassouridis  A, Lehrberger  K, Herz  A, et al. Analgesic 
effect of intra-articular morphine after arthroscopic knee surgery. N Engl J Med. 
1991;325(16):1123-6. 
186. Cox BM, Opheim KE, Teschemacher H, Goldstein A. A peptide-like substance from 
pituitary that acts like morphine. 2. Purification and properties. Life Sci. 1975;16(12):1777-
82. 
187. Teschemacher H, Opheim KE, Cox BM, Goldstein A. A peptide-like substance from 
pituitary that acts like morphine. I. Isolation. Life Sci. 1975;16(12):1771-5. 
188. Tachibana S, Araki K, Ohya S, Yoshida S. Isolation and structure of dynorphin, an opioid 
peptide, from porcine duodenum. Nature. 1982;295:339-40. 
189. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin (1-13), an 
extraordinarily potent opioid peptide. Proc Natl Acad Sci U S A. 1979;76(12):6666-70. 
190. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification 
of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 
1975;258(5536):577-80. 
191. Goldstein A, Fischli W, Lowney LI, Hunkapiller M, Hood L. Porcine pituitary dynorphin: 
complete amino acid sequence of the biologically active heptadecapeptide. Proc Natl Acad 
Sci U S A. 1981;78(11):7219-23. 
192. Fischli W, Goldstein A, Hunkapiller MW, Hood LE. Isolation and amino acid sequence 
analysis of a 4,000-dalton dynorphin from porcine pituitary. Proc Natl Acad Sci U S A. 
1982;79(17):5435-7. 
193. Minamino N, Kangawa K, Fukuda A, Matsuo H, Iagarashi M. A new opioid octapeptide 
related to dynorphin from porcine hypothalamus. Biochem Biophys Res Commun. 
1980;95(4):1475-81. 
194. Kangawa K, Matsuo H. alpha-Neo-endorphin : a "big" Leu-enkephalin with potent opiate 
activity from porcine hypothalami. Biochem Biophys Res Commun. 1979;86(1):153-60. 
195. Kangawa K, Minamino N, Chino N, Sakakibara S, Matsuo H. The complete amino acid 
sequence of alpha-neo-endorphin. Biochem Biophys Res Commun. 1981;99(3):871-8. 
 165 
 
196. Minamino N, Kangawa K, Chino N, Sakakibara S, Matsuo H. Beta-neo-endorphin, a new 
hypothalamic "big" Leu-enkephalin of porcine origin: its purification and the complete 
amino acid sequence. Biochem Biophys Res Commun. 1981;99(3):864-70. 
197. Civelli O, Douglass J, Goldstein A, Herbert E. Sequence and expression of the rat pro-
dynorphin gene. Proc Natl Acad Sci U S A. 1985;82(12):4291-5. 
198. Gulya K, Orpana AK, Sikela JM, Hoffman PL. Pro-dynorphin and vasopressin mRNA levels 
are differentially affected by chronic ethanol ingestion in the mouse. Brain Res Mol Brain 
Res. 1993;20(1–2):1-8. 
199. Horikawa S, Takai T, Toyosato M, Takahashi H, Noda M, Kakidani H, et al. Isolation and 
structural organization of the human pre-proenkephalin B gene. Nature. 
1983;306(5943):611-4. 
200. Watson SJ, Khachaturian H, Taylor L, Fischli W, Goldstein A, Akil H. Pro-dynorphin 
peptides are found in the same neurons throughout rat brain: immunocytochemical study. 
Proc Natl Acad Sci U S A. 1983;80(3):891-4. 
201. Dupuy A, Lindberg I, Zhou Y, Akil H, Lazure C, Chrétien M, et al. Processing of pro-
dynorphin by the prohormone convertase PC1 results in high molecular weight intermediate 
forms. FEBS Lett. 1994;337(1):60-5. 
202. Berman Y, Ageyeva L, Veksler B, Wood D, Devi LA. Dynorphin A processing enzyme: 
tissue distribution, isolation, and characterization. J Biochem. 1999;125(3):641-7. 
203. Day R, Lazure C, Basak A, Boudreault A, Limperis P, Dong W, et al. Pro-dynorphin 
processing by proprotein convertase 2. Cleavage at single basic residues and enhanced 
processing in the presence of carboxypeptidase activity. J Biol Chem. 1998;273(2):829-36. 
204. Dalayeun JF, Nores JM, Bergal S. Physiology of beta-endorphins. A close-up view and a 
review of the literature. Biomed Pharmacother. 1993;47(8):311-20. 
205. Szeto HH. Dynorphin and the hypothalamo-pituitary-adrenal axis during fetal development. 
Life Sci. 2003;73(6):749-58. 
206. Vindrola O, Mayer AMS, Citera G, Spitzer JA, Espinoza LR. Prohormone convertases PC2 
and PC3 in rat neutrophils and macrophages. Neuropeptides.27(4):235-44. 
207. Sun B, Tipton CM, Bidlack JM. The expression of pro-dynorphin gene is down-regulated by 
activation with lipopolysaccharide in U-937 macrophage cells. J Neuroimmunol. 
2006;174(1-2):52-62. 
208. Zhang S, Tong Y, Tian M, Dehaven RN, Cortesburgos L, Mansson E, et al. Dynorphin A as 
a potential endogenousl Ligand for four members of the opioid receptor gene family. J 
Pharmacol Exp Ther. 1998;286(1):136. 
 166 
 
209. Chavkin C, Goldstein A. Specific receptor for the opioid peptide dynorphin: structure-
activity relationships. Proc Natl Acad Sci U S A. 1981;78(10):6543-7. 
210. Carroll FI, Carlezon WA. Development of kappa-opioid receptor antagonists. J Med Chem. 
2013;56(6):2178-95. 
211. Bidlack JM. Detection and function of opioid receptors on cells from the immune system. 
Clin Diagn Lab Immunol. 2000;7(5):719-23. 
212. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, et al. Cloning and functional 
comparison of kappa- and delta-opioid receptors from mouse brain. Proc Natl Acad Sci U S 
A. 1993;90(14):6736-40. 
213. Guan L, Townsend R, Eisenstein TK, Adler MW, Rogers TJ. Both T cells and macrophages 
are targets of kappa-opioid-induced immunosuppression. Brain Behav Immun. 
1994;8(3):229-40. 
214. Chao CC, Gekker G, Hu S, Sheng WS, Shark KB, Bu DF, et al. Kappa-opioid receptors in 
human microglia downregulate human immunodeficiency virus-1 expression. Proc Natl 
Acad Sci U S A. 1996;93(15):8051-6. 
215. Gavériaux-Ruff C, Peluso J, Simonin F, Laforet J, Kieffer B. Identification of kappa- and 
delta-opioid receptor transcripts in immune cells. FEBS Lett. 1995;369(2-3):272-6. 
216. Minneman KP, Iversen IL. Enkephalin and opiate narcotics increase cyclic GMP 
accumulation in slices of rat neostriatum. Nature. 1976;262(5566):313-4. 
217. Rusin KI, Giovannucci DR, Stuenkel EL, Moises HC. Kappa-opioid receptor activation 
modulates Ca2+ currents and secretion in isolated neuroendocrine nerve terminals. J 
Neurosci. 1997;17(17):6565-74. 
218. Spencer RJ, Jin W, Thayer SA, Chakrabarti S, Law PY, Loh HH. Mobilization of Ca2+ from 
intracellular stores in transfected neuro2a cells by activation of multiple opioid receptor 
subtypes. Biochem Pharmacol. 1997;54(7):809-18. 
219. Kam AY, Chan AS, Wong YH. Kappa-opioid receptor signals through Src and focal 
adhesion kinase to stimulate c-Jun N-terminal kinases in transfected COS-7 cells and human 
monocytic THP-1 cells. J Pharmacol Exp Ther. 2004;310(1):301-10. 
220. Chou JZ, Chait BT, Wang R, Kreek MJ. Differential biotransformation of dynorphin A (1-
17) and dynorphin A (1-13) peptides in human blood, ex vivo. Peptides. 1996;17(6):983-90. 
221. Müller S, Hochhaus G. Metabolism of dynorphin A 1-13 in human blood and plasma. Pharm 
Res. 1995;12(8):1165-70. 
 167 
 
222. Reed B, Zhang Y, Chait BT, Kreek MJ. Dynorphin A(1-17) biotransformation in striatum of 
freely moving rats using microdialysis and matrix-assisted laser desorption/ionization mass 
spectrometry. J Neurochem. 2003;86(4):815-23. 
223. Yu J, Butelman ER, Woods JH, Chait BT, Kreek MJ. In vitro biotransformation of 
dynorphin A (1-17) is similar in human and rhesus monkey blood as studied by matrix-
assisted laser desorption/ionization mass spectrometry. J Pharmacol Exp Ther. 
1996;279(2):507-14. 
224. Klintenberg R, Andren PE. Altered extracellular striatal in vivo biotransformation of the 
opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's 
disease. J Mass Spectrom. 2005;40(2):261-70. 
225. Nissen JB, Iversen L, Kragballe K. Characterization of the aminopeptidase activity of 
epidermal leukotriene A4 hydrolase against the opioid dynorphin fragment 1-7. Br J 
Dermatol. 1995;133(5):742-9. 
226. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of 
inflammation and innate immunity. Nat Rev Immunol. 2004;4(8):617-29. 
227. Guan L, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of T cell superantigen responses 
following treatment with the kappa-opioid agonist U50,488H. J Neuroimmunol. 1997;75(1-
2):163-8. 
228. Morgan EL. Regulation of human B lymphocyte activation by opioid peptide hormones. 
Inhibition of IgG production by opioid receptor class (mu-, kappa-, and delta-) selective 
agonists. J Neuroimmunol. 1996;65(1):21-30. 
229. Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ. Suppression of 
peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther. 
1993;267(2):703-6. 
230. Alicea C, Belkowski S, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of primary murine 
macrophage cytokine production in vitro following treatment with the kappa-opioid agonist 
U50,488H. J Neuroimmunol. 1996;64(1):83-90. 
231. Belkowski SM, Alicea C, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of interleukin-1 
and tumor necrosis factor-alpha synthesis following treatment of macrophages with the 
kappa opioid agonist U50, 488H. J Pharmacol Exp Ther. 1995;273(3):1491-6. 
232. Foster JS, Moore RN. Dynorphin and related opioid peptides enhance tumoricidal activity 
mediated by murine peritoneal macrophages. J Leukoc Biol. 1987;42(2):171-4. 
233. Hagi K, Uno K, Inaba K, Muramatsu S. Augmenting effect of opioid peptides on murine 
macrophage activation. J Neuroimmunol. 1994;50(1):71-6. 
 168 
 
234. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK. Activated microglia mediate 
neuronal cell injury via a nitric oxide mechanism. J Immunol. 1992;149(8):2736-41. 
235. Ruff MR, Wahl SM, Mergenhagen S, Pert CB. Opiate receptor-mediated chemotaxis of 
human monocytes. Neuropeptides. 1985;5(4-6):363-6. 
236. Sharp BM, Keane WF, Suh HJ, Gekker G, Tsukayama D, Peterson PK. Opioid peptides 
rapidly stimulate superoxide production by human polymorphonuclear leukocytes and 
macrophages. Endocrinology. 1985;117(2):793-5. 
237. Tosk JM, Grim JR, Kinback KM, Sale EJ, Bozzetti LP, Will AD. Modulation of 
chemiluminescence in a murine macrophage cell line by neuroendocrine hormones. Int J 
Immunopharmacol. 1993;15(5):615-20. 
238. Binder W, Machelska H, Mousa S, Schmitt T, Riviere PJ, Junien JL, et al. Analgesic and 
anti-inflammatory effects of two novel kappa-opioid peptides. Anesthesiology. 
2001;94(6):1034-44. 
239. Wilson JL, Nayanar V, Walker JS. The site of anti-arthritic action of the kappa-opioid, 
U50,488H, in adjuvant arthritis: importance of local administration. Br J Pharmacol. 
1996;118(7):1754-60. 
240. Binder W, Walker JS. Effect of the peripherally selective kappa-opioid agonist, asimadoline, 
on adjuvant arthritis. Br J Pharmacol. 1998;124(4):647-54. 
241. Lai J, Rankin DR, Cai AT, Lee Y-S, Hruby VJ, Porreca F. Dynorphin A is a competitive, 
partial agonist at the bradykinin receptors. FASEB J. 2011;25(1 Supplement):626.3. 
242. Voorn P, van de Witte SV, Li K, Jonker AJ. Dynorphin displaces binding at the glycine site 
of the NMDA receptor in the rat striatum. Neurosci Lett. 2007;415(1):55-8. 
243. Quillan JM, Sadee W. Dynorphin peptides: antagonists of melanocortin receptors. Pharm 
Res. 1997;14(6):713-9. 
244. Gabrilovac J, Balog T, Andreis A. Dynorphin A(1-17) decreases nitric oxide release and 
cytotoxicity induced with lipopolysaccharide plus interferon-gamma in murine macrophage 
cell line J774. Biomed Pharmacother. 2003;57(8):351-8. 
245. Sugiyama K, Furuta H. Histamine release induced by dynorphin (1-13) from rat mast cells. 
Jpn J Pharmacol. 1984;35(3):247-52. 
246. Kovalitskaya YA, Navolotskaya EV. Non-opioid effect of β-endorphin. Biochemistry. 
2011;76(4):379-93  
247. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The "toll" of opioid-induced glial 
activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol 
Sci. 2009;30(11):581-91. 
 169 
 
248. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, et al. Evidence 
that opioids may have Toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 
2010;24(1):83-95. 
249. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. 
Immunol Rev. 2008;226:10-8. 
250. Welters ID, Menzebach A, Goumon Y, Cadet P, Menges T, Hughes TK, et al. Morphine 
inhibits NF-kappaB nuclear binding in human neutrophils and monocytes by a nitric oxide-
dependent mechanism. Anesthesiology. 2000;92(6):1677-84. 
251. Borner C, Kraus J. Inhibition of NF-kappaB by opioids in T cells. J Immunol. 
2013;191(9):4640-7. 
252. Laughlin TM, Bethea JR, Yezierski RP, Wilcox GL. Cytokine involvement in dynorphin-
induced allodynia. Pain. 2000;84(2-3):159-67. 
253. Hook MA, Washburn SN, Moreno G, Woller SA, Puga D, Lee KH, et al. An IL-1 receptor 
antagonist blocks a morphine-induced attenuation of locomotor recovery after spinal cord 
injury. Brain Behav Immun. 2011;25(2):349-59. 
254. Lam K, Schleimer R, Kern RC. The etiology and pathogenesis of chronic rhinosinusitis: a 
review of current hypotheses. Curr Allergy Asthma Rep. 2015;15(7):41. 
255. Ball SL, Mann DA, Wilson JA, Fisher AJ. The role of the fibroblast in inflammatory upper 
airway conditions. Am J Pathol. 2016;186(2):225-33. 
256. Kou W, Hu GH, Yao HB, Wang XQ, Shen Y, Kang HY, et al. Regulation of transforming 
growth factor-beta1 activation and expression in the tissue remodeling involved in chronic 
rhinosinusitis. ORL J Otorhinolaryngol Relat Spec. 2012;74(3):172-8. 
257. Bachert C, Gevaert P, Holtappels G, Cuvelier C, van Cauwenberge P. Nasal polyposis: from 
cytokines to growth. Am J Rhinol. 2000;14(5):279-90. 
258. Akdis CA, Bachert C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM, et al. Endotypes 
and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European 
Academy of Allergy and Clinical Immunology and the American Academy of Allergy, 
Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. 
259. Kumar V, Abbas AK, Aster J. Robbins Basic Pathology. 9th ed. Philadelphia: Elsevier 
Saunders; 2013. 
260. Daines SM, Orlandi RR. Inflammatory cytokines in allergy and rhinosinusitis. Curr Opin 
Otolaryngol Head Neck Surg. 2010;18(3):187-90. 
261. Riechelmann H, Deutschle T, Rozsasi A, Keck T, Polzehl D, Burner H. Nasal biomarker 
profiles in acute and chronic rhinosinusitis. Clin Exp Allergy. 2005;35(9):1186-91. 
 170 
 
262. Takeno S, Hirakawa K, Ueda T, Furukido K, Osada R, Yajin K. Nuclear factor-kappaB 
activation in the nasal polyp epithelium: relationship to local cytokine gene expression. 
Laryngoscope. 2002;112(1):53-8. 
263. Wang Z, Zhang Q, Li Y, Li P, Zhang G, Li Y. Involvement of mitogen-activated protein 
kinases and nuclear factor-kappaB pathways in signaling COX-2 expression in chronic 
rhinosinusitis. Inflamm Res. 2009;58(10):649-58. 
264. Piromchai P, Kasemsiri P, Laohasiriwong S, Thanaviratananich S. Chronic rhinosinusitis 
and emerging treatment options. Int J Gen Med. 2013;6:453-64. 
265. Horwell D. Kappa opioid analgesics. Drugs Future. 1988;13:1061-71. 
266. Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF. Roles of mu, delta and kappa opioid 
receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate 
analgesia in the mouse. J Pharmacol Exp Ther. 1984;230(2):341-8. 
267. Walker JS. Anti-inflammatory  effects  of  κ-opioids:  relevance  to  rheumatoid  arthritis. 
Pain Rev. 2001;8:113-9. 
268. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat 
Rev Drug Discov. 2009;8(1):33-40. 
269. Wan F, Lenardo MJ. The nuclear signaling of NF-kappaB: current knowledge, new insights, 
and future perspectives. Cell Res. 2010;20(1):24-33. 
270. Lee JI, Burckart GJ. Nuclear factor kappaB: important transcription factor and therapeutic 
target. J Clin Pharmacol. 1998;38(11):981-93. 
271. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002;109 Suppl S81-96. 
272. Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell ALM, et al. Interplay 
between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol. 
2014;49(2):116-39. 
273. Trask OJ, Jr. Nuclear factor-kappaB (NF-kappaB) translocation assay development and 
validation for high content screening. In: Sittampalam GS, Coussens NP, Brimacombe K, 
Grossman A, Arkin M, Auld D, et al., editors. Assay Guidance Manual. Bethesda (MD): Eli 
Lilly & Company and the National Center for Advancing Translational Sciences; 2004. 
274. Chung KF. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug 
Targets. 2006;7(6):675-81. 
275. Williams RO, Paleolog E, Feldmann M. Cytokine inhibitors in rheumatoid arthritis and other 
autoimmune diseases. Curr Opin Pharmacol. 2007;7(4):412-7. 
276. Roy S, Cain KJ, Chapin RB, Charboneau RG, Barke RA. Morphine modulates NF-kappaB 
activation in macrophages. Biochem Biophys Res Commun. 1998;245(2):392-6. 
 171 
 
277. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on 
Toll-like receptors. Nat Immunol. 2010;11(5):373-84. 
278. Holden NS, Tacon CE. Principles and problems of the electrophoretic mobility shift assay. J 
Pharmacol Toxicol Methods. 2011;63(1):7-14. 
279. Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. ELISA and 
multiplex technologies for cytokine measurement in inflammation and aging research. J 
Gerontol A Biol Sci Med Sci. 2008;63(8):879-84. 
280. Blaecke A, Delneste Y, Herbault N, Jeannin P, Bonnefoy JY, Beck A, et al. Measurement of 
nuclear factor-kappa B translocation on lipopolysaccharide-activated human dendritic cells 
by confocal microscopy and flow cytometry. Cytometry. 2002;48(2):71-9. 
281. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: 
monitoring single cell signaling events. Cytometry A. 2003;55(2):61-70. 
282. Noursadeghi M, Tsang J, Haustein T, Miller RF, Chain BM, Katz DR. Quantitative imaging 
assay for NF-κB nuclear translocation in primary human macrophages. J Immunol Methods. 
2008;329(1-2):194-200. 
283. Auwerx J. The human leukemia cell line, THP-1: a multifacetted model for the study of 
monocyte-macrophage differentiation. Experientia. 1991;47(1):22-31. 
284. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and 
characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 
1980;26(2):171-6. 
285. Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, et al. Induction of 
maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res. 
1982;42(4):1530-6. 
286. Mittar D, Paramban R, McIntyre C. Flow cytometry and high-content imaging to identify 
markers of monocyte-macrophage differentiation. BD Bioscience Application Note 
[Internet]. 2011. 
287. Schwende H, Fitzke E, Ambs P, Dieter P. Differences in the state of differentiation of THP-1 
cells induced by phorbol ester and 1,25-dihydroxyvitamin D3. J Leukoc Biol. 
1996;59(4):555-61. 
288. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and 
rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989;119(2):203-
10. 
289. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63. 
 172 
 
290. Kanduri M, Tobin G, Åleskog A, Nilsson K, Rosenquist R. The novel NF-κB inhibitor IMD-
0354 induces apoptosis in chronic lymphocytic leukemia. Blood Cancer J. 2011;1(3):e12. 
291. Mizuno K, Toyoda Y, Fukami T, Nakajima M, Yokoi T. Stimulation of pro-inflammatory 
responses by mebendazole in human monocytic THP-1 cells through an ERK signaling 
pathway. Arch Toxicol. 2011;85(3):199-207. 
292. Azuma Y, Ohura K. Endomorphins 1 and 2 inhibit IL-10 and IL-12 production and innate 
immune functions, and potentiate NF-kappaB DNA binding in THP-1 differentiated to 
macrophage-like cells. Scand J Immunol. 2002;56(3):260-9. 
293. Chanput W, Mes JJ, Wichers HJ. THP-1 cell line: an in vitro cell model for immune 
modulation approach. Int Immunopharmacol. 2014;23(1):37-45. 
294. Zhou JY, Tang FD, Mao GG, Bian RL. Effect of alpha-pinene on nuclear translocation of 
NF-kappaB in THP-1 cells. Acta Pharmacol Sin. 2004;25(4):480-4. 
295. Zhou L, Shen LH, Hu LH, Ge H, Pu J, Chai DJ, et al. Retinoid X receptor agonists inhibit 
phorbol-12-myristate-13-acetate (PMA)-induced differentiation of monocytic THP-1 cells 
into macrophages. Mol Cell Biochem. 2010;335(1-2):283-9. 
296. Chanput W, Mes J, Vreeburg RA, Savelkoul HF, Wichers HJ. Transcription profiles of LPS-
stimulated THP-1 monocytes and macrophages: a tool to study inflammation modulating 
effects of food-derived compounds. Food Funct. 2010;1(3):254-61. 
297. Spano A, Monaco G, Barni S, Sciola L. Expression of cell kinetics and death during 
monocyte-macrophage differentiation: effects of actinomycin D and vinblastine treatments. 
Histochem Cell Biol. 2007;127(1):79-94. 
298. Spano A, Barni S, Bertone V, Sciola L. Changes on lysosomal compartment during PMA-
induced differentiation of THP-1 monocytic cells: Influence of type I and type IV collagens 
Adv Biosci Biotechnol. 2013;4:8-18. 
299. Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS. Optimized THP-1 differentiation is 
required for the detection of responses to weak stimuli. Inflamm Res. 2007;56(1):45-50. 
300. Tangirala RK, Murao K, Quehenberger O. Regulation of expression of the human monocyte 
chemotactic protein-1 receptor (hCCR2) by cytokines. J Biol Chem. 1997;272(12):8050-6. 
301. Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and 
deactivation by LPS. Microbes Infect. 2002;4(9):903-14. 
302. Plescia J, Altieri DC. Activation of Mac-1 (CD11b/CD18)-bound factor X by released 
cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochem J. 
1996;319(Pt 3):873-9. 
 173 
 
303. Zhou H, Liao J, Aloor J, Nie H, Wilson BC, Fessler MB, et al. CD11b/CD18 (Mac-1) is a 
novel surface receptor for extracellular double-stranded RNA to mediate cellular 
inflammatory responses. J Immunol. 2013;190(1):115-25. 
304. Ding J, Lin L, Hang W, Yan X. Beryllium uptake and related biological effects studied in 
THP-1 differentiated macrophages. Metallomics. 2009;1(6):471-8. 
305. Aldo PB, Craveiro V, Guller S, Mor G. Effect of culture conditions on the phenotype of 
THP-1 monocyte cell line. Am J Reprod Immunol. 2013;70(1):80-6. 
306. Gordon S. The macrophage: past, present and future. Eur J Immunol. 2007;37 (Suppl 1):S9-
17. 
307. Mantovani A, Locati M. Orchestration of macrophage polarization. Blood. 
2009;114(15):3135-6. 
308. Qin H, Holdbrooks AT, Liu Y, Reynolds SL, Yanagisawa LL, Benveniste EN. SOCS3 
deficiency promotes M1 macrophage polarization and inflammation. J Immunol. 
2012;189(7):3439-48. 
309. Arnold CE, Gordon P, Barker RN, Wilson HM. The activation status of human macrophages 
presenting antigen determines the efficiency of Th17 responses. Immunobiology. 
2015;220(1):10-9. 
310. Chanput W, Mes JJ, Savelkoul HFJ, Wichers HJ. Characterization of polarized THP-1 
macrophages and polarizing ability of LPS and food compounds. Food Funct. 
2013;4(2):266-76. 
311. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage M1–M2 
polarization balance. Front Immunol. 2014;5:614. 
312. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: 
cancer as a paradigm. Nat Immunol. 2010;11(10):889-96. 
313. Aderem A. Role of Toll-like receptors in inflammatory response in macrophages. Crit Care 
Med. 2001;29(7 Suppl):S16-8. 
314. Anderson KV. Toll signaling pathways in the innate immune response. Curr Opin Immunol. 
2000;12(1):13-9. 
315. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death-a new 
approach to cancer therapy. J Clin Invest. 2005;115(10):2625-32. 
316. Schmitz ML, Baeuerle PA. The p65 subunit is responsible for the strong transcription 
activating potential of NF-kappaB. EMBO J. 1991;10(12):3805-17. 
 174 
 
317. Sugita A, Ogawa H, Azuma M, Muto S, Honjo A, Yanagawa H, et al. Anti-allergic and anti-
inflammatory effects of a novel IB kinase inhibitor, IMD-0354, in a mouse model of 
allergic inflammation. Int Arch Allergy Immunol. 2009;148(3):186-98. 
318. Faden AI, Ellison JA, Noble LJ. Effects of competitive and non-competitive NMDA 
receptor antagonists in spinal cord injury. Eur J Pharmacol. 1990;175(2):165-74. 
319. Meyer ME. Intrastriatal injections of dynorphin A fragments potentiate the dorsal immobility 
response in rats. Pharmacol Biochem Behav. 1993;44(2):329-32. 
320. Ishihara S, Tsuchiya S, Horie S, Murayama T, Watanabe K. Gastric acid secretion by central 
injection of dynorphin A (1-17), an endogenous ligand of kappa-opioid receptor, in urethane-
anesthetized rats. Jpn J Pharmacol. 2001;87(1):14-20. 
321. Kumar S, Rai U. Dynorphin regulates the phagocytic activity of splenic phagocytes in wall 
lizards: involvement of a kappa-opioid receptor-coupled adenylate-cyclase-cAMP-PKA 
pathway. J Exp Biol. 2011;214(Pt 24):4217-22. 
322. Banerjee P, Chromy BA, Berry-Kravis E, Hammond D, Singh JK, Dawson G. Stable 
expression and heterologous coupling of the kappa- opioid receptor in cell lines of neural 
and non-neural origin. Life Sci. 1996;58(15):1277-84. 
323. Buchner RR, Vogen SM, Fischer W, Thoman ML, Sanderson SD, Morgan EL. Anti-human 
kappa opioid receptor antibodies: characterization of site-directed neutralizing antibodies 
specific for a peptide kappa R(33-52) derived from the predicted amino terminal region of 
the human kappa receptor. J Immunol. 1997;158(4):1670-80. 
324. Gaveriaux-Ruff C, Peluso J, Befort K, Simonin F, Zilliox C, Kieffer BL. Detection of opioid 
receptor mRNA by RT-PCR reveals alternative splicing for the delta- and kappa-opioid 
receptors. Brain Res Mol Brain Res. 1997;48(2):298-304. 
325. Suzuki S, Chuang LF, Doi RH, Bidlack JM, Chuang RY. Kappa-opioid receptors on 
lymphocytes of a human lymphocytic cell line: morphine-induced up-regulation as 
evidenced by competitive RT-PCR and indirect immunofluorescence. Int 
Immunopharmacol. 2001;1(9-10):1733-42. 
326. Gabrilovac J, Cupic B, Zapletal E, Brozovic A. IFN-gamma up-regulates kappa-opioid 
receptors (KOR) on murine macrophage cell line J774. J Neuroimmunol. 2012;245(1-2):56-
65. 
327. Radulovic J, Miljevic C, Djergovic D, Vujic V, Antic J, von Horsten S, et al. Opioid 
receptor-mediated suppression of humoral immune response in vivo and in vitro: 
involvement of kappa-opioid receptors. J Neuroimmunol. 1995;57(1-2):55-62. 
 175 
 
328. Frankowski KJ, Hedrick MP, Gosalia P, Li K, Shi S, Whipple D, et al. Discovery of small 
molecule kappa-opioid receptor agonist and antagonist chemotypes through a HTS and hit 
refinement strategy. ACS Chem Neurosci. 2012;3(3):221-36. 
329. Walker JS. Anti-inflammatory effects of opioids. Adv Exp Med Biol. 2003;521:148-60. 
330. Quirion R, Pert CB. Dynorphins: similar relative potencies on μ-, δ- and κ-opiate receptors. 
Eur J Immunol. 1981;76(4): 467-8. 
331. Pablo Huidobro-Toro J, Yoshimura K, Lee NM, Loh HH, Leong Way E. Dynorphin 
interaction at the κ-opiate site. Eur J Pharmacol. 1981;72(2):265-6. 
332. Hewlett WA, Barchas JD. Regional interactions of opioid peptides at μ and δ sites in rat 
brain. Peptides. 1983;4(6):853-8. 
333. Akil H, Meng F, Devine DP, Watson SJ. Molecular and neuroanatomical properties of the 
endogenous opioid system: implications for treatment of opiate addiction. Semin Neurosci. 
1997;9(3-4):70-83. 
334. Aldrich JV, McLaughlin JP. Peptide kappa-opioid receptor ligands: potential for drug 
development. AAPS J. 2009;11(2):312-22. 
335. Pasternak G. Opioids and their receptors: Are we there yet? Neuropharmacology. 2014;76(0 
0):198-203. 
336. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, et al. Structural basis for 
allosteric regulation of GPCRs by sodium ions. Science. 2012;337(6091):232-6. 
337. Blume AJ. Interaction of ligands with the opiate receptors of brain membranes: Regulation 
by ions and nucleotides. Proc Natl Acad Sci U S A. 1978;75(4):1713-7. 
338. Walker JM, Moises HC, Coy DH, Baldrighi G, Akil H. Non-opiate effects of dynorphin and 
des-Tyr-dynorphin. Science. 1982;218(4577):1136-8. 
339. Lacy P, Stow JL. Cytokine release from innate immune cells: association with diverse 
membrane trafficking pathways. Blood. 2011;118(1):9-18. 
340. Cheng K, Gao M, Godfroy JI, Brown PN, Kastelowitz N, Yin H. Specific activation of the 
TLR1-TLR2 heterodimer by small-molecule agonists. Sci Adv. 2015;1(3). 
341. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of 
interleukin-1beta to the inflammation-induced increase in nerve growth factor levels and 
inflammatory hyperalgesia. Br J Pharmacol. 1995;115(7):1265-75. 
342. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. Interleukin-1beta-
mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. 
Nature. 2001;410(6827):471-5. 
 176 
 
343. Ren K, Torres R. Role of interleukin-1betaduring pain and inflammation. Brain Res Rev. 
2009;60(1):57-64. 
344. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77(8):1627-52. 
345. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 
1992;10:411-52. 
346. Schäfer M, Mousa SA, Zhang Q, Carter L, Stein C. Expression of corticotropin-releasing 
factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Proc Natl Acad 
Sci U S A. 1996;93(12):6096-100. 
347. Azuma Y, Ohura K. Endomorphin-2 modulates productions of TNF-, IL-1, IL-10, and IL-
12, and alters functions related to innate immune of macrophages. Inflammation. 
2002;26(5):223-32. 
348. Fu X, Zhu ZH, Wang YQ, Wu GC. Regulation of pro-inflammatory cytokines gene 
expression by nociceptin/orphanin FQ in the spinal cord and the cultured astrocytes. 
Neuroscience. 2007;144(1):275-85. 
349. Gein SV, Gorshkova KG, Tendryakova SP. Role of beta-endorphin in the regulation of pro-
inflammatory cytokine production by peripheral blood monocytes in vitro. Bull Exp Biol 
Med. 2007;143(2):214-7. 
350. Gein SV, Gorshkova KG, Tendryakova SP. Regulation of interleukin-1beta and interleukin-
8 production by agonists of μ- and δ-opiate receptors in vitro. Neurosci Behav Physiol. 
2009;39(6):591-5. 
351. Gein SV, Tendryakova SP. Agonists of μ- and δ-opioid receptors in the regulation of IL-2, 
IL-4, and IFN-γ production by peripheral blood cells in vitro. Hum Physiol. 2015;41(3):323-
7. 
352. van den Bergh P, Dobber R, Ramlal S, Rozing J, Nagelkerken L. Role of opioid peptides in 
the regulation of cytokine production by murine CD4+ T cells. Cell Immunol. 
1994;154(1):109-22. 
353. Sullivan KE, Cutilli J, Piliero LM, Ghavimi-Alagha D, Starr SE, Campbell DE, et al. 
Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting 
and stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 
2000;7(6):920-4. 
354. Beaudet L, Rodriguez-Suarez R, Venne MH, Caron M, Bédard J, Brechler V, et al. 
AlphaLISA immunoassays: the no-wash alternative to ELISAs for research and drug 
discovery. Nat Methods. 2008;5. 
 177 
 
355. Mehta VB, Hart J, Wewers MD. ATP-stimulated release of interleukin (IL)-1beta and IL-18 
requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol 
Chem. 2001;276(6):3820-6. 
356. Kuijk LM, Mandey SH, Schellens I, Waterham HR, Rijkers GT, Coffer PJ, et al. Statin 
synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of 
caspase-1. Mol Immunol. 2008;45(8):2158-65. 
357. Parmentier M, Hirani N, Rahman I, Donaldson K, MacNee W, Antonicelli F. Regulation of 
lipopolysaccharide-mediated interleukin-1beta release by N-acetylcysteine in THP-1 cells. 
Eur Respir J. 2000;16(5):933-9. 
358. Huang H, Fletcher A, Niu Y, Wang TT, Yu L. Characterization of lipopolysaccharide-
stimulated cytokine expression in macrophages and monocytes. Inflamm Res. 
2012;61(12):1329-38. 
359. Moreira-Tabaka H, Peluso J, Vonesch J-L, Hentsch D, Kessler P, Reimund J-M, et al. 
Unlike for human monocytes after LPS activation, release of TNF-α by THP-1 cells is 
produced by a TACE catalytically different from constitutive TACE. PLoS One. 
2012;7(3):e34184. 
360. Takashiba S, Van Dyke TE, Amar S, Murayama Y, Soskolne AW, Shapira L. Differentiation 
of monocytes to macrophages primes cells for lipopolysaccharide stimulation via 
accumulation of cytoplasmic nuclear factor-kappaB. Infect Immun. 1999;67(11):5573-8. 
361. Hajarol Asvadi N. Beta-endorphin biotransformation and modulation of inflammatory 
signals [PhD thesis]: The University of Queensland; 2015. 
362. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and 
infectious diseases. Front Immunol. 2014;5:491. 
363. Guijarro-Munoz I, Compte M, Alvarez-Cienfuegos A, Alvarez-Vallina L, Sanz L. 
Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-kappaB signaling 
pathway and pro-inflammatory response in human pericytes. J Biol Chem. 
2014;289(4):2457-68. 
364. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27-37. 
365. Schildberger A, Rossmanith E, Eichhorn T, Strassl K, Weber V. Monocytes, peripheral 
blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns 
following stimulation with lipopolysaccharide. Mediators Inflamm. 2013;2013(Article ID 
697972):10 pages. 
 178 
 
366. Jansky L, Reymanova P, Kopecky J. Dynamics of cytokine production in human peripheral 
blood mononuclear cells stimulated by LPS or infected by Borrelia. Physiol Res. 
2003;52(5):593-8. 
367. Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact? Br J 
Anaesth. 2011;107(1):8-18. 
368. Paul D, Pick CG, Tive LA, Pasternak GW. Pharmacological characterization of nalorphine, a 
kappa-3 analgesic. J Pharmacol Exp Ther. 1991;257(1):1-7. 
369. Smith MA, French AM. Age-related differences in sensitivity to the antinociceptive effects 
of kappa opioids in adult male rats. Psychopharmacology (Berl). 2002;162(3):255-64. 
370. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor 
function. Nature. 1999;399(6737):697-700. 
371. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA. A role for 
heterodimerization of mu- and delta-opiate receptors in enhancing morphine analgesia. Proc 
Natl Acad Sci U S A. 2004;101(14):5135-9. 
372. Li JG, Zhang F, Jin XL, Liu-Chen LY. Differential regulation of the human kappa-opioid 
receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-
induced internalization and phosphorylation. J Pharmacol Exp Ther. 2003;305(2):531-40. 
373. Borner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, et al. Mechanisms of 
opioid-mediated inhibition of human T cell receptor signaling. J Immunol. 2009;183(2):882-
9. 
374. Olson KG, Welch SP. The effects of dynorphin A (1-13) and U50, 488H on free intracellular 
calcium in guinea pig cerebellar synaptosomes. Life Sci. 1991;48(6):575-81. 
375. Efanov AM, Koshkin AA, Sazanov LA, Borodulina OI, Varfolomeev SD, Zaitsev SV. 
Inhibition of the respiratory burst in mouse macrophages by ultra-low doses of an opioid 
peptide is consistent with a possible adaptation mechanism. FEBS Lett. 1994;355(2):114-6. 
376. Williamson SA, Knight RA, Lightman SL, Hobbs JR. Effects of beta-endorphin on specific 
immune responses in man. Immunology. 1988;65(1):47-51. 
377. Zaitsev SV, Sazanov LA, Koshkin AA, Sud'ina GF, Varfolomeev SD. Respiratory burst 
inhibition in human neutrophils by ultra-low doses of [D-Ala2]methionine enkephalinamide. 
FEBS Lett. 1991;291(1):84-6. 
378. Li MH, Seatter SC, Manthei R, Bubrick M, West MA. Macrophage endotoxin tolerance: 
effect of TNF or endotoxin pre-treatment. J Surg Res. 1994;57(1):85-92. 
 179 
 
379. van der Bruggen T, Nijenhuis S, van Raaij E, Verhoef J, van Asbeck BS. 
Lipopolysaccharide-induced TNF- production by human monocytes involves the raf-
1/MEK1-MEK2/ERK1-ERK2 pathway. Infect Immun. 1999;67(8):3824-9. 
380. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off 
regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for 
joint and gut-associated immunopathologies. Immunity. 1999;10(3):387-98. 
381. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk H-D, et al. MAPKAP 
kinase-2 is essential for LPS-induced TNF- biosynthesis. Nat Cell Biol. 1999;1(2):94-7. 
382. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 
1995;270(28):16483-6. 
383. Takashiba S, Shapira L, Amar S, Van Dyke TE. Cloning and characterization of human 
TNF- promoter region. Gene. 1993;131(2):307-8. 
384. Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther. 
2011;336(2):296-302. 
385. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, et al. Beta-arrestin-
mediated activation of MAPK by inverse agonists reveals distinct active conformations for G 
protein-coupled receptors. Proc Natl Acad Sci U S A. 2003;100(20):11406-11. 
386. Al-Hashimi M, Scott SW, Thompson JP, Lambert DG. Opioids and immune modulation: 
more questions than answers. Br J Anaesth. 2013;111(1):80-8. 
387. Ninkovic J, Roy S. Role of the mu-opioid receptor in opioid modulation of immune function. 
Amino Acids. 2013;45(1):9-24. 
388. Jan WC, Chen CH, Hsu K, Tsai PS, Huang CJ. L-type calcium channels and mu-opioid 
receptors are involved in mediating the anti-inflammatory effects of naloxone. J Surg Res. 
2011;167(2):e263-72. 
389. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel 
strategy to control inflammation. Pharmacol Rev. 2004;56(1):1-29. 
390. Wang X, Loram LC, Ramos K, de Jesus AJ, Thomas J, Cheng K, et al. Morphine activates 
neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci U S A. 
2012;109(16):6325-30. 
391. Govers C, Tomassen MMM, Rieder A, Ballance S, Knutsen SH, Mes JJ. Lipopolysaccharide 
quantification and alkali-based inactivation in polysaccharide preparations to enable in vitro 
immune modulatory studies. Bioact Carbohydr Dietary Fibre. 2016;8(1):15-25. 
 180 
 
392. Jessen DL, Osei-Owusu P, Toosky M, Roughead W, Bradley DS, Nilles ML. Type III 
secretion needle proteins induce cell signaling and cytokine secretion via Toll-like receptors. 
Infect Immun. 2014;82(6):2300-9. 
393. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine. 
2008;43(3):342-9. 
394. Laughlin TM, Larson AA, Wilcox GL. Mechanisms of induction of persistent nociception 
by dynorphin. J Pharmacol Exp Ther. 2001;299(1):6-11. 
395. Pålsson-McDermott EM, O'Neill LAJ. Signal transduction by the lipopolysaccharide 
receptor, Toll-like receptor 4. Immunology. 2004;113(2):153-62. 
396. Dodson S, Davis R, Figueroa L, Stevens C. Opioid-induced alterations of TLR4 protein 
expression in a human microglial cell line. FASEB J. 2015;29(1):Suppl 770.4.  
397. Figueroa-Hall LK, Das S, Stevens CW, Davis RL. Characterization of Toll-like receptor 4 
neuroinflammatory signaling and the effects of fentanyl citrate on CHME-5 human 
microglial cells. FASEB J. 2016;30:1179.5. 
398. Grace PM, Maier SF, Watkins LR. Opioid-induced central immune signaling: implications 
for opioid analgesia. Headache. 2015;55(4):475-89. 
399. Lorenz E, Patel DD, Hartung T, Schwartz DA. Toll-like receptor 4 (TLR4)-deficient murine 
macrophage cell line as an in vitro assay system to show TLR4-independent signaling of 
Bacteroides fragilis lipopolysaccharide. Infect Immun. 2002;70(9):4892-6. 
400. Davis RL, Buck DJ, Saffarian N, Stevens CW. The opioid antagonist, beta-funaltrexamine, 
inhibits chemokine expression in human astroglial cells. J Neuroimmunol. 2007;186(1-
2):141-9. 
401. Davis RL, Buck DJ, Saffarian N, Mohan S, DeSilva U, Fernando SC, et al. Beta-
funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells. 
J Neuroimmune Pharmacol. 2008;3(3):150-3. 
402. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol. 
2010;87(6):989-99. 
403. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced 
glial activation: mechanisms of activation and implications for opioid analgesia, dependence, 
and reward. ScientificWorldJournal. 2007;7:98-111. 
404. Kutuzova GD, Albrecht RM, Erickson CM, Qureshi N. Diphosphoryl lipid A from 
Rhodobacter sphaeroides blocks the binding and internalization of lipopolysaccharide in 
RAW 264.7 cells. J Immunol. 2001;167(1):482-9. 
 181 
 
405. Seyfried CA, Tobler P. High-performance liquid chromatographic system for the separation 
of dynorphin A (1-17) fragments and its application in enzymolysis studies with rat nerve 
terminal membranes. J Chromatogr. 1990;529(1):43-54. 
406. Prokai L, Kim HS, Zharikova A, Roboz J, Ma L, Deng L, et al. Electrospray ionization mass 
spectrometric and liquid chromatographic-mass spectrometric studies on the metabolism of 
synthetic dynorphin A peptides in brain tissue in vitro and in vivo. J Chromatogr A. 
1998;800(1):59-68. 
407. Müller S, Grundy BL, Hochhaus G. Metabolism of dynorphin A 1-13 in human CSF. 
Neurochem Res. 1996;21(10):1213-9. 
408. Magnusson K, Hallberg M, Bergquist J, Nyberg F. Enzymatic conversion of dynorphin A in 
the rat brain is affected by administration of nandrolone decanoate. Peptides. 
2007;28(4):851-8. 
409. Adams ML, Morris DL, Brase DA, Dewey WL. Stereoselective effect of morphine on 
antinociception and endogenous opioid peptide levels in plasma but not cerebrospinal fluid 
of dogs. Life Sci. 1991;48(9):917-24. 
410. Boarder MR, Weber E, Evans CJ, Erdelyi E, Barchas J. Measurement of total opioid 
peptides in rat brain and pituitary by radioimmunoassay directed at the alpha-N-acetyl 
derivative. J Neurochem. 1983;40(6):1517-22. 
411. Qi L, Liu HR, Yi T, Wu LY, Liu XR, Zhao C, et al. Warming moxibustion relieves chronic 
visceral hyperalgesia in rats: relations to spinal dynorphin and orphanin-FQ system. Evid 
Based Complement Alternat Med. 2013;2013:920675. 
412. Desiderio DM. Quantitative analytical mass spectrometry of endogenous neuropeptides in 
human pituitaries. Life Sci. 1992;51(3):169-76. 
413. Pan S, Aebersold R, Chen R, Rush J, Goodlett DR, McIntosh MW, et al. Mass spectrometry 
based targeted protein quantification: methods and applications. J Proteome Res. 
2009;8(2):787-97. 
414. Kay RG, Roberts K. MS and antibody-based approaches for the analysis of biotherapeutics: 
Future Science Ltd; 2013. 
415. Terato K, Do CT, Cutler D, Waritani T, Shionoya H. Preventing intense false positive and 
negative reactions attributed to the principle of ELISA to re-investigate antibody studies in 
autoimmune diseases. J Immunol Methods. 2014;407:15-25. 
416. Zhao X, Kang L, Zhang T, Chen J, Ren X, Bao Y, et al. Rapid quantification of a chemically 
synthesized peptide GAP162 in rat plasma by liquid chromatography/triple quadrupole 
 182 
 
tandem mass spectrometry and application to a pharmacokinetic study. RSC Adv. 
2015;5(64):51708-16. 
417. Yan L, Fridland G, Tseng JL, Desiderio DM. Evidence of an intermediate-size beta-
endorphin-containing precursor molecule in bovine pituitary by mass spectrometry. Biochem 
Biophys Res Commun. 1993;196(2):521-6. 
418. Asvadi NH, Morgan M, Herath HM, Hewavitharana AK, Shaw PN, Cabot PJ. Beta-
endorphin 1-31 biotransformation and cAMP modulation in inflammation. PLoS One. 
2014;9(3):e90380. 
419. Herath HM, Cabot PJ, Shaw PN, Hewavitharana AK. Study of beta-endorphin metabolism 
in inflamed tissue, serum and trypsin solution by liquid chromatography-tandem mass 
spectrometric analysis. Anal Bioanal Chem. 2012;402(6):2089-100. 
420. French D. The challenges of LC-MS/MS analysis of opiates and opioids in urine. 
Bioanalysis. 2013;5(22):2803-20. 
421. Karol MD. Mean residence time and the meaning of AUMC/AUC. Biopharm Drug Dispos. 
1990;11(2):179-81. 
422. Yee KK, Pribitkin EA, Cowart BJ, Rosen D, Feng P, Rawson NE. Analysis of the olfactory 
mucosa in chronic rhinosinusitis. Ann N Y Acad Sci. 2009;1170:590-5. 
423. Darwin C. On the Origin of Species by Natural Selection. London: John Murray; 1859. 
424. Haley PJ. Species differences in the structure and function of the immune system. 
Toxicology. 2003;188(1):49-71. 
425. Akhtar A. The flaws and human harms of animal experimentation. Camb Q Healthc Ethics. 
2015;24(4):407-19. 
426. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, 
monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin 
Drug Metab Toxicol. 2006;2(6):875-94. 
427. Gruber W, Hundt D, Klarwein M, Mollering H. Comparison of control materials containing 
animal and human enzymes. Comparison of enzymes of human and animal origin, III. J Clin 
Chem Clin Biochem. 1977;15(10):579-82. 
428. Platt FM, Boland B, van der Spoel AC. Lysosomal storage disorders: The cellular impact of 
lysosomal dysfunction. J Cell Biol. 2012;199(5):723-34. 
429. Mankidy R, Ahiahonu PW, Ma H, Jayasinghe D, Ritchie SA, Khan MA, et al. Membrane 
plasmalogen composition and cellular cholesterol regulation: a structure activity study. 
Lipids Health Dis. 2010;9(1):62. 
 183 
 
430. Bateman JF, Boot-Handford RP, Lamande SR. Genetic diseases of connective tissues: 
cellular and extracellular effects of ECM mutations. Nat Rev Genet. 2009;10(3):173-83. 
431. Silberring J, Castello ME, Nyberg F. Characterization of dynorphin A-converting enzyme in 
human spinal cord. An endoprotease related to a distinct conversion pathway for the opioid 
heptadecapeptide? J Biol Chem. 1992;267(30):21324-8. 
432. Tang Q, Gandhoke R, Burritt A, Hruby VJ, Porreca F, Lai J. High-affinity interaction of 
(des-Tyrosyl) dynorphin A (2-17) with NMDA receptors. J Pharmacol Exp Ther. 
1999;291(2):760-5. 
433. Cox BM, Molineaux CJ, Jacobs TP, Rosenberger JG, Faden AI. Effects of traumatic injury 
on dynorphin immunoreactivity in spinal cord. Neuropeptides. 1985;5(4-6):571-4. 
434. Dubner R, Ruda MA. Activity-dependent neuronal plasticity following tissue injury and 
inflammation. Trends Neurosci. 1992;15(3):96-103. 
435. Hauser KF, Aldrich JV, Anderson KJ, Bakalkin G, Christie MDJ, Hall ED, et al. 
Pathobiology of dynorphins in trauma and disease Front Biosci. 2005;10:216-35. 
436. Malan TP, Ossipov MH, Gardell LR, Ibrahim M, Bian D, Lai J, et al. Extraterritorial 
neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-
injured rats. Pain. 2000;86(1-2):185-94. 
437. Redell JB, Moore AN, Dash PK. Expression of the pro-dynorphin gene after experimental 
brain injury and its role in behavioral dysfunction. Exp Biol Med 2003;228(3):261-9. 
438. Sharma HS, Nyberg F, Olsson Y. Dynorphin A content in the rat brain and spinal cord after 
a localized trauma to the spinal cord and its modification with p-chlorophenylalanine. An 
experimental study using radioimmunoassay technique. Neurosci Res. 1992;14(3):195-203. 
439. Knapp PE, Rizzo JP, Alimova Y, Singh I, Goody RJ, Hauser KF. Glutamatergic effects of 
dynorphin peptides on cultured oligodendrocytes. J Neurochem. 2002;81:46-8. 
440. Tan-No K, Cebers G, Yakovleva T, Hoon Goh B, Gileva I, Reznikov K, et al. Cytotoxic 
effects of dynorphins through nonopioid intracellular mechanisms. Exp Cell Res. 
2001;269(1):54-63. 
441. Sibinga NE, Goldstein A. Opioid peptides and opioid receptors in cells of the immune 
system. Annu Rev Immunol. 1988;6:219-49. 
442. Capuozzo E, Pecci L, Giovannitti F, Baseggio Conrado A, Fontana M. Oxidative and 
nitrative modifications of enkephalins by human neutrophils: effect of nitroenkephalin on 
leukocyte functional responses. Amino Acids. 2012;43(2):875-84. 
443. Gabrilovac J. Leu-enkephalin modulates the migration inhibition of mouse splenocytes 
induced by cAMP-elevating agents. Int J Immunopharmacol. 1993;15(5):557-65. 
 184 
 
444. Gabrilovac J, Antica M, Osmak M. In vivo biderectional regulation of mouse natural killer 
(NK) cell cytotoxic activities by leu-enkephalin: reversibility by naloxone. Life Sci. 
1992;50(1):29-37. 
445. Qinyang W, Hultenby K, Lindgren UJ. Tissue levels of leu-enkephalin in rats with adjuvant 
arthritis. J Neuroimmunol. 2005;158(1–2):34-9. 
446. Ji RR, Xu ZZ, Strichartz G, Serhan CN. Emerging roles of resolvins in the resolution of 
inflammation and pain. Trends Neurosci. 2011;34(11):599-609. 
447. Zeilhofer HU. Prostanoids in nociception and pain. Biochem Pharmacol. 2007;73(2):165-74. 
448. Stein C, Clark JD, Oh U, Vasko MR, Wilcox GL, Overland AC, et al. Peripheral 
mechanisms of pain and analgesia. Brain Res Rev. 2009;60(1):90-113. 
449. Subramanian P, Mitroulis I, Hajishengallis G, Chavakis T. Regulation of tissue infiltration 
by neutrophils: role of integrin α3β1 and other factors. Curr Opin Hematol. 2016;23(1):36-
43. 
450. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 
2007;13(11):460-9. 
451. Daley JM, Reichner JS, Mahoney EJ, Manfield L, Henry WL, Jr., Mastrofrancesco B, et al. 
Modulation of macrophage phenotype by soluble product(s) released from neutrophils. J 
Immunol. 2005;174(4):2265-72. 
452. Morgan M, Heffernan A, Benhabib F, Wagner S, Hewavitharana AK, Shaw PN, et al. The 
efficacy of dynorphin fragments at the κ-, μ- and δ-opioid receptor in transfected HEK cells 
and in an animal model of unilateral peripheral inflammation. Peptides. 2017;89:9-16. 
453. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory 
therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 
2005;1754(1-2):253-62. 
454. Dhalendra G, Satapathy T, Roy A. Animal models for inflammation. Asian J Pharm Res. 
2013;3(4):207-12. 
 
185 
 
Appendi ces 
APPENDIX 1    Chemicals and materials 
Item Catalogue number Source 
2-(N-Morpholino) ethanesulfonic acid 
(MES)  
M3671 Sigma Aldrich, NSW, Australia 
24-well cell culture plates, Costar® CLS3524 Sigma Aldrich 
384-well microplate, OptiPlate-384 6007299 Perkin-Elmer, VIC, Australia 
4’,6-diamidino-2-phenylindole (DAPI) 28718-90-3 
Cayman Chemicals (through 
Sapphire Bioscience, NSW, 
Australia) 
96-well cell culture plates, Costar® CLS3596 Sigma Aldrich 
96-well CellBIND® plates CLS3340 Sigma Aldrich 
96-well special optics plates, Corning® CLS3720 Sigma Aldrich 
Acetonitrile gradient grade for liquid 
chromatography, LiChrosolv® 
1.00030.4000 
Merck Millipore, VIC, 
Australia 
AlphaLISA IL-1β kit assay  AL220C Perkin Elmer 
AlphaLISA TNF-α kit assay AL208C Perkin Elmer 
Anti-CD11b antibody [EP1345Y] ab52478 Abcam, VIC, Australia 
Bovine serum albumin (BSA) RES1328A-A102X Research Organics, OH, USA 
Dimethyl sulfoxide (DMSO), Hybri-
Max™  
D2650 Sigma Aldrich 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
D5796 Sigma Aldrich  
Foetal bovine serum (FBS), HyClone® HYCSH3007103 
In Vitro Technologies, QLD, 
Australia) 
Formaldehyde (molecular biology 
grade) 
F8775 Sigma Aldrich  
Formic acid, Optima™ LC/MS grade  64-18-6 
Thermo Fisher Scientific, 
QLD, Australia 
Goat Anti-Rabbit IgG H&L (Alexa 
Fluor® 555)  
ab150078 Abcam  
Goat Anti-Mouse IgG H&L (Alexa 
Fluor® 647) 
ab150115 Abcam 
Goat serum G9023 Sigma Aldrich 
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HEK-Blue™ hTLR4 cells hkb-htlr4 
InvivoGen (through Jomar Life 
Research, VIC, Australia) 
HEK-Blue™ Selection hb-sel InvivoGen 
Mouse Kappa Opioid Receptor, 
monoclonal antibody 
MO15098-100 
Neuromics (Edina, MN, USA) 
through Jomar Life Research, 
(VIC, Australia) 
IMD-0354 I3159 Sigma Aldrich 
LPS ALX-581-013-L002 
Enzo Life Sciences (through 
Sapphire Bioscience) 
LPS-RS tlrl-rslps InvivoGen 
MetaXpress® software  
Molecular Devices 
Corporation, PA, USA 
Normocin™ ant-nr-1 InvivoGen 
Penicillin-Streptomycin, Gibco™  15140122 Thermo Fisher Scientific 
Phorbol 12-myristate 13-acetate (PMA) AG-CN2-0010-M001 
Adipogen® Life Sciences 
(through Sapphire Bioscience) 
Phosphate buffered saline (PBS) tablets P4417 Sigma Aldrich 
QUANTI-Blue™ rep-qb2 InvivoGen  
Rabbit monoclonal anti-NF-κB/p65 
[E379]  
ab32536 Abcam 
RPMI 1640 medium  R8758 Sigma Aldrich 
Sucrose, ≥99.5%, S0389 Sigma Aldrich  
Thiazolyl blue tetrazolium bromide  M2128 Sigma Aldrich 
THP-1 cells ATCC® TIB-202™ 
Associate Professor Marie-
Odile Parat, The School of 
Pharmacy, The University of 
Queensland, Brisbane, 
Australia 
Tissue culture flasks, Corning® 
CLS430641 (75 cm2); 
CLS430639 (25 cm2) 
Sigma Aldrich 
Triton™ X-100, laboratory grade T8787 Sigma Aldrich 
Tryphan blue solution T8154 Sigma Aldrich  
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(Composition: 30 mg/L glycine, 84 mg/L L-arginine, 63 mg/L L-cystine, 584 mg/L L-glutamine, 
42 mg/L L-histidine, 105 mg/L L-isoleucine, 105 mg/L L-leucine, 146 mg/L L-lysine HCl, 30 
mg/L L-methionine, 66 mg/L L-phenylalanine, 42 mg/L L-serine, 95 mg/L L-threonine, 16 mg/L 
L-tryptophan, 104 mg/L L-tyrosine disodium salt dehydrate, 94 mg/L L-valine, 4 mg/L choline 
chloride, 4 mg/L D-Ca2+ pantothenate, 4 mg/L folic acid, 7.2 mg/L i-inositol, 4 mg/L 
niacinamide, 4 mg/L pyridoxine HCl, 0.4 mg/L riboflavine, 4 mg/L thiamine, 200 mg/L calcium 
chloride, CaCl2, 0.1 mg/L ferric nitrate, Fe(NO3)3, 97.67 mg/L magnesium sulphate, MgSO4, 
400 mg/L potassium chloride, KCl, 3700 mg/L sodium bicarbonate, NaHCO3, 6400 mg/L 
sodium chloride, NaCl, 125 mg/L sodium phosphate, NaH2PO4, 4500 mg/L D-glucose, 15 mg/L 
phenol red) 
 
APPENDIX 2    Buffers and solutions  
 
2.1 Antibody dilution buffer 
10X PBS           4 mL 
Bovine serum albumin         0.4 g 
Triton X-100           120 µL  
Deionised water          to 40 mL 
 
2.2 AlphaScreen Immunoassay buffer (1X), store at 2-8 °C 
Composition: 
HEPES, pH 7.4          25 mM 
Casein            0.1 % 
Dextran-500           1 mg/mL  
Triton X-100           0.5 % 
Proclin-300           0.05 % 
 
2.3 Blocking buffer 
10X PBS           2.5 mL 
Goat serum           1.25 mL 
Triton X-100           75 µL  
Deionised water          to 25 mL 
 
2.4 Complete growth media for HEK-Blue™-hLTR4 culture - 50mL aliquots, store at  
4 °C, expiry 1 month 
FBS            50 mL  
Pen-Strep            2.5 mL 
Normocin™ (100 µg/mL)         1 mL 
HEK-Blue™ Selection         2 mL 
DMEM           444.5 mL  
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(Composition: 10 mg/L glycine, 200 mg/L L-arginine, 65 mg/L L-cystine, 300 mg/L L-
glutamine, 15 mg/L L-histidine, 50 mg/L L-isoleucine, 20 mg/L L-glutamic acid, 20 mg/L L-
aspartic acid, 50 mg/L L-asparagine, 20 mg/L L-proline, 50 mg/L L-leucine, 40 mg/L L-lysine 
HCl, 15 mg/L L-methionine, 15 mg/L L-phenylalanine, 30 mg/L L-serine, 20 mg/L L-threonine, 
5 mg/L L-tryptophan, 29 mg/L L-tyrosine disodium salt dehydrate, 20 mg/L L-valine, 3 mg/L 
choline chloride, 0.25 mg/L D-Ca2+ pantothenate, 1 mg/L folic acid, 35 mg/L i-inositol, 1 mg/L 
para-aminobenzoic acid, 0.005 mg/L vitamin B12, 0.2 mg/L biotin, 3 mg/L choline chloride, 1 
mg/L niacinamide, 1 mg/L pyridoxine HCl, 0.2 mg/L riboflavine, 1 mg/L thiamine HCl, 200 
mg/L calcium chloride, CaCl2, 0.1 mg/L ferric nitrate, Fe(NO3)3, 100 mg/L calcium nitrate, 
Ca(NO3)2.4H2O, 48.84 mg/L magnesium sulphate, MgSO4, 400 mg/L potassium chloride, KCl, 
2000 mg/L sodium bicarbonate, NaHCO3, 6000 mg/L sodium chloride, NaCl, 800 mg/L sodium 
phosphate, NaH2PO4, 2000 mg/L D-glucose, 5 mg/L phenol red) 
 
2.5 Complete growth media for THP-1 cells - 50mL aliquots, store at 4 °C, expiry 1 month) 
FBS            50 mL  
Pen-Strep           5.0 mL 
RPMI 1640           445 mL  
 
 
 
 
 
 
 
 
2.6 Freezing media 
FBS            5 mL  
Growth media          4 mL 
DMSO           1 mL  
 
2.7 MES buffer (0.01 M, adjusted to pH 5.5) 
MES            0.195 g  
NaCl            0.845 g 
Deionised water          100 mL 
 
2.8 QUANTI-Blue™ solution, filtered, store at 2-8 °C, expiry 14 days 
Quanti-Blue™ powder         1 pouch 
Endotoxin-free water         to100 mL 
*Quanti-Blue™ is a confidential proprietary component of undisclosed composition 
 
2.9 PBS (1X), pH 7.4, store at room temperature 
Composition: 
NaCl            137 mM 
KCl            2.7 mM 
NaH2PO4 (sodium phosphate, dibasic)       10 mM 
KH2PO4 (potassium phosphate, dibasic)       1.8 mM 
 
 
 189 
 
2.10 PBS (10X), pH 7.4, store at room temperature 
Composition: 
NaCl            1.37 M 
KCl            27 mM 
NaH2PO4 (sodium phosphate, dibasic)       100 mM 
KH2PO4 (potassium phosphate, dibasic)       18 mM 
 
2.11 Sucrose solution (0.32 M), store at 2-8 °C, expiry 1 month 
Sucrose           54.7 g  
Deionised water           500 mL 
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APPENDIX 3    Supplementary data 
 
3.1  Non-specific binding of Alexa Fluor® 555-labelled secondary antibodies 
Specificity of CD11b primary antibody was confirmed through lack of non-specific binding with 
Alexa Fluor® 555-labelled secondary antibody. PMA-differentiated THP-1 cells were plated in 
microtiter plate as described in Chapter 3, section 3.3.3.2. After fixation with 3.7 % formaldehyde 
and blocked with blocking buffer for an hour, cells were incubated with Alexa Fluor® 555 goat anti-
rabbit IgG (H+L) polyclonal antibody (2 mg/mL, diluted at 1:500 in antibody dilution buffer), for 2 
h at room temperature followed by DAPI staining for 10 min at room temperature. Expression of 
CD11b in PMA-differentiated THP-1 cells was confirmed by immunofluorescence assay.  
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3.1 Non-specific binding of secondary Alexa Fluor® 555-labelled antibody in 
PMA-differentiated THP-1 cells.PMA-differentiated THP-1 cells were stained with anti-rabbit 
Alexa Fluor® 555-labelled secondary antibody in the absence of primary anti CD11b antibody. 
Lack of immunofluorescence supports specific binding of anti-CD11b primary antibody. 
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3.2  Effect of DMSO 0.1 %v/v on LPS-induced NF-κB/p65 nuclear translocation in 
differentiated THP-1 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3.2 Effect of DMSO 0.1 % v/v on LPS-induced NF-κB/p65 nuclear 
translocation in differentiated THP-1 cells. Differentiated THP-1 cells (1.5 x 105 cells/mL) were 
incubated with and without LPS (1 µg/mL) for an hour, using water and DMSO 0.1 %v/v as diluent 
control separately. The treated cells were fixed, permeabilised and immunolabelled with primary 
anti-NF-κB/p65 rabbit monoclonal antibody and visualised using Alexa Fluor 555® goat anti-rabbit 
secondary antibody. DAPI staining was used to identify the nuclei. The nuclear translocation of NF-
κB/p65 in each treatment group was assessed using the ImageXpress® imaging system. The 
percentage of NF-κB/p65 nuclear translocation in each treatment group was normalised and 
expressed relative to the LPS control group (water as diluent control). Data are represented as mean 
± SEM of at least three independent experiments performed in triplicate, *p ≤ 0.05 (One-way 
ANOVA, Bonferroni post-hoc test).  
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3.3  Effect of ML-190 on LPS-induced NF-κB/p65 nuclear translocation in differentiated 
THP-1 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3.3 Effect of ML-190 on LPS-induced NF-κB/p65 nuclear translocation in 
differentiated THP-1 cells. Differentiated THP-1 cells (1.5 x 105 cells/mL) were incubated with 
and without LPS (1 µg/mL) for an hour, in the presence of ML-190 (1 µM) or DMSO (0.1 % v/v, as 
diluent control). The treated cells were fixed, permeabilised and immunolabelled with primary anti-
NF-κB/p65 rabbit monoclonal antibody and visualised using Alexa Fluor 555® goat anti-rabbit 
secondary antibody. DAPI staining was used to identify the nuclei. The nuclear translocation of NF-
κB/p65 in each treatment group was assessed using the ImageXpress® imaging system. The 
percentage of NF-κB/p65 nuclear translocation in each treatment group was normalised and 
expressed relative to the LPS control group. Data recorded are mean ± SEM of at least three 
independent experiments performed in triplicate, *p ≤ 0.05 (One-way ANOVA, Bonferroni post-
hoc test). 
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3.4  Modulation of DYN 1-17 and its biotransformation fragments on NF-κB/p65 nuclear 
translocation in non-LPS-stimulated, PMA-differentiated THP-1 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3.4 Modulation of DYN 1-17 and its biotransformation fragments on NF-
κB/p65 nuclear translocation in non-LPS-stimulated, PMA-differentiated THP-1 cells. The 
non-LPS-stimulated, differentiated THP-1 cells (1.5 x 105 cells/mL) were incubated with (A) DYN 
1-17 and the N-terminal fragments and (B) the intermediate and C-terminal fragments at 1 μM and 
10 nM for an hour. The nuclear translocation of NF-κB/p65 in each treatment group was assessed 
using the ImageXpress® imaging system. The NF-κB/p65 translocation percentage in each 
treatment group was normalised and expressed relative to non-stimulated (NS) control group. Data 
shown are mean ± SEM of at least three independent experiments in triplicate, *p ≤ 0.05 (One-way 
ANOVA, Bonferroni post-hoc test).  
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3.5  Verification of specificity of mouse KOR antibody 
 
To verify specificity of the mouse KOR monoclonal antibody, DOR-expressing HEK cells were 
plated on the imaging plate as described in Chapter 3, section 3.3.3.2. After fixation with 3.7 % 
formaldehyde and blocked with blocking buffer for an hour, cells were incubated with mouse KOR 
monoclonal antibody (30 µg/mL) for overnight at 4 °C followed by Alexa Fluor® 647 goat anti-
mouse IgG (H+L) polyclonal antibody (2 mg/mL, diluted at 1:300 in antibody dilution buffer), for 2 
h at room temperature. Cells were then stained with DAPI for 10 min for nuclei acid detection. 
Expression of KOR in HEK-DOR cells were viewed using a 20× Nikon Eclipse Ti inverted 
fluorescent microscope.  
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3.5 Verification of mouse anti-KOR monoclonal antibody in DOR-
expressing cells. HEK-DOR cells (2 x 106 cells/mL) were immunolabelled for KOR expression 
with mouse KOR monoclonal antibody. The expression of KOR was visualised using Alexa Fluor 
647® goat anti-mouse secondary antibody (red). The nuclei were counterstained with DAPI (blue). 
The images were acquired using Nikon Eclipse Ti inverted fluorescent microscope (20×) with 
suitable Cy5 and DAPI filters. Lack of immunofluorescence verifies the specificity of mouse KOR 
primary antibody used in the experiment. Scale bars: 25 µm.  
 
 
 
 
 
 195 
 
3.6  IL-1β standard curve  
Lyophilised human IL-1β (0.1 g) was reconstituted in 100 µL H2O (stock: 1 x 10-6 g/mL) and 
serially diluted in RPMI 1640, supplemented with 1 % FBS to provide a concentration range as 
indicated in the below table.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tube 
Volume of human IL-
1β (µL) 
Vol of diluent (µL) 
(RPMI 1640/1 % FBS) 
[IL-1β] in 
standard curve 
(g/mL in 5 µL) 
A 
5 µL of reconstituted 
human IL-1β 
45 1e-07 
B 30  µL of tube A 70 3e-08 
C 30  µL of tube B 60 1e-08 
D 30  µL of tube C 70 3e-09 
E 30 µL of tube D 60 1e-09 
F 30  µL of tube E 70 3e-10 
G 30  µL of tube F 60 1e-10 
H 30  µL of tube G 70 3e-11 
I 30  µL of tube H 60 1e-11 
J 30  µL of tube I 70 3e-12 
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Appendix Figure 3.6 Human IL-1β analyte standard curve. The standard curve prepared 
through serial dilution of IL-1β in RPMI 1640 supplemented with 1 % FBS. The AlphaLISA signal 
was read using an EnSpire® Alpha 2390 plate reader equipped with AlphaScreen® module.  
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3.7  TNF-α standard curve  
Lyophilised human TNF-α (0.1 g) was reconstituted in 100 µL H2O (stock: 1 x 10-6 g/mL) and 
serially diluted in RPMI 1640, supplemented with 1 % FBS to provide a concentration range as 
indicated in the below table. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tube 
Volume of human 
TNF-α (µL) 
Vol of diluent (µL) 
(RPMI 1640/1 % FBS) 
[TNF-α] in 
standard curve 
(g/mL in 5 µL) 
A 
5 µL of reconstituted 
human IL-1β 
45 1e-07 
B 30  µL of tube A 70 3e-08 
C 30  µL of tube B 60 1e-08 
D 30  µL of tube C 70 3e-09 
E 30 µL of tube D 60 1e-09 
F 30  µL of tube E 70 3e-10 
G 30  µL of tube F 60 1e-10 
H 30  µL of tube G 70 3e-11 
I 30  µL of tube H 60 1e-11 
J 30  µL of tube I 70 3e-12 
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Appendix Figure 3.7 Human TNF-α analyte standard curve. The standard curve prepared 
through serial dilution of TNF-α in RPMI 1640 supplemented with 1 % FBS. The AlphaLISA 
signal was read using an EnSpire® Alpha 2390 plate reader equipped with AlphaScreen® module.  
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3.8  Effects of DYN 1-17 and its biotransformation fragments on IL-1β and TNF-α release 
in unstimulated, PMA-differentiated THP-1 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3.8 Modulation of DYN 1-17, its biotransformation fragments and U50,488H 
on the release of (A) IL-1β and (B) TNF-α in non-LPS-stimulated, PMA-differentiated THP-1 
cells. The non-stimulated THP-1 cells were treated with the respective peptides (10-11 M to 10-7 M) 
for 24 h. The culture supernatants were collected and both cytokines release were measured using 
IL-1β and TNF-α AlphaLISA assays. The signal was measured using an EnSpire® Alpha 2390 plate 
reader. The release of cytokine in each treatment group was normalised and expressed relative to 
non-stimulated control group. Data shown are mean ± SEM of at least three independent 
experiments performed in triplicate (One-way ANOVA, Bonferroni post-hoc test). 
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3.9  Effects of ML-190 and DMSO on IL-1β and TNF-α release in differentiated THP-1 
cells with and without LPS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3.9 Effects of ML-190 and DMSO on the release of (A) IL-1β and (B) TNF-α 
in differentiated THP-1 cells. THP-1 cells, with or without LPS stimulation, were treated with 
ML-190 (1 µM) or DMSO (0.1 % v/v) for 24 h. The culture supernatants were collected and both 
cytokines release were measured using IL-1β and TNF-α AlphaLISA assays. The signal was 
measured using an EnSpire® Alpha 2390 plate reader. The release of cytokine in each treatment 
group was normalised and expressed relative to non-stimulated control group. Data shown are mean 
± SEM of at least three independent experiments performed in triplicate (One-way ANOVA, 
Bonferroni post-hoc test). 
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3.10  Modulation of LPS-induced TLR4 activation by DYN 1-17 and its biotransformation 
fragments 
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Appendix Figure 3.10 Modulatory effects of DYN 1-17 and its biotransformation fragments 
on LPS-induced TLR4 activation. HEK-Blue™-hTLR4 reporter cell lines were stimulated with 
LPS 1 ng/mL and treated with (A) DYN 1-17, (B) DYN 1-6, (C) DYN 1-7, (D) DYN 1-9, (E) DYN 
1-10, (F) DYN 1-11, (G) DYN 2-17, (H) DYN 6-12, (I) DYN 7-17, (J) DYN 3-17, (K) DYN 4-17, 
(L) DYN 3-6 and (M) fentanyl at 0.1 µM, 1 µM, 3 µM and 10 µM for 24 h. The percentage of 
TLR4 activation in each treatment group was normalised and expressed relative to LPS control 
group. Data are represented as mean ± SEM of at least three independent experiments in triplicate 
(One-way ANOVA, Bonferroni post-hoc test). 
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3.11  Modulatory effect of DYN 3-14 on TLR4 activation in non-LPS-stimulated HEK-
Blue™-hTLR4 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3.11 Modulatory effect of DYN 3-14 on TLR4 activation in non-LPS-
stimulated HEK-Blue™-hTLR4 cells. HEK-Blue™-hTLR4 reporter cell lines were treated with 
DYN 3-14 at 0.1 µM, 1 µM, 3 µM and 10 µM for 24 h. The percentage of TLR4 activation in each 
treatment group was normalised and expressed relative to control group. Data are represented as 
mean ± SEM of at least three independent experiments in triplicate (One-way ANOVA, Bonferroni 
post-hoc test). 
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3.12  TIC spectra of water  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure for Appendix 3.12: Blank TIC chromatogram obtained with Milli-Q water  
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3.13  TIC spectra of homogenised inflamed human nasal tissue  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure for Appendix 3.13: TIC spectra of homogenised inflamed human nasal tissue in at (A) pH 
5.5 and (B) pH 7.4 Mass spectra of the fragments detected following incubation of DYN 1-17 at 37 
°C with homogenised inflamed human nasal tissue at pH 7.4. 
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3.14  Mass spectra of the fragments detected following incubation of DYN 1-17 at 37 °C with 
homogenised inflamed human nasal tissue at pH 7.4  
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectra of DYN 13-17 and DYN 3-15 identified in the peak 1 of Figure 6.2 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 2-8 identified in the peak 2 of Figure 6.2 (A) 
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Mass spectra of DYN 11-17 and DYN 9-17 identified in the peak 3 of Figure 6.2 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 7-17 identified in the peak 4 of Figure 6.2 (A) 
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Mass spectra of DYN 12-17, DYN 8-17 and DYN 7-14 identified in the peak 5 of Figure 6.2 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 1-7 identified in the peak 6 of Figure 6.2 (A) 
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Mass spectrum of DYN 1-11 identified in the peak 7 of Figure 6.2 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 1-6 identified in the peak 8 of Figure 6.2 (A) 
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Mass spectrum of DYN 3-14 identified in the peak 9 of Figure 6.2 (A) 
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3.15  Mass spectra of the fragments detected following incubation of DYN 1-17 at 37 °C with 
homogenised inflamed human nasal tissue at pH 5.5  
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectra of DYN 13-17 and DYN 3-15 identified in the peak 1 of Figure 6.4 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectra of DYN 11-17 and DYN 9-17 identified in the peak 2 of Figure 6.4 (A) 
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Mass spectra of DYN 7-17 and DYN 9-15 identified in the peak 3 of Figure 6.4 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 8-17 identified in the peak 4 of Figure 6.4 (A) 
 
 
 
 
 214 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 1-7 identified in the peak 5 of Figure 6.4 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 1-11 identified in the peak 6 of Figure 6.4 (A) 
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Mass spectrum of DYN 1-6 identified in the peak 7 of Figure 6.4 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 2-17 identified in the peak 8 of Figure 6.4 (A) 
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Mass spectrum of DYN 1-10 identified in the peak 9 of Figure 6.4 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 1-15 identified in the peak 10 of Figure 6.4 (A) 
 
 
 
 
 217 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 3-14 identified in the peak 11 of Figure 6.4 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 1-5 identified in the peak 12 of Figure 6.4 (A) 
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Mass spectrum of DYN 2-8 identified in the peak 13 of Figure 6.4 (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 9-16 identified in the peak 14 of Figure 6.4 (B) 
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Mass spectrum of DYN 2-10 identified in the peak 15 of Figure 6.4 (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 12-17 identified 30 min post incubation in homogenised human 
inflamed nasal tissue at pH 5.5  
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Mass spectrum of DYN 7-14 identified 60 min post-incubation in homogenised human 
inflamed nasal tissue at pH 5.5  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of DYN 7-15 identified 15 min post-incubation in homogenised human 
inflamed nasal tissue at pH 5.5  
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Mass spectrum of DYN 8-13 identified 60 min post-incubation in homogenised human 
inflamed nasal tissue at pH 5.5  
 
